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EXECUTIVE SUMMARY 
 
This rapid review of the evidence relating to liver disease epidemiology, treatment 
and service provision was conducted by a research team at Newcastle University 
between August and October 2007. This work was commissioned by the Department 
of Health. The aims of this review were: to summarise from published literature and 
relevant unpublished data what is currently known about liver disease; to identify 
gaps in the evidence-base; and to suggest what might be done to tackle liver disease in 
England. 
 
What the review found: 
 
• England, in common with the rest of the UK, is seeing a marked increase in 
liver disease with reports of rising morbidity and mortality, particularly in 
younger age groups.  
 
• These trends have become apparent over time and look set to continue into the 
future. 
 
• UK trends are in the opposite direction to general world trends; where liver 
disease rates are falling. 
 
• Our closest comparator countries (USA, Canada and France) have experienced 
a decrease in liver disease rates over recent years. 
 
• UK patterns are now closest to those seen in Scandinavia; but they are still 
someway behind Eastern Europe. 
 
• The key risk factors for liver disease are: excessive drinking, infection with 
hepatitis B or C, and obesity. 
o These risk factors are relevant to a large proportion of the population. 
o These risk factors are modifiable. 
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• People can acquire liver disease for other reasons such as genetic inheritance, 
immune response and paediatric conditions. 
o These factors account for a small proportion of liver disease. 
o These factors are generally not modifiable. 
 
• Health professionals and the general public are unaware of the wider range of 
reasons (modifiable and unmodifiable) that can lead to liver disease. 
o Better understanding of risk factors could help preventive efforts. 
o Better uptake of screening would enable earlier treatment. 
o Better awareness that liver disease can result from mainstream 
behaviour may help to reduce stigma often associated with it.  
 
• Regarding the key (modifiable) risk factors, different trends are emerging in 
different parts of England.  
o Heavier drinking in the North of England. 
o Higher rates of chronic viral hepatitis in the West and South East of 
England. 
o Higher rates of obesity particularly in areas of high social deprivation. 
 
• The co-occurrence of key risk factors for liver disease has the potential to lead 
to a rapid increase in this condition in England (as recently seen in Scotland). 
 
• There are evidence-based interventions that can be used to change lifestyle 
behaviour and modify the risk factors for developing liver disease. 
o Brief alcohol interventions to reduce heavy drinking. 
o Behaviour change interventions plus weight modification and exercise 
regimes to reduce levels of obesity. 
o Needle exchange schemes to prevent hepatitis B and C infections. 
 
• There is also evidence to support other health care interventions and 
treatments which can reduce morbidity and mortality from liver disease. 
o Hepatitis B vaccination of high risk groups. 
o Early treatment for hepatitis C. 
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• There is much less evaluative work on the prevention of liver disease than on 
treatment and limited economic evaluation of different treatment options for 
alcohol and obesity-related liver disease; although NICE recommend that 
treatment for chronic hepatitis B and C is effective and cost effective.  
 
• There is no central database of clinical activity on liver disease; service 
provision data are only available piecemeal from numerous disparate sources 
which limits the ability to gain a clear picture of NHS liver care. 
 
• There appears to be a lack of trained Hepatologists in England to meet the 
current and growing demand for liver care. 
 
• Current Hospital Episode statistics are difficult to interpret since they are 
based on data codes which do not clearly distinguish between all the different 
types and causes of liver disease. 
 
• New cases of liver disease seem to be increasing each year in English hospitals 
and there is more demand for treatment than services can currently meet. 
 
• Over the past 5 years, the number of liver transplants in England has risen by 
62%; in 2005/6 the number of people waiting for a transplant rose by 38%. 
 
• There are 6 transplant centres in England but none in the South West or the 
North West of England; the latter is where some of the highest rates of liver 
disease are reported. 
 
• Survival rates from liver transplants are improving in both adults and children 
which means that more people will need specialist care whilst living with this 
condition for longer (for surviving children this is needed over their lifetime). 
 
• There is almost no research on the experiences of patients with liver disease 
who need to access care for this condition in England. 
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Evidence gaps have been noticed in the following areas: 
 
• We noted a lack of high quality epidemiological data on various aspects of 
liver disease in England 
o Experience of liver disease in ethnic minority groups 
o Rates of liver disease by age/sex/region/socio-economic status 
o Numbers of new cases emerging in England each year 
o Total numbers of cases requiring (or likely to require) NHS treatment 
o These incidence and prevalence rates need to be derived piece meal or 
more often extrapolated from work in other countries 
 
• There appear to be evidence gaps relating to prevention, treatment and 
palliative care for people with liver disease. Key gaps identified were: 
o How to improve screening for hepatitis B and C in high risk groups 
(as only 1-2% of HCV patients are aware of their disease) 
o Efficient means of reducing obesity in England 
o The utility of different methods of case identification to facilitate 
identification of liver disease at an early stage  
o The cost-effectiveness of different options for treating liver disease 
o Ways of improving quality of life in people with liver disease 
 
• We need a better understanding of clinical aspects of liver disease including: 
o Progression from one form of liver disease to a more serious condition 
o The synergistic relationship between different modifiable risk factors 
for liver disease particularly the interaction of obesity and alcohol-
related liver disease with each other and with the viral liver diseases 
o The interaction between modifiable and non-modifiable causes of liver 
disease 
o Reasons underlying the rising incidence of cholangiocarcinoma, where 
there has been a 20 fold increase in 20years, and its treatment. 
 
• We need to establish how best to get research evidence about liver disease 
prevention, treatment and palliation into clinical practice 
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o Dissemination routes – getting the evidence to clinicians 
o Translation work – converting the evidence into models for care 
o Implementation strategies – means of encouraging clinicians to change 
practice  
 
• We need to evaluate different models of service provision for liver disease and 
explore ways of expanding the workforce including: 
o New roles (e.g. lifestyle advisors)  
o Expanded roles (dieticians, specialist nurses for alcohol interventions 
and delivering antiviral therapy) 
o New ways of working (shared care, different skill-mix) 
o Better division of labour (primary, secondary and tertiary care) 
 
• We need research that includes patients’ perspective of liver disease covering: 
o Accessibility and acceptability of screening services to different 
sections of the population 
o What it feels like to experience a diagnosis of liver disease 
o How to access timely and appropriate care 
o How the negotiate generalist and specialist aspects of care 
o Patients’ experience of treatment and care delivery 
 
Suggestions for tackling liver disease in England: 
 
• Identify deaths from alcohol induced liver disease, hepatitis B, hepatitis C and 
obesity related cirrhosis as separate entities within the ONS reporting system. 
 
• Implement screening and brief interventions to reduce heavy drinking 
 
• Use behaviour change interventions to help tackle obesity 
 
• Promote early detection (via screening) and treatment for hepatitis C 
 
• Promote vaccination of high risk groups for hepatitis  B 
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• Promote detection (via screening of ethnic minorities and other high risk 
groups) and treatment for chronic hepatitis B. 
 
• Use effective treatment to ameliorate existing obesity 
 
• Develop effective treatment for cholangiocarcinoma 
 
• Educate health professionals and the public about risk factors for liver disease 
 
• Address current misinformation and prejudice concerning liver disease 
 
• Ensure equitable access to treatment for liver disease in all areas of England 
by promoting hepatology networks. 
 
• Plan ahead in terms of the likely need for more liver services in England. 
 
• Ensure that there is an appropriately configured and trained workforce to deal 
with the growing problem of liver disease in England. 
 
• Establish a hepatology research network within the comprehensive research 
network (UKCRN) to develop and evaluate new therapies where there is 
unmet clinical need. 
 
• Develop a national audit tool with appropriate IT support to monitor the 
changing incidence of liver disease in England; this would have the potential 
added-value of being able to capture the impact of interventions used to 
prevent liver disease in the future. 
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1. REVIEW METHOD 
 
 
1. We compiled a comprehensive list of key informants on liver disease from 
recently published work 1 and consulted a group of expert clinicians to ensure 
that all relevant individuals and treatment centres were included. 
 
2. We wrote to all key informants (individuals and agencies) to request relevant 
data and research reports (published or unpublished) on liver disease. 
 
3. We used responses in 2 to access further key informants whom we emailed to 
request further information [see Appendix I for the full list]. 
 
4. We searched electronic medical databases (Medline, Embase, EconLit, 
Cochrane Library) for relevant literature on liver disease epidemiology, 
treatment and service provision. 
 
a. Given recent reviews of liver disease 1-5 we focused on material from 
2005/7.  
b. We used a reported search strategy for epidemiological studies 2 with 
additional key words and a health economics search strategy developed 
in other work [see Appendices II-IV for search strategies and relevant 
acronyms]. 
 
5. We conducted key-word searches on internet search engines (Google, Google 
Scholar) to access recent papers and reports and tracked down hard copies via 
e-journals or inter-library loans. 
 
6. Given the time-frame for this rapid review and the large volume of material, 
we were not able to formally appraise the research studies that were identified. 
However, the vast majority of the material was from peer-reviewed journals 
and so we felt the content was quality-assured and authoritative. 
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7. We did not conduct formal data abstraction of the material instead we 
synthesised it into a descriptive (best-evidence) summary. This narrative was 
structured around the patient journey into liver disease:  
a. Who develops liver disease and what are the consequences?  
b. How do people get liver disease and can it be prevented?  
c. At what stage is liver disease identified?  
d. What happens to people with liver disease in terms of NHS treatment? 
 
8. We used the evidence to recommend what could be done to tackle liver 
disease now; and identified gaps in the literature to identify areas where 
further research is required. 
 
9. We produced an initial report in November 2007 which was circulated to the 
expert clinician group and other key experts for feedback and validation of the 
content. 
 
10. We incorporated suggestions and comments from the peer review process to 
produce this final report of our review. 
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2. LIVER DISEASE – GENERAL EPIDEMIOLOGY 
The liver is a large organ in the upper right abdomen that aids in digestion and 
removes waste products from the blood.  
In the simplest terms, liver disease refers to any disorder of the liver and includes the 
following conditions:  
• Steatosis or fatty deposits in the liver 
• Fibrosis or scarring of the liver; 
• Hepatitis or inflammation of the liver;  
• Cirrhosis where scarring and inflammation spread through the liver and 
irreversibly disrupt its shape or function causing permanent cell damage and 
ultimately liver failure and leading to liver cancer. 
• Liver cancer which causes ultimately liver failure and death 
 
Liver disease mortality 
As many as one in 10 people in England have some form of liver disease 6 and many 
of them die prematurely from this condition. Liver disease is currently the fifth most 
common cause of mortality in the UK for both men and women. 3 However, whilst the 
mortality rates for the other 4 major causes of death are falling, the trend for liver 
disease is steadily rising in both sexes (See Figures 1 & 2).  
 
The codes defined by the 10th revision of the International Classification of Diseases 
(ICD-10) for all diseases of the liver are K70-K76 [see Appendix V]. Chronic liver 
disease, which includes alcoholic liver disease, is specified by the codes K70 and 
K73-K74.   
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Males: Age-standardised mortality rates per 100,000 for major diseases (Source: ONS, HSQ 35)
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Fem ales: Age-standardised m ortality rates per 100,000 for m ajor d iseases (Source: O NS , HSQ  35)
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Figures 1 and 2. Standardised mortality rates per 100,000 for 5 major diseases in 
the UK for Males and Females (Death rates for 2006 are provisional). Source 
ONS, Data: selected causes and sex, 1971 – 2006. 7 
 
In 2006, the mortality rate for males from all types of liver disease was 161 male 
deaths (age standardized per million population) compared to 87 in 1996, representing 
an 85% increase over the last decade. The corresponding rate for females was 86 
deaths compared to 52 in 1996, representing a 65% increase over the last decade.3 
 
Death rate changes over the last 25 years (1981 to 2006) showed a 177% increase for 
men and 100% for women (in 1981 there were 58 male deaths and 43 female deaths). 
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Recent estimates suggest that liver disease mortality may double again in the next 
decade. 3  
 
Although the death rates for liver disease are lower than the other four main causes of 
death in the UK, the persistently increasing rates for liver disease are concerning.  
 
The significant upward trend for both men (R2 = 0.98) and women (R2 = 0.95) shown 
in figure 3 for chronic liver disease indicates a clear need to plan ahead in terms of 
NHS treatment services. For context, R2 is a statistical measure of how well a 
regression line approximates real data points; an R2 1.0 (100%) indicates a perfect fit. 
 
Age standardised mortality rate (per 100,000) from Chronic Liver Disease 
(ICD9 571 adjusted, ICD10 K70, K73-K74), England & Wales, 1992 to 2005.
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Figure 3. Deaths from chronic liver disease in England and Wales. Source: 7 
 
Cirrhosis and primary liver cancer accounts for one in every 40 (2.5%) deaths 
worldwide. 8 Historically, the UK has experienced relatively low rates of liver disease 
compared to mainland Europe, particularly Mediterranean countries. However, since 
the 1970’s UK increases in deaths due to liver disease have been accompanied by a 
corresponding fall in European figures (see figure 4).  
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Figure 4. Trends in standardised mortality rates (per 100,000 population) for 
chronic liver disease in the UK and in Europe, 1970-1998. Source: 9 
 
 Liver Cirrhosis 
 
The majority of liver deaths are due to cirrhosis 2 and it has recently been reported 
that there are about 4-5000 deaths from cirrhosis in the UK each year. 10 11 
 
A recent population-based study reported a 41% increase in new cases of cirrhosis 
each year (incidence) in the UK between 1992-2001. 12 In this General Practice study, 
3,360 new cases were identified and the incidence rate was 14 cases per 100,000 
population. Median age at diagnosis was 56 years for men and 61 years for women. 12 
 
Detailed analyses of liver cirrhosis data between 1991 and 2001 showed that mortality 
in men rose by two-thirds in England and Wales (67%) and more than doubled in 
Scotland (112%). The corresponding increases in women were 35% in England and 
Wales and 63% in Scotland. 13 14 This work reported particularly large increases in 
younger age groups (15-44) see Figure 5. 
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Figure 5. UK data for deaths due to liver cirrhosis, Leon and McCambridge in 
2006; corrected figures. 14 
 
These data are notable since liver disease has typically been considered a disease of 
older age. However, a growing number of reports show that cirrhosis in England is 
occurring in younger people. 14-16 See Table 1 and Figure 6-7. Deaths of individuals in 
their twenties have been reported and whilst the absolute numbers are low, the 
proportionate increases are not. 16 
 
 
Table 1. Numbers of deaths in England from chronic liver disease. Source: 16 
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Figure 6. Deaths from chronic liver disease by age-group. Source 17 
 
 
 
Regional trends 
 
Within England, the greatest numbers of deaths from chronic liver disease are found 
in the North West and North East of England. These two regions were reported to 
have the highest rates of heavy drinking in England and alcohol-related hospital 
admissions. 18 These areas also have some of the highest rates of social deprivation in 
England. 
 
Mortality rate per 100,000 from chronic liver disease in England, 1994-2005 (MALES)
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Mortality rate per 100,000 from chronic liver disease in England, 1994-2005 (FEMALES)
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Figure 7. Distribution of deaths from liver disease across England. Source: 19 
 
International trends 
 
Recent worldwide assessment of mortality due to liver cirrhosis shows a favourable 
downward trends in most countries of the world except for the UK, Eastern Europe 
and parts of Scandinavia 20 see Figures 8-10.  
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Figure 8. Male (top, black bars) and female (bottom, pink bars) age-standardized 
mortality rates for diseases of the liver. Shown are countries with increasing 
trend for years with available data between 1950-2005. Source 17 
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Figure 9. Male (top, black bars) and female (bottom, pink bars) age-standardized 
mortality rates for diseases of the liver. Shown are countries with decreasing 
trend for years with available data between 1950-2005. Source17 
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Figure 10. Male (top, black bars) and female (bottom, pink bars) age-
standardized mortality rates for diseases of the liver in New Zealand, Canada, 
Australia, Japan and the USA. Shown are years with available data between 
1950-2004. Source17  
 
 
Liver cancer 
 
The other main cause of death from liver disease is due to liver cancer; although it 
should be noted that cirrhosis is a specific precursor of liver cancer. 8 Liver cancer can 
either arise in the hepatobiliary system itself (primary liver cancer) or metastasize 
from a tumour elsewhere in the body (secondary liver cancer).  
 
Most liver cancer (95%) is a secondary cancer. 1 
 
Nevertheless, primary liver cancer caused 2091 deaths in England and Wales in 2001 
1
 and mortality rates have steadily increased over the last three decades (West et al. 
2006). There are about 2300 new cases each year, with an overall incidence of 4 per 
100,000 population. 1  Liver cancer is more common in men compared to women and 
it predominately occurs in older people, peaking in the 7th decade. 21 
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Primary liver cancer consists of either Hepatocellular carcinoma (HCC) which arises 
in liver cells (hepatocytes) or Cholangiocarcinoma (CCA) which arises in the bile 
ducts either within (intrahepatic) or outside of the liver (extra-hepatic). HCC is 
responsible for the majority (70-85%) of primary liver cancer world-wide. 8 However, 
recent rises in primary liver cancer have been attributed to a rapid rate of increase in 
CCA. 21 
 
Incidence of CCA has increased 16-fold in England and Wales since 1971 whilst 
HCC has increased three-fold over this time. CCA has increased dramatically in both 
men and women in England and Wales; it is the commonest type of primary liver 
cancer in English women. 22 HCC increases have only been significant in males; it is 
the commonest type of primary liver cancer in English men. 22 
 
Conclusion 
 
A large number of people die from liver disease in England each year, and these 
individuals are dying earlier than they used to. The highest death rates from liver 
disease are found in the North of England. International data show that the pattern of 
liver disease in England is closer to that of Scandinavia rather than the pattern seen in 
our usual comparator countries (the USA, Canada, France). 
 
In the following section we describe the patient journey into liver disease (how they 
developed this condition), what the consequences of liver disease are for them 
(morbidity and premature death); and how we can prevent and/or treat people with 
this condition. 
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3.  MAJOR LIVER DISEASE 
 
 
In this section we describe the key risk factors that cause individuals to develop liver 
disease. All these risk factors involve a behavioural component. Thus these risk 
factors are all potentially modifiable. 
 
The key risk factors for liver disease in England are: 
 
 Excessive alcohol consumption 
 
 Infection with the hepatitis  C virus (HCV) 
 
 Infection with the hepatitis  B virus (HBV) 
 
 Obesity and the metabolic syndrome 
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ALCOHOLIC LIVER DISEASE (ALD) 
 
Alcohol is responsible for 70% of cirrhosis deaths in the UK. 16 Thus cirrhosis deaths 
and chronic liver disease are often used as a proxy for the prevalence of ALD in the 
population.  
 
Likewise, alcohol death statistics are sometimes used as an indicator of alcoholic liver 
deaths. In the Office for National Statistics (ONS) data, cirrhosis accounts for 85% of 
the total alcohol deaths. 23 Generally however, it is thought that liver disease accounts 
for between 15% and 25% of all alcohol-related deaths. 24 25  
 
ALD has only been recorded separately from liver disease in England and Wales since 
January 2001. 26 It is important to be aware of this when considering the data 
presented below.  
 
Who gets ALD and what are the consequences?  
 
Alcohol consumption accounts for the greatest proportion of liver disease in the UK; 
recent studies report that between 50 and 60% of liver disease is alcohol-related. 3  
 
Mortality from ALD has increased rapidly in England over the last three decades. 
Thirty years ago the leading causes of mortality from liver disease were non-alcohol-
related. However, over the past 30 years mortality from alcohol-related cirrhosis has 
overtaken and exceeded deaths from non-alcohol-related liver disease; the mortality 
rate from alcohol-related cirrhosis rose from 1 to 8 per 100,000 deaths between 1975 
to 2000. 2  
 
There are geographical variations in the prevalence of ALD in the UK. In 2005 the 
highest mortality rate from chronic liver disease was in the North West of England for 
both men and women, 18.7 per 100,000 in men and 10.3 per 100,000 in women. Rates 
were lowest in men (8.1 per 100,000) and women (5.1 per 100,000) in the South East 
of England. 27  
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Thus the Association of Public Health Observatories reported that there was an 
emerging north-south divide in mortality rates for chronic liver disease which was 
primarily due to alcohol. It is widely reported that Scotland has the highest rates of 
cirrhosis and alcohol-related deaths in the UK 14 15 and there is concern that if rates 
continue to rise in the North of England they will soon equal those found in Scotland.  
 
Data consistently show that cirrhosis and other alcohol-related mortality is higher 
amongst those in the lower socioeconomic classes. 28 29 Recent trends in alcohol-
related deaths in the UK, illustrate clear differences in mortality rates between the 
least and most deprived areas. 23 For males living in the most deprived areas the rates 
of deaths due to alcohol was more than five times higher than those living in the least 
deprived areas rising, that is 31.9 compared to 6.2 deaths per 100,000. For females 
alcohol-related death rates in the most deprived areas were over three times those in 
the least deprived areas, that is 11.3 compared to 3.7 deaths per 100,000 respectively. 
In both males and females, the North-West of England had the highest alcohol-related 
death rates in the most deprived areas. 28 
 
Few studies have considered variations in ALD by ethnicity. However there is some 
evidence of higher mortality rates from ALD in Black and Asian men with this 
condition compared to White British men. 2 30 In their analysis of mortality from liver 
disease in the West Midlands between 1993 and 2000, Fisher et al 30 found that Asian 
men had a mortality ratio 3.79 times greater than that of white men. This study was 
based on a small sample but the authors concluded that this area was worth further 
study. Indeed demographic analyses of alcohol-related deaths commonly excludes 
ethnicity and this issue needs further investigation.  
 
Recent data for 2001-2005 reported variation in alcohol-related mortality by 
occupation. For males, sea-farers and coal mine operators had the highest standardised 
mortality ratio, while for women, publicans and bar staff had the highest rates, men in 
the alcohol industry also had high rates. 31    
 
People die younger from alcohol-related liver disease compared to non-alcohol related 
liver disease. In 2004, the mean age at death was 53.7 years for men with alcohol-
related liver disease compared to 66.4 years for men with non-alcohol related liver 
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disease. The same data shows that the mean age at death was 54.8 years for women 
with alcohol-related liver disease compared to 65.6 years for women with non-alcohol 
related liver disease. 32  
 
Overall, the mean age of death from liver disease has decreased over the twenty years 
from 1984 – 2005 , falling from 60 years in men in 1984 to 58 years in 2005 and from 
63 years to 61 years in women during the same period. 3 It is likely that the increase in 
deaths from alcohol-related liver disease have brought down this average.  
 
The growing levels of ALD are putting an increasing burden on the National Health 
Service. Hospital Episode Statistics (HES) for England reveal that hospital admissions 
for ALD doubled between 1997/98 and 2004/2005 rising from 17,732 to 35,335. In 
these patients, the average length of stay fell slightly from 8.4 days in 1999/98 to 7.1 
days in 2004/2005 but still remained high. 33  
 
How do people get ALD and can we prevent this? 
 
There is a well established relationship between individuals’ daily alcohol 
consumption and risk of developing liver disease. 34 Drinking above the 
recommended weekly limits advised in the UK results in increased risk of developing 
liver disease. 11 35 
 
A US study found that for men who die between the ages of 35 and 69 years the risk 
of death from liver cirrhosis increases from 5 per 100,000 with no alcohol 
consumption to 41 per 100,000 if drinking 4 or more drinks per day. 28  
 
The pattern of alcohol consumption and the types of alcohol that are consumed are 
important in determining the risk of ALD. A steady pattern of drinking rather than 
binge drinking is more likely to be harmful to the liver. 2 Drinking without food is 
also likely to increase the risk of developing liver disease 36 and some studies have 
shown that drinking wine carries a lower risk of developing liver disease than beer 
and spirits. 37 However, a recent study has challenged this finding and identified 
increases in wine consumption as the main contributing factor to increases in cirrhosis 
mortality in the UK. 38  
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There is also emerging evidence that the majority of people admitted to hospital with 
ALD are not alcohol-dependent drinkers but are heavy drinkers whose social drinking 
has got out of control. 39  
 
The specific risk of liver disease due to heavy drinking is concerning since numerous 
data sources describe a high prevalence of heavy drinking in the UK. Data from the 
General Household Survey (GHS) in 2005 showed that one in four men (24.5%) and 
one in seven women (14.5%) were consuming hazardous or harmful levels of alcohol. 
27
   
 
Hazardous drinking is defined as consumption above recommended limits which 
increases the risk of physical or psychological harm. Harmful drinking is defined by 
the presence of physical or psychological symptoms.  
 
Similarly the Alcohol Needs Assessment Research Project (ANARP) carried out in 
2004 found that 26% of people aged between 16-64 years have an alcohol use 
disorder (AUD), which is equivalent to 8.2 million people in England. 40 In ANARP, 
an AUD included hazardous, harmful or dependent drinking. 
 
The proportion of women drinking at hazardous and harmful levels is particular 
noteworthy as these figures have increased over recent years while heavy drinking in 
men seems to have stabilised. Self reported GHS data showed that the proportion of 
women drinking above recommended limits increased between 1988 and 2002 from 
10% to 16% in women while in men the figure remained around 27% during this 
period. 27    
 
Population studies have consistently found a strong relationship between cirrhosis 
mortality rates and per capita alcohol consumption in the population, see Figure 11. 41 
However, there is a lag in this relationship, thus cirrhosis mortality rates are 
influenced by the alcohol consumption rates of several previous years. 41 42   
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Figure 11. Trends in alcohol consumption per inhabitant 15+ (solid line) and age-
adjusted cirrhosis rates per 100,000 from 1950-1995. (Males ●, Females ◦). 
Source: 41 
 
Despite the greater risk of cirrhosis from heavy drinking, high alcohol consumption is 
not always the full story, since just one in five people drinking at hazardous or 
harmful levels progress to cirrhosis. 2 28 Thus genetic and environmental factors may 
also be important in determining which patients progress from a fatty liver in the first 
instance to fibrosis and cirrhosis thereafter. 43 However, more research is required on 
this issue and particularly to confirm that genetic susceptibility may be more 
pronounced in women compared to men. 43 
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Most studies 35 have found that women are more likely to develop liver disease at 
lower doses of alcohol than men. It has been reported that the risk of developing liver 
disease is significant for women drinking above 7-13 drinks (84-156g) per week and 
in men drinking 14-27 drinks (168-324g) per week. 35 This may be due to the fact that 
women have a lower amount of body water per weight than men, hence blood alcohol 
concentration rises higher and faster because it is dissolved in a smaller volume of 
water. 44 
 
Overlapping risk factors 
However, there are within-sex differences of developing ALD. Recent studies have 
suggested that excess weight 45 or BMI score 46 are independent risk factors for the 
development of ALD.  This combined with women’s higher body fat ratio compared 
to men could be an additional factor influencing their increased susceptibility to ALD. 
 
Individuals with hepatitis C infection who drink over 50/ 60g of alcohol per day have 
an increased risk of developing cirrhosis. 47 48  One explanation given for the 
increasing rates of cirrhosis in UK men while levels of alcohol consumption have 
remained stable over recent years is the increased prevalence of obesity and hepatitis 
C infections in the population. 13  The additional risks for hepatitis C patients that 
consume alcohol within recommended daily limits is currently unclear. 2 48   
 
Prevention 
The most effective preventative measure for alcohol-related liver disease at an 
individual level is not to drink alcohol. Unlike some other alcohol-related illness, such 
as heart disease, ALD does not occur in those people that have never consumed 
alcohol. 34 However, it should be emphasised that not drinking alcohol does not 
prevent individuals from developing liver disease from other causes.   In addition, 
moderate alcohol consumption is known to have coronary protective effects. 49 Thus 
the safest policy recommendation is for individuals to drink within the recommended 
daily or weekly limits. 
 
At a societal level there is evidence from comparative studies that increasing the price 
of alcohol via taxation and restricting the availability of alcohol are effective at 
reducing cirrhosis deaths. 28 50 Methods for restricting the availability of alcohol 
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included increasing the drinking age and reducing the number of outlets selling 
alcohol. 28 It has been concluded that, in populations with a relatively high number of 
heavy drinkers, the most cost-effective interventions to reduce hazardous drinking 
were increased price via taxation and restricted access. 51 Brief alcohol interventions 
delivered in primary care were also highly effective 52 but were considered more 
expensive to implement than the policy options. 51 
 
The first Alcohol Harm Reduction Strategy for England included several strategies 
aimed at reducing the prevalence of heavy drinking in the population including: a 
campaign to promote responsible drinking among young people, a clampdown on 
irresponsible promotion, and extra funding for services for people with alcohol 
problems. 49 However, the evidence relating to educational campaigns is weak and not 
regarded to be cost-effective. 51 53 Also, whilst young people are an important target 
group in terms of future liver disease, the people currently at greatest risk are the adult 
population who may have been drinking heavily for a number of years. The recently 
refreshed Alcohol Strategy 54 has broadened the focus to harmful adult drinkers which 
is a good step in tackling liver disease. Future work could broaden further to 
hazardous drinkers. Although this may be perceived as unpopular, the fact that one in 
five people are hazardous drinkers and one in five people are overweight or obese (it 
is not clear what overlap exists in these figures), brings the issue of liver disease into 
the mainstream population. The prevalence of heavy drinking in obese people and 
vice versa is a clear gap in our current knowledge. 
 
The refreshed alcohol strategy has also proposed an independent national review into 
the relationship between alcohol pricing and promotion and heavy drinking. 54 This is 
a positive development given the international evidence on this issue.  
 
It is increasingly apparent that secondary risk factors of ALD need to be addressed if 
ALD is to be prevented. If firmer evidence confirms the link between genetic factors 
and increased likelihood of developing liver disease, then targeted counselling of 
those with increased risk might be a future option. 55 However, more immediately, 
strategies which aim to reduce obesity may also achieve positive gains in the 
prevention of ALD. It would be very helpful to increase public awareness of the 
possible ‘double hit’ to the liver from excessive weight and heavy drinking. There is 
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also a clear opportunity to link food and drink issues in health promotion work in a 
‘two for the price of one’ approach to achieving health gains in the population. 
 
As ALD does not show symptoms until the most advanced stages, where mortality is 
high, detection of harmful or hazardous drinkers at an early stage in primary care 
settings is a key aim for secondary preventive work. 39 56 There is a growing call for a 
roll-out of screening and brief interventions in England to help reduce hazardous and 
harmful drinking. 54 4 These interventions are supported by robust evidence 52 and are 
known to be cost-effective ways of reducing heavy drinking in health setting. 50  
 
Once ALD develops the most effective form of tertiary prevention, to reduce the risk 
of advancing to a further stage, is to stop drinking. 3 Improving the support provided 
to liver disease patients to remain abstinent and reduce their risk of progressing to a 
more advanced stage is key 4 and there is evidence that nurse-led services are 
effective in supporting this work. 39 57 
 
 
At what stage is liver disease detected?  
 
The symptoms of ALD are slow and silent. ALD is often not detected until the 
advanced stages, with variceal haemorrhage or decompensated liver with ascites, at 
which time the prognosis is poor. 56 Verrill et al. 56 reported that 67% of a sample of 
patients with ALD were not admitted to hospital with an alcohol-related condition 
prior to being diagnosed with liver disease. These authors concluded that primary care 
has the most potential for detecting heavy drinking which puts patients at risk from 
liver disease. Indeed there is evidence that heavy drinkers visit their GP twice as often 
as lighter drinkers 58 59 making primary care the optimal setting for earlier 
identification of heavy drinking and brief intervention.  
 
 A recent small scale American study has shown that alcohol screening questionnaires 
can predict subsequent hospitalizations for alcohol-related GI conditions. 60  
 
Liver function tests have been advocated for use in primary care. 3 4 61 However 1 in 
25 people have abnormal liver function results 4 and there is concern about the 
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accuracy of these tests at identifying liver disease. 62 Thus there is a need for an 
evidence based protocol of work-up, referral and further investigation. 4 
 
Detection or diagnosis of alcohol-related cirrhosis requires liver biopsy or the 
presence of oesophageal varices. 61  These are costly procedures which can carry 
inherent risks. Thus the ideal policy option is to promote earlier identification of risk 
behaviour in the population and brief (and cheap) interventions to reduce excessive 
drinking (and ideally associated risks factors such as weight gain) to achieve a 
reduction in the currently high rates of ALD in England. 
 
 
What happens to patients with ALD? Treatment issues. 
 
The stage of disease that patients present to health services and subsequent alcohol 
consumption are the two most important factors in prognosis of ALD. 43 
 
Alcoholic fatty liver develops in the majority of people that consume heavy amounts 
of alcohol, however if detected early, this first stage of ALD is reversed with 
abstinence. Of those that continue to drink up to 30% develop cirrhosis within 10 
years. 43 
 
Alcoholic hepatitis develops in 10-35% of people that develop fatty liver and does not 
develop until 15-20 years of heavy drinking. 11 The five year prognosis for patients 
that reduce their intake or abstain is almost 80% while for patients that continue to 
drink this decreases to 60%. 43  
 
The levels of mortality in patients with alcoholic hepatitis despite abstinence, have led 
to the development of additional treatments.  Corticosteroids are the main therapy to 
show benefit in some stages of the disease and in some though not all patients. 43  
 
The final stage and irreversible stage of liver disease is cirrhosis. For patients 
developing cirrhosis prognosis varies between those with compensated and 
decompensated stages of the disease. If the cirrhosis is caught when it is compensated 
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average survival is 10 years for decompensated cirrhosis average survival is two years 
or less. 43 
 
Despite cirrhosis taking 10-20 years of drinking heavily to develop 11 anecdotal 
evidence has revealed that in recent years individuals as young as 21 years have died 
from ALD. 
 
Liver transplants are the main treatment option for patients with end-stage liver 
disease 63 although transplants are only suitable for certain patients. Data from the UK 
Transplant 2000 -2002 showed that the greatest proportion (16.4%) of patients listed 
for liver transplants had a diagnosis of ALD. 64  Six months abstinence from alcohol is 
one condition for patients before they will be considered for transplant. This remains 
controversial, as period of abstinence does not reliably predict abstinence afterwards. 
63
 
 
A key concern for ALD patients that have transplants is whether they continue 
drinking post-transplant since this can lead to graft damage or non compliance.  It is 
reported that short and long term survival for patients that have transplantation for 
ALD are similar to those that have other types of liver disease. 63 Furthermore the 
number of patients that return to alcohol consumption after transplant is similar to 
those treated for other conditions. Less than 10% continue drinking more than 21 
units per week 65 and less than 5% damage their graft as a result of alcohol 
consumption. 63 
 
More needs to be done to support ALD patients to remain abstinent for longer post-
transplant. As pathways of care are currently inconsistent it is recommended that 
pathways of care might be best managed through a multidisciplinary approach. 4 The 
British Society of Gastroenterology recently proposed a number of recommendations 
for the care of patients with alcohol-related disorders which included the employment 
of an alcohol health worker who can amongst other factors provide ongoing support to 
patients with alcohol-related liver disease and access to community services. 4 
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Conclusions  
 
The Department of Health needs to recognise the importance of early detection of 
hazardous and harmful drinkers in primary care and the value of brief interventions to 
reduce risky alcohol consumption at the earliest stage when it is most responsive to 
change.  
 
The patterns of drinking that leads to ALD are not confined to ‘stereotypical’ 
dependent drinkers, they are shown by mainstream people who drink heavily. Health 
professionals need to be aware that brief screening questionnaires can identify 
excessive drinking more easily and cheaply than blood tests. 66 A more extensive 
programme of screening for excessive drinking in the population may be required to 
tackle liver disease problems now and in the future.  
 
The key issue is to better understand the inter-relationships between obesity, chronic 
hepatitis infection and heavy drinking in the genesis and progression of liver disease. 
Future health promotion campaigns may need to consider linking the ‘big-hitting’ 
issues of heavy drinking and over-eating if the burden of liver disease is to be reduced 
in England. 
 
Evidence gaps  
 
There is strong evidence about the risk factors associated with ALD. However 
cirrhosis and alcohol-related deaths from all causes are frequently used as proxy 
indicators of ALD. There is a need for specific and up-to-date information about ALD 
including the incidence and prevalence of the different stages of the disease.  
 
This review has found limited information about how or where the different stages of 
ALD are detected. There is a gap in our knowledge about identification and 
management of liver disease in primary care. Better data about how ALD is first 
detected and its stage of development would inform work on developing appropriate 
targeted prevention and detection pathways.  
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We found very little work on heavy drinking in minority groups in England or on the 
experience of people from these population sub-groups who receive treatment for 
liver disease. 
 
We need more work on possible synergistic relationships between alcohol, obesity 
and chronic hepatitis in the development of liver disease.  
 
We found no work on patient perspectives of ALD and experience of treatment. 
Previous work has suggested that a key barrier to tackling liver disease might be poor 
public perception of the types of people who acquire this condition. Given that 
mainstream behaviour such as heavy drinking and over-eating can increase the risk of 
liver disease this should be reversed. Sensitive qualitative research with people 
experiencing liver disease would appear to be a research priority.  
 
There are several small studies reporting the effectiveness of nurse-based and 
multidisciplinary aftercare services in England and Wales for increasing abstinence 
from alcohol after treatment for liver disease.  This evidence-base needs to be 
developed with an emphasis on the effectiveness of treatment services on the 
prognosis of patients with, or recovering from treatment for, ALD.  
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CHRONIC HEPATITIS INFECTION AND LIVER DISEASE. 
 
Globally, chronic viral hepatitis infections account for the majority of liver disease, 
both cirrhosis of the liver and hepatocellular carcinoma (HCC), in nearly all regions 
of the world. 8  
Chronic hepatitis is a complex syndrome with multiple causes, varying stages of 
inflammation and liver damage, different prognoses and responses to treatment. 67 
The major sources of chronic hepatitis are due to infection with hepatitis C and B.  [A 
brief description of the other hepatitis viruses in found in Appendix VI] 
Around 25% of all liver disease cases in the UK are due to hepatitis infections and 
this number is likely to increase in the future. 68   
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LIVER DISEASE DUE TO THE HEPATITIS C VIRUS (HCV) 
 
Hepatitis C is a blood borne virus, which affects 180 million people worldwide. As 
hepatitis C is an RNA virus, it mutates rapidly and therefore the immune system is 
unable to locate and destroy it effectively.  
There are 6 major strains of the virus, known as genotypes 1 to 6. Different strains 
predominate in different parts of the world. The most common viral forms in England 
are genotypes 3a (37%), 1a (32%) and 1b (15%). 47 69 For comparison, the prevalence 
of genotype 1b is 78% in Japan, 68% in Italy and 21% in the USA. 36  
Symptoms of hepatitis C infection include fatigue, pain in the liver area, digestive 
problems, concentration difficulties and flu-like symptoms such as headaches, 
shivering and aching joints. 70 The presence or absence of symptoms is no indication 
of how much damage the virus is doing to the liver, which is why hepatitis C is also 
called 'the silent killer'.  
Approximately 20-50% 71 of those infected with hepatitis C naturally clear the virus 
from their body and experience no long-term affects from the infection.   
A major cause of hepatitis C transmission was via blood transfusion prior to 
September 1991 (when screening was introduced in England) or blood products prior 
to 1986 (when viral inactivation measures were introduced). 72 
 
A global review exploring hepatitis C transmission via blood transfusions reported 
that, after an average of 15 years later, approximately 75% of the adult patients tested 
positive for HCV, and the frequency of liver cirrhosis was 15–20%. 73 More 
favourable outcomes were observed in children and young women. 73 
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Who gets HCV and what are the consequences? 
The exact prevalence of hepatitis C is difficult to establish but current estimates 
suggest that around 200,000 to 500,000 people in the UK are infected with the virus 
(0.4 to 1% of the population), with many cases going undiagnosed. 3 47 74 The recent 
Health Protection Agency annual report stated that 0.5% of the general population 
was affected by the hepatitis C virus.75 These figures equates to every GP having 
around 8 to 18 infected patients on their patient list, based on an average list size of 
1,800. 76  
Due to the asymptomatic nature of the infection, the prevalence of HCV in children in 
the UK is unknown. 77 Between 1997 and 1998, the British Paediatric Surveillance 
Unit identified 182 infected children, most of whom were infected through blood 
products. However, it is now likely that most infected children are born to HCV 
positive mothers. It is estimated that 1150 pregnancies annually in the UK involve  a 
woman infected with HCV, leading to approximately 70 infected babies being born 
each year.77 Transmission from mother to baby is almost always confined to women 
who have detectable HCV RNA.  
At present, only 50,000 patients have been diagnosed with chronic hepatitis C in the 
UK, meaning that up to eight out of ten cases have no idea they are infected. 78 Under 
diagnosis and subsequently under reporting are well documented problems with 
hepatitis C infection. Thus it is difficult to accurately plan treatment services since 
planning data are mostly educated estimates. 69 79  
Compared to other countries (see Figure 12), the prevalence of hepatitis C infections 
in the UK is low; 4.1 million people in the USA (1.6% of the population) 80 and 6.7 
million Europeans suffer from chronic hepatitis C infection (0.9% of the population). 
81
. However, it is difficult to establish if the UK rate is genuinely lower than in other 
countries or if we are less adept at identifying cases (see above). 
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Figure 12. The prevalence rates of hepatitis C in the England in comparison to 
the rest of the UK and Europe. 1  
The incidence of hepatitis C in the USA has declined in all ages and ethnic groups 
since the mid 1990s after a peak in the late 1980s.82 This decline is primarily due to a 
decrease in cases amongst injecting drug users (IDUs), as a result of harm reduction 
strategies within this high risk group. However, even though the number of new cases 
has declined, a substantial burden of chronic hepatitis C persists. 80   
It is difficult to quantify the incidence of hepatitis C infections since the number of 
reported cases reflects the number of individuals being tested, rather than the actual 
incidence of disease. Furthermore, in the majority of identified cases the infection 
may have been contracted many years previously as there are no laboratory assays to 
detect acute infections. 69  
 
Many people with hepatitis C are unaware that they have this infection and some live 
out their normal lifespan with no symptoms. This absence of physical symptoms also 
contributes enormously to the lack of detection of the disease. However, around 20% 
of people living with chronic hepatitis C infection will develop cirrhosis some 20 or 
30 years after contracting the virus. 15  
 
Recent analysis of around 50,000 laboratory-confirmed diagnoses of hepatitis C in 
England, demonstrated that 69% of cases were males and 53% were aged between 25 
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and 39 (see Figure 12).69 Thus hepatitis C affects relatively young people. However, it 
must be noted that laboratory diagnosis of hepatitis C predominantly occurs in current 
or former IDU’s.  
 
 
Figure 12. Age and sex distribution of laboratory reports of hepatitis C infection 
from England: 1996 to 2005.69 
 
This age-trend is seen in the USA where the greatest incidence of hepatitis C was in 
the 25 to 39 age group. Interestingly however, this group has seen the greatest decline 
in rates since the mid-1990s; it has been found that since 1992 the incidence rate has 
declined by 92%. 82 
 
There are gender variations in the prevalence, treatment and response to hepatitis C.  
Hepatitis C is less common in women and they tend to develop a more benign course 
of liver disease compared to men as they are more likely to have an enhanced 
response to interferon treatment. 48 However, women are more sensitive to the 
hepatotoxic effects of alcohol, a co-risk factor for liver disease. 48  
    
Hepatitis C also exhibits geographical variation (see Table 2), with an apparent 
East/West divide. The highest number of cases are reported in the North West and 
South West and the lowest numbers in the North East, Yorkshire and East Midlands. 1 
69
 Incident rates of hepatitis C and B are associated with deprivation, poverty and 
level of education; thus socio-economic status is also a contributing risk factor. 1 80  
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Table 2. Laboratory reports of hepatitis C infection by English region:1992 to 
2005. Source: 69 
 
 
In terms specific ethnic groups, a study conducted in the USA concluded that 
incidence rates were similar across ethnic/racial populations (see figure 13).82 This 
finding was in contract to previous findings in the 1990s. 82  
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Figure 13. Incidence* of acute hepatitis C, by race/ ethnicity and year – United 
States, 1992-2005†  Source: 82 
 
Recently funded case finding work has begun to explore hepatitis C infections in 
ethnic minority populations living in East & West London, Walsall and Bradford. 69 
The results of this project will better advise the incidence rates and subsequent needs 
of cultural minority groups in England.   
 
Statistical modelling of the prevalence of HCV antibodies in England and Wales 
(combining a variety of data sources from 1995 to 2003) reported that 231,000 people 
within the ages of 15-59 were predicted to have HCV antibodies in 2003. 83 This 
predicted figure gave a prevalence rate of 0.53% in this age group and a ratio of 
infected males to females of 2.4 : 1. 
 
This statistical modelling was unable to estimate an overall population prevalence due 
to the lack of data for the over 60s population. 83 This statistical model should be 
updated and refined as new information becomes available.  
 
Liver disease – A rapid review of epidemiology, treatment and service provision 
 
44 
About a third (31%) of chronic hepatitis C infections are in current IDUs, 57% are in 
ex-IDUs and 12% are in the non-IDU population i.e. contracted through infected 
blood/blood products transfusions and sexual transmission particularly men who have 
sex with men (MSM) and those with multiple sex partners. 69 83  
 
The prevalence of former IDUs in the UK is estimated at around 0.22%-0.8% of the 
general population, though many analysts think this is an underestimation. 47  Due to 
the illicit and thus hidden nature of IDU, this population is difficult to study. 
Historical trends in the size and pattern of IDUs have significantly affected the 
number of people infected with hepatitis C. Therefore, modification of future injecting 
patterns may have the potential to produce major changes in the overall prevalence of 
hepatitis C.  
 
However, there is evidence to suggest that incident rates of hepatitis C amongst IDUs 
may be rising; studies from abroad have suggested that 10% of current drug users may 
be infected every year. 84 In addition, there was a noticeable increase in IDU in the 
UK during the 1960s to 1980’s. Given the prolonged incubation period for hepatitis C 
and the time-lag in the development of liver disease, it is possible that the full 
ramification of this activity may only come to notice over the next decade.   
 
How did they get HCV and can we prevent this? 
HCV is transmitted by blood-to-blood contact: via blood transfusions (before 1991); 
by sharing equipment and paraphernalia for injecting or snorting drugs; by medical or 
dental treatments with inadequate sterilisation; by sharing razors or toothbrushes that 
come into contact with broken skin (in both people); by tattooing, piercing or 
cosmetic treatments performed with unsterile equipment; or from mother to baby at 
birth. 69 
Data collected from 1996 to 2005 demonstrated that only 23% of laboratory reports 
confirming hepatitis C infection included risk factor information. From this 
information it was shown that the single most important risk factor was injecting drug 
use (92% of all cases). 69 Other risk factors were rare, but were listed in descending 
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order as, transfusion, blood product recipient, sexual exposure, renal failure, mother to 
baby, occupational and other unknown.69  
 
The introduction of mass screening for all blood and blood products by the National 
Blood Donor Service vastly reduced the risk of cross-contamination through blood/ 
blood product transfusions infected with HCV, within the UK. The numbers of new 
blood donors who are hepatitis C positive continues to decline since the introduction 
of blood donor screening in 1991, 28 per 100,000 of new donors were detected whilst 
1 per 100,000 of repeat donors tested positive for the virus. 69 This trend is further 
evidence of the low incident rate of HCV in blood donors, confirming the reality that 
they are fundamentally a low-risk population.   
 
Since the implementation of screening all blood donors for hepatitis C (1991) the 
main risk groups are past and present injecting drug users. It is well recognised that 
these groups are notoriously difficult to reach through health care services. 85  
 
The effectiveness and cost effectiveness of testing for hepatitis C in former injecting 
drug users in a variety of settings has been evaluated. 47 86 On the basis that NHS 
commissioners currently view £30,000 per quality adjusted life year (QALY) an 
acceptable return on investment, there is a 74% probability that case-finding for 
hepatitis C would be cost effective. Case-finding for HCV is likely to result in an 
additional life-year for an investment of £20,084 (£16,514 per QALY). 47 Future 
development in HCV treatment to inhibit disease progression is likely to significantly 
improve the cost effectiveness of case-finding for HCV. 
The issue of proactive case finding for hepatitis C in primary care has been explored 
using a cost-utility modelling approach. 74 This study reported a 75% probability that 
such initiatives would be cost effectiveness in primary care. 74 A recent intiative, the 
Sentinel Surveillance scheme gives individuals the opportunity to access testing via 
their GP Surgeries and, although there has been limited uptake of the scheme, around 
9,000 tests were performed in 2006. 79 69 79A recent paper exploring the sentinel 
laboratory surveillance of hepatitis C antibody testing in England concluded that these 
data provide valuable supplementary data to national surveillance. 87 In addition, it 
has been proposed that testing for the hepatitis C virus among prisoners as part of an 
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active case finding campaign would also be beneficial, given that the last extensive 
study of the prevalence of hepatitis B and C in the prison population was conducted  
between 1997-98.88 
 
Overlapping risk factors 
Co-factors influencing the progression of hepatitis C to chronic liver disease include 
alcohol abuse, the age at which the infection was acquired, duration of the infection, 
overweight, male sex and co-infection with hepatitis A, B or HIV. 3 It has also been 
stated that heavy alcohol consumption, diabetes and viral hepatitis exert independent 
and synergistic effects on the risk of developing HCC in the USA. 89 
 
In people with hepatitis C, alcohol consumption over 50-60g/day has been associated 
with a 60% increase in risk of cirrhosis. 48 Thus moderating alcohol consumption in 
people with liver disease due to HCV would be beneficial. In addition, 40% of IDUs 
are thought to have high alcohol intake in addition to their drug use.47 Thus alcohol 
risk reduction would be beneficial in this high-risk group. 
There has been a suggestion of a link between hepatitis C and Non-alcoholic Fatty 
Liver Disease (NAFLD), as these conditions co-exist more frequently than would be 
expected by chance.90-92 A prospective study concluded that patients with chronic 
hepatitis C and Non-alcoholic steatohepatitis (NASH) differ significantly from those 
with this virus and fatty changes (steatosis), and those with HCV alone in terms of 
biological and metabolic factors and more advanced liver cell damage.91  
It has also been suggested that genotype 3 form of the hepatitis virus and a high BMI 
may interact to cause steatosis in patients with hepatitis C. 90 This possible linkage 
between hepatitis C infection and metabolic causes of liver disease, including NASH, 
need to be explored in more detail. 91  
Prevention 
The FaCe-It campaign, launched nationally in December 2004, aimed to raise public 
awareness of hepatitis C; its prevention, diagnosis and treatment in support of the 
Government’s Hepatitis C Action Plan for England .78 FaCE-It also aimed to raise 
professional awareness of hepatitis C by encouraging the provision of advice about 
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the risks of hepatitis C infection, and testing to individuals at risk.78 The FaCe It 
exhibition had a potential audience of 16 million people and more than 1.2 million 
leaflets were distributed. 69 The impact of this 3 year campaign has recently been 
evaluated, which demonstrated that public awareness of the disease increased from 
15% to 29%, whilst testing for hepatitis C by Primary Health Care professionals had 
increased by 60% since 2002. 93The campaign also proved to be a useful resource as 
over a quarter of a million people accessed the website. 93    
Other health promotion campaigns include World Hepatitis Awareness Day, the 1st 
October and ‘What not to share’, a Hepatitis C Trust campaign which has received 
celebrity endorsement.    
There is currently no vaccination for hepatitis C due mainly to the complexity of the 
virus and the rapid rate at which the virus can mutate. However encouragingly, two 
pharmaceutical companies have recently announced promising results from the early 
phases of small drug trials. This ongoing development of Vertex VX-950 and AVI- 
4065 NEUGENE signifies a possible new approach to tackling the hepatitis C disease 
for the future.94 95   
Currently however, the primary aim in controlling HCV is to prevent exposure to the 
infection in first instance, whilst the secondary emphasis for preventing hepatitis 
induced liver disease is focused on early detection followed by anti-viral treatment.  
The National Screening Committee and National Institute for Health and Clinical 
Excellence (NICE) have not recommended an antenatal screening programme as there 
is still insufficient evidence regarding effective interventions to prevent mother-to-
baby transmission. 
 
Thus early identification of hepatitis C infection is important to improve outcomes 
from this condition and for broader public health. Early diagnosis increases the 
probability of successful treatment for hepatitis C (see below) and also the impact of 
positive lifestyle changes can limit cross-infection in the population. 3 96 
 
An Italian survey 97 examined the impact of a hepatitis C diagnosis on patients’ 
lifestyle and concluded that most drinkers (74%) modified their alcohol consumption 
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whilst a minority of smokers (21%) modified their habits. These changes were long-
lasting as the time period between diagnosis and the survey was 5 years. Thus early 
detection of hepatitis C can generate positive changes in behaviour which can 
ameliorate the effects of the infection. 
 
At what stage is liver disease from HCV detected? 
 
Chronic hepatitis C infection is often asymptomatic until liver failure becomes 
apparent. The rate of progression to cirrhosis is unpredictable but usually slow, with 
decades elapsing between infection and the development of serious complications. 
 
Screening tests for hepatitis C infections use Enzyme Linked Immunosorbent Assays 
(ELISA). Antibody tests cannot reliability diagnose acute hepatitis C as the incubation 
period of acute hepatitis C is usually between 6 and 9 weeks, with specific antibodies 
only present after 3 months from infection, and in some cases it may take up to 6 
months before antibody is detected.  98 Also hepatitis C antibodies usually appear 
relatively late in the course of infection, which causes false negative results. Finally, 
there are currently no laboratory tests which differentiate between acute or chronic or 
resolved presentations of the virus.  
 
Thus HCV antibody tests can only detect if exposure to HCV has occurred in patients, 
they cannot determine if patients are still exposed to the virus or if it has resolved 
naturally. HCV RNA tests are needed to identify whether the virus itself is in the 
blood stream. This test may also be used after treatment to see if the virus has been 
eliminated from the body.   
 
The timely management of acute hepatitis C infections is imperative as there is strong 
evidence to suggest that the rate of chronicity is reduced from 80% to 50% in those 
who have received interferon treatment. 98    
 
In the UK there are 4 clinical specialities that deal with hepatitis C; Gastroenterology 
(GI), Genito-Urinary Medicine (GUM), Hepatology and Infectious Disease 
Specialists (ID). Diagnostic and treatment pathways for patients with hepatitis C in 
these different departments are unclear. A study conducted by Parkes et al. 85 found 
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that over half of the patients who were referred to a comprehensive service provider 
(CSP) had been previously diagnosed with hepatitis C; 41% came from Primary Care, 
24% from drug and alcohol services, 14% from Prisons and 14% from GUM 
physicians.  
Since many IDU’s spend a period of time in prison, it is an extremely important 
opportunity to target this high risk population. 99  
Screening for HCV in prisons has been explored and the uptake of testing found to be 
very low due to personal and institutional factors. 99 Encouragingly, prisoners were 
reasonably familiar with harm minimisation strategies, such as needle and other 
paraphernalia exchanges, and had utilised these facilities in the community. 99  
Some innovative health promotion programmes are currently underway in the English 
prison service including: the development of the Music4Messages CD with specially 
commissioned ‘rap’ music and a discussion of health issue which provides primary 
prevention information to juveniles and young offenders on the risks of Hepatitis C; 
and an educational DVD, called Hepatitis C: Inside and Out, produced by Offender 
Health in collaboration with Munro and Forster (a media Company who worked on 
the national FaCe It campaign). These initiatives are attempting to address the need to 
improve health promotion activity in prisons and, in particular, to reduce the stigma 
associated with hepatitis C infection and treatment options.  
 
What happens to people with HCV liver disease? Treatment issues  
 
Treatments for hepatitis C are expensive but have success rates now around 50% for 
genotype 1 and 80% for genotypes 2 and 3. 78 For 55% of patients with varying 
genotypes who have moderate to severe hepatitis, the combination therapy of 
pegylated interferon and ribavirin is successful in clearing the infection, leaving no 
detectable virus in the blood 6 months after treatment. The issue of whether the 
infection with genotype 1b carries a worse prognosis than other genotypes due to 
lower responsiveness to interferon treatment remains unclear. 36 However, recent 
findings suggest that independent risk factors associated with end-stage liver disease 
included HCV genotype 1, alcohol abuse and HIV co-infection. 100 
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The duration of treatment is usually 6 months for patients with genotype 2 and 3, and 
12 months for genotype 1. Current NICE guidance acknowledges the fact that the 
duration of treatment will vary depending on individual case factors such as: the 
specific drug; viral genotype; initial viral load; response to treatment; and treatment 
regime.  
 
Drug treatments are associated with significant side effects. Thus if patients default or 
if they are unresponsive to treatment, they can progress to liver cirrhosis and/or liver 
cancer with many needing a liver transplant. Approximately 20-40% of all liver 
transplants performed in Europe and the USA are due to cirrhosis caused by chronic 
hepatitis C. 101 However, in England, about 15% of liver transplants are due to liver 
damage caused by the hepatitis C. 72  
Although fulminant or acute liver failure associated with hepatitis C infection is rare, 
the co-occurrence of hepatitis C with another chronic liver condition (e.g. chronic 
hepatitis B) may act synergistically and precipitate liver failure. In patients with 
chronic hepatitis C, who develop cirrhosis, approximately 1-4% progress to 
Hepatocellular Carcinoma (HCC). The development of HCC is rare in patients with 
chronic hepatitis C who do not have cirrhosis. 
At present the most effective treatment for hepatitis C involves viral eradication 
therapy through the use of a combination of anti-viral agents, which is supported by 
NICE guidance published in 2004 for patients with moderate to severe chronic 
hepatitis C. In addition, NICE have since conducted a review on treatment guidance 
aimed at patients with mild chronic forms of the virus, which has been published as an 
extension to the original document (2006).  
 
NICE guidance state that combination therapy, comprising peginterferon alfa-2a and 
ribavirin or peginterferon alfa-2b and ribavirin, is recommended for the treatment of 
mild chronic hepatitis C. Monotherapy with peginterferon alfa-2a or peginterferon 
alfa-2b is also recommended for the treatment of mild chronic hepatitis C in people 
who are unable to tolerate ribavirin, or for whom ribavirin is contraindicated. 
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 In general, the treatment modality of interferon -∞ and ribravirin has also been 
proven to be cost-effective, except for patients aged over 65 with genotype 1 strain of 
the virus. 101  
 
Due to current under-diagnosis, it is estimated that only 1-2% of those infected with 
hepatitis C are currently receiving NICE recommended therapy. 76  
 
Furthermore, not all patients diagnosed with HCV are able to undergo anti-viral 
treatment. Recent work found that in newly diagnosed hepatitis C patients only 10-
24% were eligible for the anti-viral drug treatment. 85 Eligibility criteria include age, 
gender, genotype, severity of hepatitis and co-morbidities e.g. (current/future 
drug/alcohol abuse).  
 
Many factors can increase the progression of liver disease as well as decrease the 
response to interferon treatment, for example alcohol misuse. 48 The most important 
single reason reported for ineligibility was ongoing illicit drug use. 85 However, recent 
US work concluded that a history of injecting drug use was not negatively associated 
with HCV treatment candidacy or outcomes. 102  Thus former IDU patients should be 
assessed on a case-by-case basis for HCV treatment.  
 
There is no licensed treatment for children with HCV infection. Strategies have 
followed those in adults. Combination therapy of ribavirin and inferferon has reported 
better responses than interferon monotherapy. However side effects have been found 
to be common and sometimes severe. A multicentre European Study of combination 
therapy in children is currently in progress. 77   
 
Cirrhosis due to chronic hepatitis C is the most common indicator for liver 
transplantation in the western world. 94 103 However, recurrence of the disease is 
virtually universal and current research focuses on factors which determine the pattern 
and severity of recurrence.103  
 
The management of patients with chronic hepatitis C who fail to respond to antiviral 
treatments is a key issue which has lead to exploration of new therapies for HCV. The 
main developments concentrate on the orally available anti-viral agent, Vx-950 which 
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is known as telaprevir. 94  Findings have shown that telaprevir and in combination 
with peginterferon results in a continuing decline of viral levels and thus the two 2 
agents perform a potentially synergistic elimination of the infection. 94 Preliminary 
results have suggested that the most effective treatment regime may be a short course 
of telaprevir followed by the combination of peginterferon and ribavirin as 70% of 
patients had no detectable virus after 12 weeks compared to 39% with the current 
conventional therapy. 94 
 
 
Conclusions 
 
With an increasing incidence of hepatitis C it is predicted that the future burden on 
healthcare services from consequent liver disease will increase by 60% by 2008. This 
equates to a five-fold increased demand for liver transplantation. 1 
 
Inequity of health care provision for hepatitis C may occur at all stages of the patient 
pathway. 85 Thus there should be an expansion of services, particularly in key 
geographical locations such as the West of England, to facilitate an increased uptake 
and comparable service delivery throughout the UK.  
 
The majority of hepatitis C positive patients in the UK are not receiving anti-viral 
treatment, which contrasts greatly with situation in Europe. This should be addressed. 
 
At present, there is not extensive screening for hepatitis C in England, other than in 
the blood donor programme. 85 France and Germany amongst others have more robust 
screening programmes to detect early stage hepatitis C. Increasing opportunities for 
hepatitis C screening should be considered, if not in the mainstream population then 
this should occur routinely in prisons. 
 
A recent review found that just 8% of PCTs had effectively implemented the National 
Action plan for hepatitis C ; 56% had partially implemented it and 36% had 
minimally implemented it. 104 In addition, 46% of hospitals reported significant delays 
in hepatitis C treatment. 104 Thus there needs to be more encouragement of such work 
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in primary and secondary care; including performance monitoring of this activity in 
necessary.  
 
A number of authors have reported the need to construct a comprehensive 
computerised IM&T strategy as a matter of urgency. 5 4 The development of a 
nationally-recognised database would enable evaluation of clinical data (sporadically 
collected at present) from which epidemiological trends and future treatment 
recommendations could be made. 
 
Evidence gaps 
There is currently no vaccine for hepatitis C. The work into the development of a 
vaccine should continue.  
 
More research is required on the experiences of people with hepatitis C, from 
detection through to treatment. The perception that hepatitis C is only experienced by 
particular subgroups (e.g. IDU groups) perpetuates unsympathetic attitudes to this 
condition which acts as a barrier to the uptake of health education work.   
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LIVER DISEASE FROM THE HEPATITIS B VIRUS (HBV) 
 
Who gets liver disease from HBV and what are the consequences? 
 
Hepatitis B accounts for about a fifth of the reported cases of chronic hepatitis 
infections in UK. 1 
 
The prevalence of hepatitis B in the UK has been reported as 0.1% of the population 
i.e. approximately 60,000 people. 1 However, a Department of Health strategy 
document on infectious diseases suggested that 180,000 people in the UK may have 
chronic hepatitis B. 105 The most recent prevalence estimate from the Hepatitis B 
Foundation is 325,000 individuals. 106 Given this wide range of prevalence estimates 
from different agencies, there is an urgent need for clarity on this matter.  
 
Although HBV infection in children is low, infection during childhood contributes to 
an estimated 20–65% of new chronic infections (this wide range is due to different 
prevalence rates in different ethnic groups). The number of infections in children in 
England and Wales between 1995 and 2000 was 13 per year, 75 overall. Childhood 
infection contributed to 2% of all laboratory reports, and to an estimated 21% of all 
new chronic infections. Among South Asians, infections in infants were much more 
common, contributing to 65% of new chronic infections. 107 
 
Of those people chronically infected with HBV approximately 15% to 40% will 
develop cirrhosis, liver failure, or hepatocellular carcinoma. 108 109 Chronic hepatitis B 
infection is defined as the persistence of hepatitis B antibodies (HBsAg) in the blood 
serum for six months or longer. 109 
 
Internationally, it is estimated that approximately 400 million people are infected with 
HBV worldwide,110 with around 1 million people in Europe becoming infected with 
the virus every year . Globally, hepatitis B is the leading cause of cirrhosis 111 and is 
the ninth most common cause of death, killing around 2 million people each year. In 
the USA, it is estimated that around 1.25 million people are affected by the virus at a 
cost of $700 million annually. 112 
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Hepatitis B is most common in the Far East, the Middle East, Africa and southern 
Europe. The World Health Organisation regards hepatitis B infection in China as 
endemic. 113 Around 130 million people in China are carriers of HBV (almost a third 
of the people infected with HBV worldwide); 30 million people in the country are 
chronically infected.110 The World Health Organisation categorised countries relating 
to the prevalence of hepatitis B which is based on the prevalence of HBsAg into high 
(more than 8%), intermediate (2 to 8%) and low (less than 2%) infection-rate 
countries. 109 Currently, England is a low infection-rate country. 
 
There is a variation in the geographical prevalence of hepatitis B in England; inner 
cities have a higher rate of infection than their rural counterparts. The prevalence of 
hepatitis B in the UK is also greatly affected by the settlement of legal immigrant 
populations into England, from countries with high or intermediate prevalence of the 
virus. 3For example, London has one of the lowest average rates of alcohol 
consumption yet liver disease mortality is one of the highest in England, due 
predominately to virally induced liver disease deaths. Furthermore, incident rates of 
both hepatitis B and C are linked to deprivation and poverty; thus socio-economic 
status is also a contributing risk factor for chronic hepatitis. 1  
 
The incidence of hepatitis B in the UK has been falling since the mid 80s, which 
coincided with the introduction of vaccination in high risk groups such as drug users 
and healthcare workers. Furthermore, in the USA, progress has been made to reduce 
the racial/ethnic disparities in hepatitis B rates.82 Historically in the USA, Asians and 
Pacific Islanders had disproportionately higher rates of hepatitis B and this disparity 
has declined with the successful implementation of routine hepatitis B vaccination in 
infancy.82 However, although Hispanic rates have declined in recent years they still 
remain more than two-fold higher than those amongst other racial/ethnic groups in the 
United States.82 
 
HBV is only transmitted through exposure to the blood or body fluids of an infected 
person. 82 In the England, the people most at risk of contracting hepatitis B are IDUs, 
people who have unprotected sex with different partners, close family members of 
someone with the infection, babies born to infected mothers and travellers to high-risk 
countries who come into contact with infected blood and other bodily fluids. 109  
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It is a common misconception that the hepatitis viruses are only caught by drug users. 
This stigma prevents diagnosis and treatment of existing cases. Better education and 
health promotion messages are needed to overcome this view. 3 
Hepatitis B is an occupational hazard for health workers and emergency responders 
due to exposure to trauma, needle-stick and other injuries. 109 Social contact carries no 
risk of infection and good hygiene procedures easily eliminate the virus on external 
surfaces. Thus clothing contaminated with the virus can be put through a normal hot 
wash in a washing machine to kill the virus. Similarly, washing-up liquid and hot 
water is effective for plates and cutlery. 
Surveillance in the USA found that HBV rates vary with age, consistently 25 to 44 
year olds had the highest rates (approx 3.6 per 100,000) whilst under 15 year olds had 
the lowest rates (approx 0.03 per 100,000).82 There are also gender differences, the 
incidence in males is 1.6 times greater than in females. 82 In the USA, this gender 
divide is increasing. 82    
The incidence of hepatitis B varies across ethnic groups (see figure 14). In the USA, 
non-Hispanic blacks have the highest incidence rates at 2.9 per 100,000 compared to 
non-Hispanic whites with rates of approximately 1.1 per 100,000. 82  At present, there 
is a study being conducted exploring the prevalence of hepatitis B in South Asian 
communities living in the UK. 69 
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Figure 14. Incidence* of acute hepatitis B by race/ethnicity, and year – USA 
1990-2005. 82  
 
How do people get HBV and can we prevent this? 
 
In areas of the world where HBV is endemic (e.g. sub-Saharan Africa, Pacific regions 
and Asia) or in areas where incidence rates are high (e.g. Southern parts of Eastern 
and Central Europe and the Middle East) the majority of individuals become infected 
during childhood. However, in Western and Northern Europe and North America 
where the prevalence of hepatitis B is relatively low, the virus is acquired primarily 
during adulthood. 114 
 
The age at which infection is acquired is also a major risk factor of the virus 
developing into chronic hepatitis B infection.109 
 
It has been estimated that around 6400 cases of chronic hepatitis B arrive in the UK 
annually as a result of legal immigration from countries with a higher prevalence of 
hepatitis B. 3 Consequently, in UK regions where there are high levels of immigration, 
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prevalence of hepatitis B is higher than the general prevalence rate of 0.1% of the 
population; some areas have a prevalence of 2% of the population.1  
 
Overlapping risk factors 
It has been suggested that co-morbidity with other risk factors, such as alcohol abuse, 
male gender, obesity, age at which the infection is acquired and any co-infection with 
hepatitis A or C, can increase the risk of hepatitis B progressing to chronic liver 
disease. 109 However, is an evidence gap on whether the source of the contracted 
infection effects the progression to liver disease. Furthermore, there is no conclusive 
evidence on disease progression when more than one risk factor is present. 
 
Prevention 
Compared to the high prevalence of HBV imported into the UK by migrant 
communities, chronic cases of hepatitis B arising from acute infection acquired in the 
UK by the resident population is approximately 250 cases annually. 3 Thus mass 
infant immunisation would only prevent this small number of cases, consequently a 
policy of selective immunisation was adopted. 115  
 
Most studies of mass immunisation in children and high risk groups have not been 
applicable to the UK context so it is difficult to draw conclusions on the cost-
effectiveness of such strategies in England. 3 Thus, the UK remains one of a minority 
of developed countries not to implement universal neonatal hepatitis B vaccination. 
116
 Preliminary work has estimated a cost of hepatitis B to the NHS as between £26m-
£375m, with total societal costs ranging up to £429m.117 The forecasted cost of 
implementing an infant immunisation programme in the UK, which could potentially 
be added to the routine childhood vaccination programme currently in place, is 
approximately £10.4m.117 At face value, these figures suggest that an infant 
immunisation programme could produce costs savings. However, evaluating the cost-
effectiveness of a universal vaccination programme is extremely complex with many 
variables and differing perspectives to consider. Hence more rigorous economic 
evaluation is required in this area. 
 
Due to mounting international evidence on immunisation, the BMA has recently 
endorsed the suggestion of universal vaccination for hepatitis B in the UK.118 The 
Liver disease – A rapid review of epidemiology, treatment and service provision 
 
59 
basis of this recommendation was the growing financial burden the disease puts on the 
NHS and an escalating risk of exposure to the UK population due to increased foreign 
travel and migration from overseas. 118 Furthermore, as age of infection is a major risk 
factor for developing chronic hepatitis, the importance of childhood prevention 
programmes to limit the severity of the disease has been reinforced.  
 
The USA has used a safe and effective vaccination for hepatitis B since 1981. 82 
Vaccination for hepatitis B in the UK is available on request to high risk groups (e.g. 
health workers, those travelling to high risk countries, men who have sex with men, 
current or former injecting drug users and prisoners.). Vaccination is delivered within 
GP surgeries, acute hospitals or high street travel clinics.  
 
The use of a combination vaccination combating hepatitis A and B has been proposed 
in high-risk groups, studies have concluded that a combination vaccine can reduce 
mortality, morbidity and costs associated with treating infections. 3 No guidance has 
been published to date for the proposed use of the combination vaccine in the UK.109   
 
Infants born to mothers known to carry HBV can be treated with antibodies to this 
virus. 15 If this vaccine is given within 12 hours of birth, the risk of acquiring hepatitis 
B is reduced by 95%. This treatment also allows a mother to safely breastfeed her 
child. Thus the family and other household members of someone with hepatitis B 
should be vaccinated. 
 
Whilst the debate about mass immunisation in childhood continues, the best 
preventive strategy for England is to avoid new cases of infection by focusing on 
increasing awareness and promoting positive behavioural change in high-risk groups. 
 
At what stage is HBV liver disease detected? Treatment issues. 
 
The majority of people infected with HBV do not need specific treatment, other than 
rest, and they eventually make a full recovery. This is because hepatitis B can cause 
an acute illness that resolves quickly without causing long-term liver damage; up to 
95% of adults clear the infection spontaneously without treatment. However, hepatitis 
B can also cause chronic illness that lasts more than six months or more with ongoing 
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symptoms. Nevertheless less than 10% adults who contract hepatitis B progress to 
chronic liver infection. 11 The incubation period for hepatitis B ranges from 40 to 160 
days, with an average of 60 to 90 days. 109 
 
US surveillance in 2005 reported that of hospital patients infected with hepatitis B, 
77% presented with jaundice, 40% were hospitalised and 1% died. 82 However, in 
England it has been reported that jaundice only occurs in about 10% of younger 
children and in 30 to 50% of adults.109 
 
NICE guidance published in 2006 on chronic hepatitis B outlined the most effective 
treatment options. However, these treatments do not relate to patients co-infected with 
hepatitis C, hepatitis D or HIV.  Unlike the treatment for hepatitis C, treatment for 
hepatitis B takes longer as it suppresses the virus rather than eliminates it. 
 
Treatment with interferon or peginterferon alfa 2-a is used in the first instance. NICE 
guidelines also recommend Adefovir dipivoxil as another option for adults with 
chronic hepatitis B. 119 In addition, the guidance states that Adefovir dipivoxil could 
also be used in combination with Lamivudine, but it is implicit that it should not be 
given before treatment with Lamivudine. At present, none of these drugs clear the 
infection completely but rather they stop the virus from replicating, and so prevent 
further liver damage such as cirrhosis and/or liver cancer. 
 
Treatment options for children also include Interferon, Lamivudine and Adefovir 
dipivoxil, although it is stated that the long term effectiveness and side effects of these 
treatments need further investigation. No trials are yet underway to investigate 
pegylated interferon in children. 120 
 
Drug resistance in the treatment of hepatitis B presents a serious problem to providing 
effective long-term treatment against the viral disease. It has been demonstrated that 
only 30-40% of white adults have a sustained response to interferon alfa treatment, 
and poorer response rates are seen in Asian patients. 121 This lack of performance has 
led to the exploration and development of antiviral agents, such as lamivudine and 
adefovir, as an alternative treatment option. 116 However, resistance to antiviral 
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monotherapy predictably presents a similar obstacle and work is now ongoing to 
evaluate the effectiveness of combination therapy in the fight against hepatitis B. 121  
 
Combined therapies capable of producing a sustained response against the hepatitis B 
are still not entirely proven, and they have yet to achieve the dramatic benefits such 
treatments have produced against other infections such as HIV, hepatitis C and 
tuberculosis. 122 Recently published results from a clinical trial comparing the 
antiviral efficacy of telbivudine and adefovir and the effects of switching treatments 
demonstrated that telbivudine achieved a more consistent HBV DNA suppression. 123 
This is encouraging, but more work is needed in this field.   
 
The cost effectiveness of the various treatments combinations for adults have been 
explored by a number of studies. 111 112 124 One of the most recent studies concluded 
that both Entecavir and Adefovir treatment methods are cost effective for patients 
with hepatitis B induced cirrhosis, however, selecting which treatment to use is highly 
dependant on available budgets. 111  
 
A systematic review exploring the cost-effectiveness of adefovir, dipivoxil and 
pegylated interferon alfa-2a stated that the in most cases treatments induced a 
remission of HBV and offered protection from the risk of progression to cirrhosis, 
HCC and liver transplant.124  However, some cases did not respond to the treatment or 
suffered a relapse and in these instances another treatment modality was suggested, 
occurring obvious cost implications. 124  
 
The conclusion on the cost-effectiveness of treatment for hepatitis B is that more 
evidence is required to develop comprehensive guidance on the effectiveness of anti-
viral treatments in specific sub-groups such as patients with cirrhosis, different 
genotypes, different ethnic groups and those with co-infections and /or co-morbidities. 
124
   
 
Conclusions 
 
We should improve immunisation of high-risk groups for HBV as outlined by the 
Chief Medical Office for England in 2001.15 We recognise current UK policy to offer 
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all pregnant women screening for hepatitis B to allow babies born to infected mothers 
to be immunised soon after birth. This primary prevention protects infants from 
becoming chronic carriers of the virus and developing hepatitis induced cirrhosis in 
the future.15 However, more could be done to increase the uptake of the complete 
course of vaccine to ensure immunity among babies born to infected mothers. 125  
 
We need to improve HBV screening in high risk groups (IDU, MSM, those with 
multiple sex partners) where new infections continue to occur. Better screening 
approaches would help to strengthen vaccination efforts. 82 
 
The majority of chronic hepatitis B cases occur in first generation migrants to the UK 
and account for 6500 cases of chronic hepatitis B per year. These cases cannot be 
prevented by vaccination programs in the UK and can only be addressed by better 
systems of case identification. This is essential because currently therapy reduces 
progression of the disease by around 50%. 126  
 
PCTs should focus more attention on prison health since 60% of IDUs have been in 
prison at some stage in their life. Prison is currently the most common source of 
hepatitis B infection in the UK; better health education and sensitive encouragement 
of HBV testing could also decrease incidence rates in this usually hard to reach 
population. 127 128   
 
Evidence gaps 
 
We need to assess if demanding treatments regimes for HBV, currently delivered 
entirely in secondary care, could be at least partly delivered in primary care. This 
could include specialist nurses working within the primary care setting.  Whilst 
secondary care is better equipped to deliver specialist treatment, patients may be more 
likely to adhere to prolonged therapy if it is located in more familiar surroundings and 
closer to their home. Further work is needed to explore the possibilities of shared-care 
in this area.  
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LIVER DISEASE DUE TO OBESITY 
 
There is increasing evidence that obesity can lead to liver disease. 
 
There is concern that growing obesity levels in the UK, especially in younger age 
groups, may lead to a rapid rise in future liver disease cases. 2 129 
  
Approximately 23% of adults and 20% of children in England are obese (defined as a 
Body Mass Index (BMI) of >30 kg/m2); this proportion has grown steadily over 
recent years and, if unchecked, will continue to increase. 130                                                                          
 
Who gets liver disease from obesity and what are the consequences?  
 
Obesity is a risk factor for Non-Alcoholic Fatty Liver Disease (NAFLD) and a more 
severe (progressive) form of damage called Non-Alcoholic Steatohepatitis (NASH).  
 
Essentially, fat accumulation in the liver (steatosis) leads to scarring (fibrosis) and 
inflammation (hepatitis). If this scarring and inflammation becomes irreversible the 
liver becomes cirrhotic. 3 131 132   
 
Not everyone who is overweight or obese will develop fatty liver and not everyone 
who has a fatty liver is overweight. However the majority of people with NAFLD are 
overweight or obese. 133  
 
A growing number of studies have documented obesity as a risk factor for both ALD 
134-136
 and NAFLD. 45 135 137-140 Thus the development of liver disease from metabolic 
causes appears to be a robust phenomenon. 
 
NAFLD affects a substantial proportion of the general population and is associated 
with many features of the metabolic syndrome. It is currently the most common cause 
of abnormal liver function tests in Hepatology practice and affects approximately 15-
25% of the general population in various countries, this proportion increases to 70-
90% of obese patients, or patients with Type II diabetes. 141 
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Trends in NAFLD/NASH are strongly associated with patterns of obesity and Type 2 
diabetes in a population. US data show that prevalence of NAFLD is rising with levels 
of obesity. 142 Obesity and NAFLD is present in 65-90% of liver disease cases in the 
UK, however, many people with NAFLD remain undiagnosed. 1  
 
Although NAFLD and NASH have risen over recent years, there are currently no 
clear data showing a concomitant rise in mortality figures, which may be due to a 
time-lag in the development of this disease or a lack of research. However, a rise in 
mortality due to NASH is expected in the future due to the substantial shift in the 
prevalence of obesity over recent years. 2  
 
It is highly likely that future increases in obesity will result in further cases of liver 
disease which will have an impact on health services; however the extent of this 
possible increase is not currently clear. 3  
 
According to Hospital Episode Statistics (HES) data, obesity is mentioned in less than 
1% of cases of liver disease (see Figure 15 below).  
 
These findings suggest that HES data may under-record obesity as a contributing 
factor for liver disease; previous research has found that hospital physicians do not 
always record obesity in patients’ notes. 3 143  
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Figure 15 Relative proportion of admissions for non-alcoholic liver disease 
(including NAFLD/NASH) and ALD. Source 3 
 
NAFLD has been described in persons of all ages and it is the most common liver 
disease among obese adolescents in North America 144 with a prevalence of between 
17% and 34% 132, 145. NASH has been reported to be present in around a third (33%) 
of these individuals and some may progress to cirrhosis. 146 
 
Childhood obesity is an important, early risk-factor for a substantial amount of ill-
health and premature mortality in adulthood. 147 Research on 102 obese children and 
adolescents in a paediatric weight management clinic concluded that obesity in 
childhood creates the metabolic platform for adult CVD and NAFLD. In this US 
study, African-American and Hispanic children appeared to be at the greatest risk. 147 
 
Although most of the populations in which NAFLD has been studied have been 
predominantly white, work on minority ethnic groups is increasing. One US study has 
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looked at the clinical presentation of NAFLD in different racial and ethnic groups in a 
geographically representative and racially diverse segment of the population. 148 They 
found that of 159 study patients, 44% were white, 28% were Hispanic, 17% were 
Asian, 6% were American Indian and 5% were mixed-race. 148 These data were 
against local population figures and it was concluded NAFLD may be more common 
in Hispanic groups. 148  
 
Asian-Indian men appear to have an increased susceptibility to NAFLD due to its 
linkage with the metabolic syndrome and type 2 diabetes. 149 150 
 
Until recently, NASH was thought to be confined largely to middle-aged obese 
women with diabetes. 1 However, it also occurs in men and people who are not obese. 
Studies of ‘high risk’ groups (i.e. obese populations) have reported a prevalence of 
NASH of around 25%. 151,152  
 
One study reported progression from steatosis to cirrhosis in 3% of NAFLD patients 
over a 10-year period. 153 Progression from NASH to cirrhosis occurred in 20% of 
patients and from NASH to liver-related death of 12% of patients. 153 This progression 
through various degrees of liver disease is a cause for concern. 3  
 
Studies have also shown that obesity and Type 2 diabetes are associated with 
cryptogenic cirrhosis (cirrhosis due to unidentified causes). 2, 154  
 
How do people get liver disease due to obesity and can we prevent this? 
 
The risk factors for obesity are also risk factors for NAFLD. Risk factors for obesity 
include behavioural components (exercise and weight control measures), social 
components (food choices and eating patterns in different cultural groups) and 
components of the metabolic syndrome (impaired glucose tolerance or insulin 
resistance, high blood pressure, high triglycerides, dyslipidaemia, decreased ADL 
Cholesterol, central adiposity). 
People with the metabolic syndrome are at increased risk of coronary heart disease 
(CHD), peripheral coronary vascular disease (CVD), stroke, type 2 diabetes and liver 
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disease. 147 However, it is currently unclear whether the metabolic syndrome causes 
liver disease or if a fatty liver causes hepatic insulin resistance and consequent 
metabolic changes. 155 
Recent studies have reported an association between NAFLD and CVD. 141 NAFLD is 
also associated with an increased risk of all-cause death and predicts future CVD 
events independently of other prognostic factors, including components of the 
metabolic syndrome. Thus it is important to assess the global CVD risk in patients 
with NAFLD. 141 
 
The mechanism of liver injury in NAFLD/NASH is thought to follow a ‘two hit 
phenomenon’ whereby steatosis sensitizes the liver to a variety of second hits which 
lead to fibrosis and inflammation. 156 In the first hit insulin resistance and free fatty 
acids seem to play a major role. 157  In most subjects this is related to obesity, 
abdominal fat and aspects of the metabolic syndrome, including type 2 diabetes. In the 
second hit, oxidative stress (which can come from a number of causes) appear to be 
key. 156 
 
Overlapping risk factors 
A number of studies report a synergistic relationship between different risk factors for 
liver disease. 3, 89, 158  Thus a potent ‘triple hit’ has been described from a combination 
of obesity, hepatitis C infection and alcohol use which interact to hasten progression 
of chronic liver disease. 2  
 
Being overweight appears to interact with alcohol leading to increased risk of ALD. 2 
A study carried out in France by Naverau found that being overweight was also 
associated with cirrhosis in a study of alcoholic patients. 45 
 
Prevention 
The key way to prevent the development of NAFLD/NASH is to reduce the numbers 
of people who are overweight or obese in the population. 
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Targeting child obesity in addition to obesity in adulthood has been emphasised in 
recent health policy.  The 2005 White Paper “Choosing Health: Making healthier 
choices easier” 159, linked action plans focused on improving diet and increasing 
physical activity. 160 161  More recently, child obesity became an indicator in the 2007 
Child Health PSA which was set to improve the health and wellbeing of children and 
young people. The Secretary of State for Health and the Secretary of State for 
Children, Schools and Families share joint responsibility for the progress of this 
target.   
 
There are, of course, other drivers for the focus on obesity in health policy, but 
success in implementing these strategies could lead to a reduction in liver disease. 3  
 
Weight loss through low-energy diet and increasing levels of physical activity are 
recommended for tackling obesity. 162 A recent systematic review of psychological 
interventions for the treatment of obesity. 163 reported that people who are obese or 
overweight can benefit from behavioural and cognitive behavioural interventions and 
that these types of interventions are particularly effective when combined with dietary 
and exercise advice. 163  
 
Studies which have attempted to improve community health via educational 
campaigns focused on individual behaviour (e.g. on diet and physical activity) have 
not reported significant effects. 3 Research on the potential effectiveness of policy 
interventions is required. 72 Suggestions have included: restricting the advertising of 
unhealthy foods to children and changing the formulation of processed foods to 
reduce the consumption of fat, sugar and salt in the population 72; improving the 
nutritional labelling of foods, social marketing work, promotion of leisure-time sports 
and activities, and promoting healthy schools and active transport policies. 164 
  
Clinical trials of a number of drugs for the treatment of NASH in adults and children 
are under way in the USA. 165 166  Preliminary evidence suggests that the anti-diabetic 
drugs metformin and the thioglitazones, together with pentoxifylline, may have a 
valuable role in improving NASH. 3 Controlled trials of weight reduction and physical 
activity to improve insulin sensitivity in obese patients should be a priority. 167 
Evidence on both clinical effectiveness and cost-effectiveness are required.    
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The challenge of reversing the epidemic of obesity and type 2 diabetes is enormous.  
Better control of Type 2 diabetes after implementation of the Diabetes NSF may lead 
to a reduction in NAFLD/NASH. 
 
At what stage is liver disease due to obesity detected?  
 
Most patients with NAFLD typically have no symptoms or clinical signs of liver 
disease at the time of diagnosis, although some patients may report fatigue and a 
sensation of fullness or abdominal discomfort. Thus many patients are either 
identified via chance in primary care (via liver function tests for other conditions) or 
they are diagnosed when their condition has progressed to more severe liver disease 
where symptoms become apparent, which has a negative effect on prognosis. 
 
The presence of elevated serum liver enzymes (mild to moderate) are the most 
common, and often the only abnormality found in NAFLD patients. Other 
abnormalities may be found in patients with more advanced disease (cirrhosis). 
However, liver enzymes may be in the normal range in up to 70% of patients and thus 
are relatively insensitive for the detection of NAFLD.  
 
Patients with persistently raised liver enzymes may be referred to secondary care for 
further tests. Histological manifestations of NAFLD are similar to those observed in 
patients with ALD and of other secondary causes of chronic liver disease. 141 
 
 
What happens to patients with liver disease due to obesity? Treatment issues.  
 
At present there is no therapy for NAFLD per se. 149 168 Treatment for all patients, 
whatever the severity of their disease, is generally directed at the associated risk 
factors, obesity, type 2 DM, hyperlipidemia and hypertension. 149  This strategy will 
reduce morbidity and mortality and may also be beneficial to the liver. 140   
 
The role of increased BMI and steatosis as comorbidity factors in the progression of 
fibrosis has important therapeutic implications. Gradual weight reduction is 
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recommended as a first step in the management of patients with obesity-related fatty 
liver. However, there is a lack of long-term outcome data on the effect of modest 
weight loss on liver disease or associated metabolic factors. 162  
 
Recent work has shown that modest weight loss accompanied by increased physical 
activity is beneficial in patients with NAFLD, characterised by a decrease in serum 
alanine aminotransferase (ALT) levels (17 to 26%). 162 In patients who maintained 
their weight loss, ALT levels stabilised at the reduced level, however, patients who 
regained weight showed increased ALT levels (a return to baseline levels).  
 
Weight reduction may also bring about positive improvements in steatosis, fibrosis 
and fasting insulin levels. 162 The amount of physical activity per week is significant 
in the overall success of weight loss and maintenance. Patients who maintained 
weight loss were more likely to attain realistic levels of exercise (as recommended) 
and continue exercising long term.  
 
In addition to lifestyle and behavioural interventions, the most recent NICE guidelines 
on the prevention and management of obesity have guidance on drug and surgical 
interventions. 169 In relation to surgical interventions, NICE recommends bariatric 
surgery for individuals with a BMI over 40 when all non-surgical interventions have 
been unsuccessful or for individuals with a BMI over 50 for whom non-surgical 
intervention is not considered appropriate. Importantly recent studies have found that 
patients with NAFLD show significant improvements after bariatric surgery. 168 170, 
{Mendez-Sanchez N, 2007 #467
  Although the authors do recommend that larger studies are 
needed with more long term follow up.  
Furthermore, NICE has recommended two pharmaceutical interventions (Orlistat and 
Sibutramine) as part of an overall plan for obesity. Studies have reported that 
achieving weight control with these medications is associated with improvement of 
NASH although again more work is needed to determine the long-term efficacy. 168 171 
It has been reported that the use of thiazolidinediones to change the balance between 
visceral and subcutaneous fat and muscle lipids can improve insulin sensitivity and so 
may improve NAFLD and NASH. 147 
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Once cirrhosis has developed, the natural history of NAFLD is broadly similar to 
other causes of cirrhosis, with secondary complications arising due to portal 
hypertension, liver failiure and hepatocellular carcinoma (HCC). 172 The latter is 
significant as obesity is an independent risk factor for HCC.  
 
A recent comparison of outcome for patients with compensated cirrhosis due to 
NAFLD, compared to those with hepatitis C, found that the former had lower 
mortality and less frequent ascites, hyperbilirubinaemia and HCC but higher 
cardiovascular mortality. 172 
 
Up until 2003, liver transplantation in patients with NASH was uncommon. However, 
the proportion of patients with NASH receiving a liver transplant has increased over 
the past four years. 173 Initial data suggests that their post-transplant survival outcomes 
may be better than those for patients with ALD or cirrhosis due to viral hepatitis. 173 
 
Conclusions 
 
The characteristic of the liver as the only organ to regenerate creates an opportunity 
for strategies to be developed aimed at the prevention of harm from liver diseases by 
targeting the contributory causes of liver disease. 3 The development of public 
awareness about the link between obesity and liver disease is essential. 
 
There is a need to raise awareness in the public health workforce on the link between 
obesity and liver disease. Most health professional are likely to be unaware of this 
link. The recent document ‘Foresight Tackling Obesities: Future Choices 130 included 
a limited reference to NAFLD/NASH. Thus health professionals need specific 
education to improve their knowledge and thence to improve preventive work focused 
on NAFLD and NASH. 
 
The evidence on the benefit of weight reduction and exercise on NAFLD indicates a 
clear need for dieticians and nutritional support in the treatment of NAFLD as 
suggested in other reports. 4 
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Given the clear links between Obesity, diabetes, CHD, CVD and NAFLD/NASH it is 
imperative that effective treatment of patients involves a chronic disease management 
work including support to patients regarding self-management. 4  
 
Evidence Gaps 
 
Further research is needed into the links between obesity and liver disease including 
progression from NAFLD to NASH. 155 This research will enable us to better 
understand the impact that increasing levels of obesity may place on liver services. 3 
  
There are gaps in knowledge about the incidence of NAFLD in general and in 
different population groups. Most of the work on ethnic groups has been conducted in 
the USA. UK specific work is important, given the high prevalence of obesity and 
type 2 diabetes in people from the South Asian continent. 
 
It is also not clear whether fatty liver triggers metabolic complications or vice versa. 
Given the high prevalence of obesity in the UK, unravelling this relationship is 
essential. 
 
The progression from NAFLD to NASH to cirrhosis is unclear. Better understanding 
of this process will help the development of specific/targeted prevention and treatment 
for these conditions. 
 
More controlled trials of weight reduction and physical activity to improve insulin 
sensitivity in obese patients should be a priority. 167 Evidence on clinical effectiveness 
and cost-effectiveness are required.    
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4. LESS COMMON LIVER DISEASE 
 
 
In this section, we describe a range of other causes of liver disease. These conditions 
are generally uncommon. In addition they are typically not directly due to subjects’ 
behaviour. Hence these liver diseases, in the main, are not easily modifiable. Thus we 
have not made specific recommendations for practice and policy in this section. 
 
However, two points should be notes: 
 
• Primary liver cancer often results from progressive development of earlier 
stage liver disease; thus its earliest origins may be behavioural. However, once 
a precursor condition has developed (e.g. cirrhosis), the onward development 
to liver cancer may be hard to modify via behavioural interventions. 
 
• Drug-induced liver disease due to paracetamol over-dose can be considered 
behavioural. However, an intentional suicide or parasuicide is likely to be 
triggered by psychological factors or an under-lying mental health condition. 
Hence its inclusion in this section. 
 
We have categorised these non-behavioural causes of liver disease as follows: 
 
 Primary liver cancers 
 Autoimmune liver disease 
 Genetic or inherited liver disease 
 Liver disease due to Vascular conditions 
 Drug-induced liver disease 
 Specific Paediatric liver disease 
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PRIMARY LIVER CANCER 
 
In England and Wales, the incidence of cancers of the liver, gallbladder and biliary 
tract has increased over the last three decades of the 20th century, particularly in 
males. 1  
 
In 1999–2001, liver cell cancer (Hepatocellular carcinoma or HCC) was the most 
common subsite in males and was twice as common as intrahepatic bile duct cancer 
(Cholangiocarcinoma or CCA).  In contrast, intrahepatic bile duct cancer was the 
most common in females.  
 
Rates of intrahepatic bile duct cancer increased dramatically in both sexes, whereas 
the rate of liver cell cancer increased significantly in males, but not in females.  
 
These incidence trends show some divergence from the previously reported mortality 
statistics. In addition, there were dramatic reductions in the incidence of extrahepatic 
bile duct and gallbladder cancers in both men and women. 22  
 
Table 3. Incidence of cancers of the liver, gallbladder and biliary tract in England and 
Wales by subsite and sex per 100 000 (using 3-year rolling averages for the calculation of 
rates) 
  Males Females 
Subsite 
1971-
1973 
1999-
2001 
Rate 
Ratio 95% CI 
1971-
1973 
1999-
2001 
Rate 
Ratio 95% CI 
Liver, 
gallbladder 
& biliary 
tract 3.93 6.13 1.56 1.46-1.66 3.06 3.89 1.27 1.18-1.37 
Liver cell 
cancer 1.84 2.68 1.46 1.31-1.60 0.84 0.91 1.08 0.91-1.26 
Intrahepatic 
bile ducts 0.11 1.33 12.19 
10.92-
13.46 0.09 1.06 11.94 10.68-13.20 
Liver 
unspecified 0.27a 0.58 2.15 1.74-2.56 0.13a 0.28 2.07 1.58-2.57 
Gallbladder 0.7 0.45 0.65 0.45-0.84 1.19 0.79 0.67 0.54-0.80 
Extrahepatic 
bile ducts 0.86 0.42 0.48 0.32-0.65 0.67 0.36 0.53 0.37-0.69 
Other biliary 
tract cancer 0.42 0.68 1.61 1.31-1.91 0.27 0.5 1.85 1.50-2.20 
CI, confidence interval. (a)1979-1981. Source: 22 
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Hepatocellularcarcinoma (HCC) 
 
Liver cell cancer or HCC is one of the most common malignant tumours worldwide 
but, despite scientific advances, survival rates have not improved during the last three 
decades due to the advanced stage of the disease at diagnosis and due to the limited 
therapeutic options. 174    
Who gets HCC and what are the consequences? 
 
HCC is the cause of death of more than 19,000 adults per year in the US.  The 
primary etiology is infection with hepatitis B and/or hepatitis C virus. 175    
 
The US the incidence of HCC rose from 14 per million population in 1976-80 to 24 
per million population by 1991-95. 2,176 These rates were twice as high in Blacks 
compared to Whites and the increase was particularly in the younger ages. In general, 
HCC is three times more common in males than females (see Figure 15) and the 
incidence increases with age, see Figures 16-17. 174 
 
 
 
Figure 15. Directly standardised HCC mortality rates for men and women using 
European standard population  
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Male Hepatocellular Cancer mortality by age group 
 
 
 
Female Hepatocellular cancer mortality by age group 
 
Figure 16 & 17. Directly standardised HCC mortality rates for men and women 
using European standard population  
 
A recent study examined 30,423 HCC cases in Europe and 6,976 in the US (1982-
1994) to look at incidence and survival rates.   In southern Europe, incidence was 
12/100,000 in men and 3/100,000 women in 1992-1994 whilst in northern Europe the 
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rates were similar to the US at 3/100,000 in men and <1/100,000 in women).  Over 
this study period incidence remained stable in the US and most of Europe except for a 
notable increase in southern Europe.  Five year relative survival was <10% in Europe, 
ranging from 8% (southern Europe) to 5% Eastern Europe and 6% in the US.  It was 
unaffected by sex but was better in younger patients. 177 
 
How do people get HCC and can we prevent this? 
 
A large majority of HCC arises in cirrhotic livers. 2 Whilst HCC is relatively 
uncommon in the UK, accounting for about 2% of all cancers, it is the commonest 
cancer worldwide due to high carrier rates of hepatitis B and C. 2  
 
Risk factors 
The three commonest risk factors for HCC in the US are infection with hepatitis C 
(HCV) and/or hepatitis B (HBV) virus and Alcoholic Liver Disease (ALD). 2 The 
incidence of HCC is estimated to rise in US because of the large pool of HCV 
infected individuals, even though the incidence of new HCV infection is falling. 
Modelling in US suggest that HCC incidence might double within the next 1-2 
decades. 80  Since alcoholic cirrhosis mortality and alcohol consumption have been 
declining in Canada, the upward HCC trend has been attributed to the long-term effect 
of hepatitis B and C infection. 178 
 
Prevention 
HCC prevention falls into two categories: primary prevention aimed at reducing 
chronic liver diseases from occurring in the first place and secondary prevention 
aimed at preventing the recurrence and/or the development of new HCC lesions after 
successful surgical or non-surgical HCC treatment. 174 
 
Blum argues that in order to reduce morbidity and mortality from HCC early 
diagnosis and the development of novel systematic therapies for advanced disease, 
including drugs, gene and immune therapies as well as primary HCC prevention after 
successful therapeutic interventions needs to be improved in order to make an impact 
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on survival of patients. 174  New technologies, including gene expression profiling and 
proteomic analyses, should allow to further elucidate the molecular events underlying 
HCC developments and to identify novel diagnostic markers as well as therapeutic 
and preventive targets. 174  
 
At what stage do patients present with HCC? 
 
Despite scientific advances and the implementation of measures for early HCC 
detection in patients at risk, patient survival has not improved during the last three 
decades. This was due to both the advanced stage of the disease at the time of clinical 
presentation and limited therapeutic options. 174  
 
What happens to patients with primary liver cancer? Treatment approaches 
 
Between Jan 1989 and 2004, 1619 liver transplantations were performed in 1471 
patients including 163 with a HCC in cirrhosis. 179 The primary diagnosis of patients 
was hepatitis C (41%); alcohol toxic cirrhosis (21%), cryptogenic cirrhosis (10%), 
haemochromatosis (2%); primary schlerosing cholangitis, PBC, autoimmune 
hepatitis, porphyria cutaneatuara or Budd Chiari syndrome accounted for one patient 
each.  The post-operative mortality rate was 1.7%.  One, 5 and 10 year survival rates 
were 88%, 62% and 51%.179   
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Cholangiocarcinoma (CCA) 
 
In CCA, the tumour can arise in ductular epithelium of the biliary tree, either within 
the liver (intrahepatic) or more commonly in the bile ducts outside the liver 
(extrahepatic). 21   
 
Who gets CCA and what are the consequences of this? 
 
CCA is rare. Worldwide, CCA accounts for 3% of all gastrointestinal cancers and is 
the second commonest primary hepatic tumour. 21  The peak age for patients with the 
disease is in their seventies with a slight male preponderance. 21   However, there have 
been rising incidence rates, paralleled by mortality rates around the world – see Figure 
18. 21 
 
How did they get CC – can we prevent it?:  
 
CCA has been reported to occur coincidentally with a range of diseases including 
ulcerative colitis, polycystic disease and other less common gastrointestinal 
complaints.180 181 However, primary sclerosing cholagitis is the commonest known 
predisposing condition for CCA; rates of 8-40% have been reported in patients with 
primary sclerosing cholangitis. 21 
 
In one US study, all patients (aged 65+) with intrahepatic CCA were identified 
between 1993-1999. 182  Controls were randomly chosen from individuals without any 
cancer diagnosis.  A total of 625 cases and 90,834 controls satisfied the 
inclusion/exclusion criteria.  Cases were older than controls and more likely to be 
male but the ethnic profile was similar. Several risk factors were significantly more 
prevalent amongst ‘cases’.  These included non-specific cirrhosis, hepatitis C or 
human immunodeficiency virus (HIV) infection, diabetes and inflammatory bowel 
disease. 182 
 
Liver disease – A rapid review of epidemiology, treatment and service provision 
 
80 
 
Figure 18. World-wide incidence of intra (top) and extra-hepatic CCA (bottom). 
Source: 21 
Prevention 
Due to the difficulties in diagnosing CCA, it is often only detected in a late stage and 
so it is usually considered to be a fatal condition. 21  Thus it is difficult to achieve 
effective preventive work for CCA itself, preventive approaches need to focus on the 
precursors of CCA. 
 
At what stage do patients present with CCA? 
 
The disease is usually detected late primarily because many of the early symptoms are 
non-specific.  The most common sign of the disease is abdominal pain. 181 (see table 
4).  
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Table 4. Signs and symptoms of 162 patients with cholangiocellular carcinoma  
 
What happens to people with CCA? Treatment issues 
 
Most patients with CCA die within 12 months of presenting with the disease. 21  A 
review of survival rates is shown in Table 5 below. 181 It has been reported that an 
aggressive surgical approach provides the best chance for overall survival. 181 There is 
a lack of effective non-surgical therapeutic approaches for CCA. 183   
 
 
Table 5.  Cumulative survival rates of peripheral CCA after resection in Western 
and Eastern. Source: 181 
However, not all cases are suitable for surgery and there is a shortage of liver donors. 
Hence palliative approaches are also important in people with CCA. The one and five 
years survival rates in un-resected patients are 20% and 1.5% respectively. 
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AUTOIMMUNE CONDITIONS 
 
Autoimmune conditions arise when the body’s immune system attacks the liver. This 
process can lead to inflammation or hepatitis which, if untreated, can lead to cirrhosis 
or liver failure. 
 
The main autoimmune conditions that lead to liver disease are: 
 
• primary biliary cirrhosis 
 
• primary schlerosing cholagitis  
 
• autoimmune hepatitis 
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Primary Biliary Cirrhosis (PBC) 
 
PBC is a chronic progressive disease, which leads to a progressive destruction of the 
small intrahepatic bile ducts with portal inflammation leading to fibrosis and cirrhosis. 
184
 PBC takes approximately 15 years to lead to liver fibrosis and cirrhosis. 184   
 
Who gets PBC and what are the consequences? 
 
Estimates of PBC vary between 20 and 240 cases per million population, with an 
incidence between 4 and 30 cases million per year. 184 At this time there is no cure for 
PBC. 184 
 
Much of the UK data on incidence and prevalence come from North East England. A 
study in Newcastle (1987-1994) found an incidence of definite adult cases between of 
22 per million population with no obvious trend; prevalence rose from 180 to 240 per 
million population over this time period. 185 Data from the wider region reported a 
rising prevalence rate (probable cases) from 202 to 335 per million population in 
adults between 1987 and 1994. 186  The ELDIT database from Tayside reported an 
incidence of 43 per million population in the period 1980-98 though they did not 
report on time trends. 187  However, a United States study found no change in 
incidence in the period 1975-95. 188  
 
It is currently not clear why regional or national difference in PBC incidence and/or 
prevalence rates occur. 
 
PBC typically occurs later in life and is thought to affect women more than men, with 
an annual mortality rate of 1-2 cases per 100,000 (see Figure 19 below). 2 
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Figure 19. Standardised death rates from PBC by age group. Source: 2 
 
How did they acquire PBC? 
 
Why people get PBC is unknown. It is thought that individuals may inherit a 
predisposition for this condition which is subsequently triggered by environmental 
factors (an infection or some form of poison taken in from the environment). 184 
Occasionally PBC occurs during pregnancy, although it is not clear why.   
 
We currently do not know if specific risk factors lead to the development of PBC and 
we do not know hoe to prevent this condition. 
 
At what stage is PBC detected? 
 
PBC is generally detected via blood tests. Most people who have PBC have anti-
mitochondrial antibodies in their blood.  A liver function test (LFTs) is carried out to 
determine how well the liver is working.  
 
Specific diagnosis requires ultrasound or liver biopsy. 
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What happens to people with PBC? Treatment issues 
 
It has been suggested that Ursodexoycholic acid (URSO) may help some people with 
PBC, although it is unclear how effective this drug is.  A recent study investigated 
whether the risk of mortality and malignancy in people with PBC is reduced by the 
use of ursodeoxycholic acid. 189  930 PBC cases were compared to 9,202 control 
subjects from the GP research database in the UK.  Patients with PBC had a 3-fold 
mortality increase when compared with the general population. 189  The use of 
ursodeoxycholic acid appeared to reduce mortality, but this effect was not statistically 
significant. 189  
 
The other treatment for PBC is a liver transplant once the liver is seriously damaged. 
190
  
 
Controversy exists as to whether people with primary biliary cirrhosis (PBC) have an 
increased risk of developing osteoporosis and the extent to which this may translate 
into an increased risk of fracture. 191  In a recent case-control study, 930 people with 
PBC were compared to 9202 age and sex matched controls. Results showed that there 
were approximately a 2-fold relative increases in the risk of any fracture, hip fracture, 
and ulna/radius fracture for the PBC cohort compared with the general population. 191 
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Primary Schlerosing Cholangitis (PSC) 
 
PSC is a chronic disease which causes inflammatory fibrosis of the biliary tract which 
is immune mediated although the aetiology remains unknown. 192  PSC can progress 
to cirrhosis and it also causes an increased risk of CCA. 3  
 
Who gets PSC and what are the consequences? 
 
There is limited epidemiological work on PSC. 2 It appears to be more common in 
Northern Europe. 193 A study in Norway found an incidence of 13 per million 
population, and a prevalence of 85 per million population. 194  
 
PSC can occur at any age, however, is a rare disorder in young adults and it seems not 
to exist in children. 195 It occurs at twice the rate in males as females and patients are 
usually diagnosed in their thirties. 193 
 
Mortality from PSC has increased from around 100 deaths per annum in mid-1980s to 
200 deaths per annum by 2000, despite the use of liver transplantation.2 Analysis of 
HES data shows no apparent increase in those aged under 64. 2 
 
How do people get PSC – can we prevent this? 
Risk factors 
Risk factors seem to include hepatitis C infection, human immunodeficiency virus 
(HIV), liver cirrhosis and diabetes. 182   
 
Prevention 
We currently do not have clear information on how to prevent PSC. 
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At what stage is PSC detected 
 
Cases are often diagnosed in early adult life. 193 Prevalence estimates for PSC for the 
US were 10-40 per million population and in Sweden of 60 per million population.  
There are no epidemiological data on trends in PSC. In most cases, PSC arises as a 
complication of ulcerative colitis (figures range from 20-80%). 2  Analysis of HES 
data for ulcerative colitis show very little rise in hospitalisation between 1989-2000 in 
England. 196 
What happens to patients with PSC – Treatment issues 
 
There is no treatment for PSC except transplantation. 3  Although PSC is an 
uncommon disease, it is among the most common indications for liver transplantation 
in Europe and in the United States. 182 Prognosis partly depends on the stage in the 
disease of diagnosis; because of a lead time effect-whether at first symptoms or 
abnormal LFT test or definitive diagnosis by ERCP (Endoscopic Retrograde 
Cholangiopancreatography). 197    
 
A recent case series of 9 patients who underwent live donor liver transplantation for 
PSC described the clinical course and genetic disposition of these patients. 198  
Cumulated 5 year patient and graft survival rates were 90% and 70% respectively.  
The mean time to reoccurrence was 3.3 years and recurrent PSC was diagnosed in 
50% of patients.  This report concluded that overall patient survival seemed to equal 
that of deceased donor liver transplantations, although more longer-term follow-up 
was required. 198   
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Autoimmune Hepatitis (AIH) 
 
AIH is a progressive chronic hepatitis of unknown cause in which gradual destruction 
of the hepatic parenchyma occurs, frequently leading to cirrhosis. 199, 200   
 
Variant, overlapping or mixed forms of autoimmune hepatitis share features with 
other autoimmune liver diseases: primary biliary cirrhosis and primary sclerosing 
cholangitis, however these similarities amongst these disorders at the moment are 
descriptive. 199    
 
It is however important to distinguish autoimmune hepatitis from other forms of 
chronic hepatitis because a large percentage do respond to anti-inflammatory or 
immunosuppressive therapy or both. 199   
 
Who gets AIH and what are the consequences of this? 
 
There is limited epidemiological work on AIH. The incidence of type 1 AIH in 
caucasian populations in Europe and North America ranges from 0.1 to 1.9 per 
100,000 population annually. 201  
 
Autoimmune hepatitis is more common among women than men. 199   
How did they get AIH and can we prevent this? 
 
We currently have no clear information on risk factors or prevention. 
 
At what stage is AIH detected? 
 
Patients with Auto-immune hepatitis may present with non-specific symptoms of 
varying severity, such as fatigue, lethargy, malaise, anorexia, nausea, abdominal pain 
and itching.  Physical examination may reveal no abnormalities. 199 
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AIH is the one of the most poorly diagnosed and managed liver diseases in 
Hepatology and patients commonly present late with what could have been avoidable 
cirrhosis since AIH is a treatable condition. 202 
 
What happens to people with AIH? Treatment issues 
 
A large number of AIH cases respond well to anti-inflammatory or 
immunosuppressive therapy or both. 199 In recent trials ten year survival rates among 
those treated are now considered to be over 90% 203 however the 20 year survival rate 
may be less that 80% among those without cirrhosis and less than 40% of those with 
cirrhosis. 203 
 
Although survival can be prolonged and improved the quality of a person’s life and 
avoid the need for liver transplantations, there are still considerable therapeutic 
challenges remaining. 204   
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GENETIC (INHERITED) LIVER DISEASE 
 
Inherited liver disease is rare. Although the burden of the condition for sufferers may 
be great, the small numbers of people affected by these conditions are vastly 
outweighed by the larger numbers where liver disease is caused by the other factors. 3 
 
There are a number of inherited conditions that can lead to liver disease including: 
 
• Wilson’s Disease 
 
• Alpha1-Antitrypsin Deficiency 
 
• Haemochromatosis 
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Wilson’s Disease 
 
Wilson's disease (or progressive hepatolenticluar degeneration) is a genetic disorder 
of copper metabolism, characterised by hepatic and neurological disease.  For those 
affected there is an accumulation of excess copper in the liver caused by reduced 
excretion of it in bile.  It is progressive and can remain undiagnosed and thought to be 
fatal if not treated. 205 206  
 
Wilson’s disease is caused by an autosomal recessive disorder of hepatic copper 
disposition caused by mutations in the gene ATP7B, located on chromosome 13. 2   
 
Who gets it and what are the consequences? 
 
Wilson’ Disease affects between one in 30 000 and one in 100 000 individuals.  Most 
symptoms first appear in the second and third decades of life. 3 205 206    
 
How did they get it – can we prevent it? 
Wilson’s disease is a genetic condition and so currently not preventable. However, the 
discovery of new genes and new patterns of regulation of recently identified gene 
products may in the future lead to novel interventions for the treatment of these 
disorders. 205   
 
At what stage is it detected? 
 
In Wilson’s disease, the usual age range for clinical presentation is 5−45 years, 
younger children although older adults may present with this disease. 207   
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What happens to patients with it? Treatment issues 
 
If left untreated it will invariably result in severe disability and death, however if 
discovered early there are effective treatments available. 205  There is growing 
evidence for the use of trientine for the treatment of Wilson’s disease. 205   Marcellini 
found that in children treated with oral zinc therapy for 10 years the disease was 
controlled effectively and safely and prevented its progression. 206 
 
The outlook for liver transplantation for people with Wilson’s disease is best when it 
is identified early. 207   
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Alpha 1 Anti-trypsin deficiency (A1AD) 
 
 In Alpha 1 Anti-trypsin deficiency (A1AD) the body does not produce enough of the 
enzyme Alpha 1 Anti-trypsin that digests damaged or ageing cells. 2 A1AD 
predisposes to chronic obstructive pulmonary disease (COPD) 208 and is the most 
frequent cause of liver disease in children. 209   
 
Who gets it?  
 
The American National Institutes for Health statistics estimate that 1 in 2,500 people 
have A1AD. 3  It is estimated that there are between 70,000 and 120,000 individuals 
with A1AD in Western European countries. 210   
 
A1AD is the most frequent genetic cause of liver disease in children; however it may 
also be discovered first in late childhood or early adolescence. 209   
 
How did they get A1AD and can we prevent this?  
This is a genetic (inherited) condition and currently not preventable. 
 
At what stage is it detected:  
 
A1AD is usually first discovered at birth, however, it may be discovered later in late 
childhood or early adolescence when the affected individual is seen with abdominal 
distention from hepatosplenomegaly or ascites, or has bleeding that is caused by 
esophageal variceal haemorrhage. 209   
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What happens to patients with it? Treatment issues 
 
The World Health Organization recommends screening for a1-antitrypsin deficiency 
at least once in all patients with chronic obstructive pulmonary disease, and in 
adolescents and adults with asthma. 210   The most important principle in the treatment 
of A1AD is stopping smoking. 209  Treatment options include orthotopic liver 
transplantation; shunt surgery, pharmacologic therapy, protein replacement therapy 
and gene replacement therapy. 209 
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Haemochromatosis 
 
The most common genetic liver disease is Haemochromatosis, an autosomal recessive 
trait which causes iron overload in the liver and affects its functioning. 
Clinical manifestations of Heamochromatosis are liver disease but also diabetes, 
hypermelanotic pigmentation of the skin and heart failure. 211    
 
Who gets it and what are the consequences? 
 
Estimates vary widely. Gagne reports a prevalence of 1–5 per thousand in Caucasian 
populations. 211 Other reports suggest that as many as 1 in 8 of the Caucasian 
population has the point mutation that can lead to Haemachromatosis. 2  
 
In haemochromatosis cases, 1 in 200-400 are at risk of developing iron overload. 212  
How do they get it – can we prevent it?  
Haemachromatosis is a genetic (inherited) condition and we currently do not know 
how to prevent it. 
At what stage is it detected?  
 
Screening is not yet implemented in clinical practice for haemochromatosis.  Gagne 
evaluated the cost-effectiveness of population screening for haemochromatosis via 
computer modelling of different screening scenarios.  Input data were government 
estimates of health services data and costs and a virtual population with user-defined 
demographic characteristics.  With HCC and cirrhosis as the cost driving 
complications, population based screening was not significantly more cost efficient 
than no screening, however, the life expectancy of individuals with hereditary 
haemochromatosis who were treated improved by 7 years. 211  Whitlock et al. 213 
concluded that the current evidence did not support widespread screening.   
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What happens to patients with it? Treatment issues 
The complications that arise in haemochromatosis of iron overload can be avoided if 
identified early and managed appropriately. 214  The treatment used is therapeutic 
phlebotomy which is used to remove excess iron and maintain low normal body iron 
stores. 214 
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VASCULAR CONDITIONS 
 
Abnormalities of circulation that affect the liver include congestive heart failure, 
which leads to reduced outflow of blood from the liver, constrictive pericarditis and 
obstruction of the inferior vena cava.   
 
A condition more specific to the liver results from obstruction of the hepatic veins is 
Budd-Chiari syndrome. 215 Here increased resistance to hepatic venous outflow results 
in an enlarged liver due to blood pooling which can lead to hypoxia. The hypoxia in 
turn causes hepatocyte damage with possible fibrosis and cirrhosis; the latter can be 
termed termed cardiac cirrhosis. 215 
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Budd –Chiari Syndrome (BCS) 
 
Budd-Chiari syndrome is a liver condition caused by blockage of hepatic veins. 216 It 
is a rare condition with unknown etiology. However, it is thought to predominantly 
arise in people who have a tendency towards blood clotting. Hence it is best regarded 
as a vascular condition although there may be a genetic component. 
 
Two of the hepatic veins must be blocked for clinically evident disease.  Liver 
congestion and hypoxic damage of hepatocytes eventually results in fibrosis. 216 BCS 
occurs when venous outflow from the liver is obstructed.  The obstruction may occur 
at any point from the hepatic venules to the left atrium. 217 
Who gets it and what are the consequences? 
 
It occurs in 1/100 000 in the general population.  Hypercoagulable state could be 
identified in 75% of the patients; more than one etiologic factor may play a role in 
25% of patients. 216   
 
How did they get it – can we prevent it? 
 
The syndrome occurs in patients with underlying thromobotic disorders such as 
polycythemia rubra vera, paroxysmal nocturnal hemoglobinuria and pregnancy. 217   
 
BCS should be suspected in patients with: (1) Abrupt onset of ascites and painful 
hepatomegaly; (2) Massive ascites with relatively preserved liver functions; (3) 
Sinusoidal dilation in liver biopsy without heart disease; (4) Fulminant hepatic failure 
associated with hepatomegaly and ascites; (5) Unexplained chronic liver disease; (6) 
Liver disease with thrombogenic disorder. 216 
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We currently do not know how to prevent this condition. Given the occurrence of 
BCS in people with blood clotting disorders, there is a possibility that anti-clotting 
measures may be beneficial. 
 
At what stage is it detected? 
 
BCS is complex and hard to diagnosis however increasing nurse practitioners 
awareness about this rare condition through a case presentation and review of the 
literature emphasizes the major factors for accurate diagnosis. 218 
 
What happens to patients with it? Treatment issues 
 
Liver transplantation for BCS is an effective treatment, irrespective of the underlying 
cause and should be considered before renal failure occurs. 219  
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DRUG-INDUCED LIVER INJURY 
 
Drug-induced liver injury can be classified as predictable or non-predictable/ 
idiosyncratic hepatoxicity.  
 
Predictable reactions occur in response to drugs that are known to have a dose 
dependent response; paracetamol (acetaminophen) is the main drug taken in overdose 
in the UK. 220  
 
Non-predictable/ idiosyncratic drug-induced liver injury occurs sporadically in a small 
number of individuals at recommended doses because of genetic make-up or because 
they have difficulty metabolising them. It is reported that almost 1000 drugs can cause 
drug-induced liver injury; antibacterial drugs, particularly those used to treat 
tuberculosis, are the major class of drug responsible. 221  
 
Who gets drug induced liver disease and what are the consequences? 
 
There are approximately 70,000 new cases of paracetamol overdose per year in 
Britain 222 and these overdoses cause approximately 150 deaths annually. 220 
Therefore, although death from paracetamol overdose is relatively rare, it is  still the 
most common cause of mortality from acute liver disease in the UK; accounting for 
60-65% of cases of acute liver disease. 220 
 
An American review found that drugs excluding paracetamol are responsible for 12% 
of liver failure, while paracetamol is responsible for nearly 50% of cases. 221 223   
 
Incidence of idiosyncratic drug-induced liver injury is likely to be relatively low as 
drugs that are known to be hepatoxic do not usually make it to the market. However it 
is not possible to find a figure for the incidence of this condition.  Indeed, there is 
criticism of the current reporting of drug-induced liver injury because it relies on 
spontaneous reports from clinicians who do not have fail-proof means of detection. 221 
223
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How do they get liver disease – can we prevent this? 
 
Risk factors  
 
Different risk factors have come to be associated with different drugs. However, 
common risk factors include: genetic variations, being female, underlying disease 
states (including hepatitis B or hepatitis C, or infection with human 
immunodeficiency), increased age, combination therapy, alcohol use and 
malnutrition. 221 223  
It is likely that certain genetic dispositions are the greatest risk factor associated with 
drug-induced liver injury. Associations with strong evidence include N-
Acetyltransferase 2 and CYP2E1 associated with susceptibility to drug induced 
hepatoxity caused by antituberculous drugs. 221 
 
Drug Risk Factors  
Paracetamol Chronic alcohol use, fasting, isoniazid use 
(an antituberculous drug) 
Diclofenac Female sex, osteoarthritis 
Erythromycin Young age 
Halothane Obesity 
Isoniazid Hepatitis B virus, hepatitis C virus, 
alcohol use, older age, female sex, 
rifampicin (rifampin) use 
Methotrxate Chronic alcohol use, obesity, diabetes 
mellitus, chronic hepatitis, psoriasis 
Valpoate sodium Young age, antiepileptic drug use 
 
Table 6. Examples of risk factors for drug-induced liver injury. Source: 221  
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Prevention  
 
A primary preventative measure to reduce the number of paracetamol related deaths 
was introduced in 1998 in the UK. This was a legislation that restricted the sale of 
paracetamol to16 tablets in a pack (from 25) in all outlets other than pharmacies. In a 
review of evidence on this measure it was concluded that paracetamol associated 
mortality rates, hospital admissions, severity of the overdose, admissions to liver units 
and for liver transplants have decreased since this measure came into place.220  But 
they caution that the evidence is based on a small number of studies with limited 
follow up and therefore the impacts of the measure are still unclear.   
 
The two main types of prevention for non-predictable/ idiosyncratic drug-induced 
liver injury are: clinical trials for signs of toxicity prior to a drug going on the market 
and monitoring of liver abnormalities in patients in primary or secondary care.   
 
Rigorous tests are run prior to drugs going on the market and those that detect hepatic 
injury, usually by serum enzyme activity increasing, are usually rejected for public 
use. However studies report several problems with clinical trials for detecting 
idiosyncratic toxicity. The first is that they are often conducted in samples of the 
population which would not be large enough to detect idiosyncratic reactions as these 
range from 1:1,000 to 1:10,000. Furthermore the threshold of ALT (alanine 
transaminase) abnormalities at which a drug is thought to cause significant risk of 
liver toxicity, and is thus withdrawn from the market, does not always predict severe 
outcomes and some drugs might be being withdrawn that don’t lead to severe injury. 
221
 
 
For drugs that do show liver toxicity a benefit-risk analysis is carried out. The drugs 
that do have a risk of toxicity but where the benefits are thought to outweigh the costs 
and make it onto the market regular monitoring of ALT is recommended.  
 
Correspondingly, the second approach to preventing liver injury would be the 
monitoring of patients for liver injury in primary or secondary care and when injury is 
shown their use of the drug would be ceased. However, it is noted that there are 
several problems with this method; one is that compliance to screening has been poor 
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and another is that ALT abnormalities do not always indicate severe reactions. 
Furthermore, reactions can occur following months of treatment despite normal test 
results, reactions also occur after patients have ceased taking drugs. 221 
 
At what stage is drug induced liver disease detected?  
 
A definitive diagnosis of drug-induced liver injury is not possible, even through liver 
biopsy, because drug-induced liver injury changes can resemble other liver disease 
states. Therefore, detection is often carried out through elimination of other causes of 
liver disease and then identification of a ‘drug-specific clinical signature’. Abbound 
and Kaplowitz (2007) summarise that these clinical signatures include:  
 
• The pattern of liver test abnormality 
• Duration of latency to symptomatic presentation 
• Presence or absence of immune mediated hypersensitivity 
• Response to drug withdrawal  
 
The Rousssel - Uclaf causality assessment method (RUCAM) developed in 1990 is a 
validated tool used to predict likelihood of drug-induced liver injury. There are some 
criticisms of the tool however in that the scoring factors are not all evidence based. 223 
 
What happens to patients with this liver disease? Treatment issues 
 
Treatment options for drug-induced liver injury are cessation of the drug, and support 
and monitoring for hepatic failure. 221 There are only two proven antidotes to drug-
induced liver injury acetylcysteine for paracetamol toxicity and intravenous carntine 
for valproate sodium overdose. 221 For acute liver failure, liver transplant would be the 
only cure.  
 
It is reported that survival is better for paracetamol reactions than for idiosyncratic 
cases, 62% compared to 26% respectively. 221  
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SPECIFIC PAEDIATRIC LIVER DISEASE 
 
Liver disease in children is uncommon but the effect on the lives of suffers is great. In 
addition, treatment services will be involved in the case of these individuals for many 
years. 
 
The specific liver conditions most relevant to children are: 
 
• Biliary atresia  
 
• Cystic fibrosis.  
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Biliary Atresia (BA) 
 
BA is the most common and important neonatal hepatobiliary disorder. 224 225  It is 
characterised by complete obstruction of all or part of the extrahepatic bile duct and is 
always associated with abnormalities of the intrahepatic bile duct 225 and results in 
death if left untreated. 226 
 
BA occurs exclusively in newborns and was, therefore, called ‘‘congenital 
extrahepatic biliary atresia’’. 227 However, this condition is not thought to be 
immunological in origin. 225 
 
Who gets BA and what are the consequences? 
 
Rates are thought to be higher in Asian countries than others 228 although this has not 
been well investigated.  Tiao looked at the National Health Insurance database to 
explore at this.  They identified 327 new cases of BA from 1996-2003. The overall 
incidence of BA was 1.46 cases per 10 000 live births (0.89-1.90 per 10 000).  The 5 
year overall survival rate during 1999-2003 was higher that during 1996-1998 (74.8% 
vs 61.1%, p=0.014).  Taiwan has the 2nd highest levels of BA however the 
management has been improving with a better 5 year overall survival rate.   
 
How did they get BA and can we prevent this? 
 
It was thought that BA was a genetic (inherited condition). 227 However, research 
suggests that BA might be due to an immune response, triggered by environmental 
factors (possibly viral) during the perinatal period. 229 
 
BA may be triggered by environmental factors (possibly viral) during the perinatal 
period. 229 We currently do not know how to prevent this condition. 
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At what stage is BA detected? 
 
BA is exclusively found in newborns 227.   
 
BA is identified in an infant with prolonged jaundice (beyond 2 weeks of age), pale 
stools, or dark urine. 225 230  An examination of the colour of a fresh stool specimen is 
also useful in differentiating cholestasis (pale stools) from indirect hyperbilirubinemia 
(bright yellow stools). One promising early screening strategy is to give a  stool 
colour card given to new parents and their primary care provider which will alert them 
to abnormal stools.225 
 
What happens to patients with BA? Treatment issues. 
 
The main treatment option is corrective surgery to unblock the bile ducts. The best 
time to operate is six weeks after birth, although not all children recover fully.  In the 
majority of cases the bile flow will still remain insufficient and the liver fibrosis 
worsens making a liver transplant the only option. 230   
 
It is argued that current treatment is inadequate 224 225 and it has been shown that 
earlier diagnosis (<30-45 days of life) is associated with improved outcomes. 225  
 
The gold standard for operating on BA patients is Kasai’s portoenterostomy. 227  A 
study of long term prognosis of children undergoing the Kasai operation for BA 
showed the twenty year survival rate was significantly better in children with BA 
restricted to the hepatic ducts or with cysts at the porta hepatis. 226  This work showed 
that less than 18% of infants with BA who are treated with corrective surgery may 
avoid liver transplantation, but even these patients require lifelong care. 226 
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Cystic Fibrosis (CF) 
CF is an inherited disorder of epithelial transport which affects the lungs, pancreas, 
gut, liver and exocrine glands and results from mutations of a gene located on 
chromosome 7. 231  
 
CF is usually identified in children and it is increasingly associated with liver disease. 
231
 A genetic mutation affects the Cystic fibrosis transmembrane conductance 
regulator (CFTR); a transmembrane chloride channel 231. 
 
Who gets CF and what are the consequences? 
 
Although all CF patients have abnormal CFTR, not all people with this mutation 
develop significant liver disease. 231   Thus it is hard to estimate the true risk of liver 
disease in people with CF. 231   
 
A US study of all children who attended a CF clinic (195 patients underwent tests) 
showed that 19% had abnormal liver sonograms and of these 63% had abnormal test 
results. 232  Furthermore, 8 children with abnormal results had signs of portal 
hypertension; 82% (14/17) of those with signs of cirrhosis had abnormal liver 
function. 232  It was concluded that there was a significant relationship between 
abnormal liver architecture at ultrasound and results of liver function tests in children 
with CF.  The most specific ultrasound abnormalities are signs suggestive of portal 
hypertension and cirrhosis. 232  
 
How did they get it and can we prevent it? 
 
This is a genetic (inherited) condition and we do not know how to prevent it.  
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What happens to patients with it? 
 
A case study of 2 female patients with CF who had simultaneous pancreas and liver 
transplantation reported that both recovered well with liver functions, resolution of 
portal hypertension and normal blood glucoses independent of insulin. 233 This report 
conclude that transplantation provided normalization of glucose and improved 
nutrition for patients; thus it should be considered in CF patients with CFRD. 233  
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5. TREATMENT EFFECTIVENESS – THE EVIDENCE BASE 
 
 
In earlier sections on risk factors for (and other causes of) liver disease we described a 
range of treatment approaches, used by clinicians, to manage the wide range of liver 
diseases encountered in practice.  
 
Where relevant we reported evidence supporting prevention, treatment and palliation 
of liver disease and its symptoms.  
 
In this section we briefly overview the evaluative literature on the treatment of liver 
disease to help describe: 
 
• The balance of research on prevention and treatment of liver disease  
 
• To assess the strength of evidence guiding liver disease work. 
 
 
To do this we have:  
 
Summarised the recent literature in terms of the types of papers being published. 
 
Summarised evidence reviews on prevention and treatment for liver disease published 
on the Cochrane library. 
 
Summarised current guidance for clinicians on treatments for liver disease. 
 
Appraised the health economics literature on liver disease treatment. 
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Summary of the literature on liver treatment 
 
In our search of electronic databases (2005-7) and the internet for research on liver 
disease, we identified 402 relevant references.  
 
The majority of this work (39%) was descriptive epidemiology and much of this work 
was from outside the UK.  
 
About a third (30%) of the papers reported on the treatment of liver disease, whilst 
just 13% focused on preventive care.  
 
Just 7% of papers described service provision for liver disease and a quarter (25%) 
included economic aspects of care.  
 
The rows in Table 7 breakdown the literature for specific liver disease. 
 
 Epidemiology 
(156) 
Treatment 
(119) 
Prevention 
(52) 
Services 
(29) 
Economics 
(99) 
General liver 
disease (63) 
36 31 11 12  0 
Alcohol 
(58) 
36 8 13 8 5 
Obesity 
(52) 
38 16 14 1 0 
Hepatitis 
(87) 
23 17 7 3 35 
Autoimmune 
(31) 
22 17 0 1 1 
Genetic 
(14) 
8 10 6 0 1 
Vascular 
(14) 
7 9 0 2 0 
Drugs 
(9) 
38 3 5 1 1 
Paediatric 
(11) 
8 4 0 0 0 
Economics 
(99) 
3 62 22 11 99 
Transplant 
(41) 
3 35 2 4 13 
*Please note as some papers cover more than one aspect of liver disease the rows and 
columns do not add up.   
Table 7. Summary of the literature identified in this rapid review
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Effectiveness of prevention and treatment for liver disease 
 
To make a rapid assessment of the treatment literature on liver disease we looked at 
systematic reviews and review protocols published on the Cochrane Library. The 
breakdown of material was as follows (See Table 8): 
 
• 263 reviews/protocols relating to Hepato-biliary conditions  
• 126 were relevant to our review; although 7 had been withdrawn 
• 119 reviews and protocol contained 47 were duplicate entries 
• 71 separate entries (about half were reviews and half were protocols) 
o 58 (82%) covered treatment for liver disease 
o 13 (18%) covered preventive care 
 
 
 Treatment Prevention Total 
Review 29 5 34 
Protocol 29 8 37 
Total 58 13 71 
 
Table 8. shows the breakdown of reviews/protocols by treatment/preventive 
work 
 
 
 Effective Not effective Inconclusive Total  
Treatment 5 2 22 29 
Prevention 3 0 2 5 
Total  8 2 24 34 
 
Table 9 provides a summary of conclusions drawn in published reviews 
 
 
Just 8 reviews identified effective interventions (for summary see Table 9 and for 
details Table 10). [Appendix VII has a synopsis of all reviews] 
 
• Six focused on the prevention or treatment of hepatitis infection.  
 
o Two of the reviews on hepatitis infection concluded that vaccination 
strategies were effective at preventing acute hepatitis B infection.  
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o Four reviews of treatment for hepatitis C (acute and chronic) reported 
that the use of interferon (in varying forms) was effective at reducing 
or clearing the viral load. 
 
• Two reviews focused on recurrent bleeding in liver disease.  
 
o One review, on the prevention of bleeding from gastric varices, 
reported that the use of prophylactic antibiotics was effective.  
 
o The other, on the treatment of acute oesophageal varices, concluded 
that Terlipressin was an effective treatment. 
  
Conclusion 
 
Despite a large initial number of Cochrane reviews focusing on Hepato-Biliary 
conditions, only a small number identified effective preventive or treatment and most 
of these focused on hepatitis infection.  
 
More evaluative research is required and this should focus on preventing as well as 
treating liver disease. In addition, there is a need for research which identifies 
effective means of disseminating and encouraging implementation of evidence-based 
interventions since most physicians have not had specific training in Hepatology, and 
thus are not using the most effective interventions in liver care. 234 
 
Work in other areas of the Cochrane library (Drugs and Alcohol; Metabolic 
Conditions) has reported on preventive interventions that are likely to have a positive 
impact on the field of liver disease. 
 
Brief behaviour change interventions are effective at reducing excessive drinking in 
primary care settings52 which could help to reduce the numbers of people developing 
ALD. 
 
Behaviour change interventions are effective at producing weight-loss outcomes in 
people who are obese, particularly when used in combination with diet and physical 
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activity. 163 Non-pharmacological interventions focused on diet or physical activity 
alone produced small improvements 235 and pharmacological approaches had a limited 
impact on obesity but were beneficial in conjunction with weight-loss programmes. 
236
  Use of these approaches, particularly behaviour change interventions, could play a 
positive role in preventing NAFLD/NASH. 
 
Better cross-linkages across different areas of the Cochrane library would help to 
inform clinicians about current practice to prevent liver disease. 
 
 
Treatment/ 
Prevention  
Target condition 
(or group)  
Reference  
(1st author, year & 
title) 
Intervention  
Prevention  acute hepatitis B 
 
carriers of hepatitis 
B virus 
Lee at al. 2006 
 
Hepatitis B 
immunisation for 
newborn infants of 
hepatitis B surface 
antigen-positive 
mothers.  
Vaccine, hepatitis B 
immunoglobulin, and 
vaccine plus hepatitis B 
immunoglobulin prevent 
hepatitis B occurrence in 
newborn infants of HBsAg 
positive mothers.  
 
Prevention  acute hepatitis B Chen et a. 2005 
 
Vaccines for 
preventing hepatitis B 
in health-care 
workers.  
Plasma-derived vaccines 
(PDV) significantly 
prevents hepatitis B events. 
Recombinant vaccines 
(RV) seem to be able to 
elicit similar protective 
anti-HBs levels. 
Treatment acute hepatitis C Myers et al. 2001 
 
Interferon for acute 
hepatitis C.  
Interferon α improves liver 
biochemistry and viral 
clearance in transfusion-
acquired acute hepatitis C. 
More work needed about 
long-term clinical 
outcomes.   
Treatment chronic hepatitis C Myers et al. 2002 
 
Interferon for 
interferon naive 
patients with chronic 
hepatitis C.  
Interferon is effective in 
interferon naive patients 
with chronic hepatitis C 
but the efficacy in patients 
with normal 
aminotransferases is 
unproven. 
Treatment Chronic hepatitis C Myers et al. 2002 
 
Interferon for 
Re-treatment with 
interferon leads to 
sustained HCV clearance 
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interferon- 
nonresponding and 
relapsing patients 
with chronic hepatitis  
from the blood in patients 
with previous nonresponse 
to or relapse from 
interferon therapy 
Treatment  Chronic hepatitis C Brok et al. 2005 
 
Ribavirin plus 
interferon versus 
interferon for chronic 
hepatitis C.  
Adding ribavirin to 
interferon increases the 
number that clear HCV but 
also increases the risk of 
several adverse events 
Prevention Recurrent bleeding 
from gastric varices 
Soares-Weiser et al  
2002 
 
Antibiotic 
prophylaxis for 
cirrhotic patients with 
gastrointestinal 
bleeding. 
Antibiotic prophylaxis for 
cirrhotic inpatients with 
gastrointestinal bleeding is 
effective in reducing the 
number of deaths and 
bacterial infections 
Treatment Recurrent bleeding 
from oesophageal 
varices 
Ioannou et al. 2003 
 
Terlipressin for acute 
oesophageal  variceal 
haemorrhage 
Terlipressin should be 
considered to be effective 
in the treatment of acute 
variceal haemorrhage. 
 
Table 10. Summary of effective interventions for the prevention or treatment of 
liver disease. A full list of work with inconclusive and null-effect interventions 
can be found in the Appendix VII. 
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Clinical guidance on treatment for liver disease  
 
We considered the current official guidance from the National Institute for Health and 
Clinical Excellence (NICE) which appraises the evidence for clinicians on a range of 
treatment approaches in liver disease. 
 
It is not clear how these sets of guidance relate to work reported on the Cochrane 
library (above).  
 
NICE conducts an assessment of evidence of effectiveness and cost-effectiveness of 
treatments for the Department of Health. 
 
There are 13 sets of guidance relating to liver disease published by NICE. A brief 
summary is outlined below along with a hyperlink to the publication. 
 
A number of approaches that were supported required a Hepatobiliary surgeon and/or 
a specialized multidisciplinary team or specific training to conduct the procedure (1, 
4, 5, 7). Others required special arrangements for consenting of patients and 
audit/research on outcomes (2, 3, 4, 7, 8, 11, 13). 
 
Some treatments were not recommended for practice (2, 6). 
 
1. Radiofrequency ablation (RFA) of Hepatocellular Carcinoma, 2003. 
Current evidence of safety and efficacy appears adequate to support the use of the 
procedure, provided that normal arrangements are in place for consent, audit and 
clinical governance.  Recommendations state that patient selection should be 
carried out by a multidisciplinary team that includes a hepatobiliary surgeon and 
should be monitored by CT or ultrasound.  
Radiofrequency ablation of hepatocellular carcinoma 
 
2. Photodynamic therapy for bile duct cancer, 2005 
Current evidence on the safety and efficacy of photodynamic therapy (PDT) for 
bile duct cancer does not appear adequate for this procedure to be used without 
special arrangements for consent and for audit or research 
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Photodynamic therapy for bile duct cancer 
 
3. Liver-donor liver transplantation, 2006 
Current evidence suggests that living donor liver transplantation carries significant 
risk of morbidity and a small risk of death for donors. Thus clinicians wishing to 
undertake this procedure should take the following actions: inform the clinical 
governance leads in their trusts; ensure that donors and recipients undergo 
thorough physical and psychological screening, and receive counselling about the 
morbidity and risks associated with this procedure. They should also be provided 
with clear, written information. An audit and review of clinical outcomes of all 
people donating liver tissue for transplantation should be carried out. 
Living-donor liver transplantation 
 
4. Microwave ablation for the treatment of Metastases in the liver, 2007 
Current evidence on the safety and efficacy of this procedure does not appear 
adequate for it to be used without special arrangements for consent and for audit 
or research. Clinicians wishing to use this procedure should take the following 
actions: Inform the clinical governance leads in their trusts; ensure that patients 
understand the uncertainty about the procedures safety and efficacy and provide 
them with clear written information, including about other treatment options. 
Furthermore, an audit and review of all clinical outcomes for all patients should be 
carried out. Patient selection should be carried out by a multidisciplinary team that 
includes a hepatobiliary surgeon and the procedure should be performed under 
appropriate imaging guidance. Adverse events relating to this procedure should be 
reported to the Medicines and Healthcare products Regulatory Agency. 
Microwave ablation for the treatment of metastases in the liver 
 
5. Laparoscopic liver resection, 2005 
Current evidence on the safety and efficacy of laparoscopic liver resection appears 
adequate to support the use of this procedure, provided that the normal 
arrangements are in place for consent, audit and clinical governance. Patient 
selection for laparoscopic liver resection should be carried out by a 
multidisciplinary team.  Surgeons undertaking laparoscopic liver resection should 
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have specialist training and expertise both in laparoscopic techniques and in the 
specific issues relating to liver surgery. 
Laparoscopic liver resection 
 
6. Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis 
C, 2006 
The Committee did not believe that there was sufficient evidence to recommend 
combination therapy or mono-therapy with peg-interferon-alfa for people with 
mild chronic hepatitis C who are under the age of 18 years, or those who have had 
a liver transplant 
Hepatitis C - peginterferon alfa and ribavirin 
 
7. Microwave ablation of hepatocellular carcinoma, 2007 
Current evidence on the safety and efficacy of microwave ablation of 
hepatocellular carcinoma appears adequate to support the use of this procedure 
provided that the normal arrangements are in place for consent, audit and clinical 
governance. Patient selection should be carried out by a multidisciplinary team 
that includes a hepatobiliary surgeon; and the procedure should be performed 
under appropriate imaging guidance. A number of devices are available, and there 
is some uncertainty about the energy levels that should be used. NICE 
recommends that any adverse events relating to this procedure should be reported 
to the Medicines and Healthcare products Regulatory Agency. Further research on 
long-term survival outcomes and comparisons of microwave ablation with other 
ablative techniques will be beneficial/useful 
Microwave ablation of hepatocellular carcinoma 
 
8. Extracorporeal albumin dialysis for acute –on-chronic liver failure, 2004 
Current evidence on the safety and efficacy of extracorporeal albumin dialysis for 
acuteon- chronic liver failure (AoCLF) does not appear adequate for this 
procedure to be used without special arrangements for consent and for audit or 
research. Clinicians wishing to undertake extracorporeal albumin dialysis for 
AoCLF should take the following action: Inform the clinical governance leads in 
their Trusts; ensure that patients understand the uncertainty about the procedure’s 
safety and efficacy and provide them with clear written information (Use of the 
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Institute’s Information for the Public is recommended). An audit and review 
should be carried out to look at the clinical outcomes of all patients having 
extracorporeal albumin dialysis for AoCLF and publication of safety and efficacy 
outcomes will be useful in reducing the current uncertainty.  
Extracorporeal albumin dialysis for acute-on-chronic liver failure 
 
9. Radio frequency (RF) assisted liver resection, 2007 
Although the evidence is limited on the safety and efficacy of radiofrequency 
(RF)-assisted liver resection, it appears adequate to support the use of this 
procedure as one of the options for liver resection, provided that the normal 
arrangements are in place for consent, audit and clinical governance. 
Radiofrequency-assisted liver resection 
 
10. Adefovir dipivoxil and peginterferon alfa-2a- for the treatment of chronic 
hepatitis B, 2006 
Drug treatment with peginterferon alfa-2a or adefovir dipivoxil should be initiated 
only by an appropriately qualified healthcare professional with expertise in the 
management of viral hepatitis. Continuation of therapy under shared-care 
arrangements with a general practitioner is appropriate.  
Hepatitis B (chronic) - adefovir dipivoxil and pegylated interferon alpha-2a 
 
 
11. Radiofrequency ablation for the treatment of colorectal metastases in the 
liver, 2004 
Current evidence on safety of radiofrequency ablation of colorectal metastases in 
the liver appears adequate. However, the evidence of its effect on survival is not 
yet adequate to support the use of this procedure without special arrangements for 
consent and for audit or research 
Radiofrequency ablation for the treatment of colorectal metastases in the 
liver 
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12. Selective internal radiation therapy for colorectal metastases in the liver 
Current evidence on the safety of SIRT for colorectal meta-stases in the liver 
appears adequate. With regard to efficacy, the procedure may reduce tumour bulk, 
but there is a lack of evidence of symptom relief or increased survival, and 
combination with other treatments makes interpretation of the published literature 
difficult. 
Selective internal radiation therapy for colorectal metastases in the liver 
 
13. Complete cytoreduction and heated intraperitoneal intraoperative 
chemotherapy (Sugarbaker technique) for peritoneal carcinomatosis 
Current evidence on the safety and efficacy of complete cytoreduction and heated 
intraoperative intra-peritoneal chemotherapy (the sugarbaker technique) for 
peritoneal carcinomas does not appear adequate for this procedure to be used 
without special arrangements for consent and for audit or research. 
Complete cytoreduction and heated intraperitoneal intraoperative 
chemotherapy (Sugarbaker technique) for peritoneal carcinomatosis 
 
 
14. NICE guidance currently in progress 
Recognition and treatment of neonatal jaundice 
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Health Economics of liver disease treatment 
 
To date, economic evaluation in the area of liver disease appears to have been limited. 
One of the challenges in this field is the ethical issue of assessing costs and effects of 
differing care options in patients with a severe, and often life threatening condition, 
One promising approach is the use of decision-analysis modelling. 
  
Economic modelling in liver disease 
Decision analysis models do not use actual patients but instead use a hypothetical 
cohort of people who are assigned characteristics similar to the actual patient 
population.  A model brings together data from a variety of sources such as clinical 
trials, meta-analysis databases and hospital records. Use of a decision model allows 
the investigator to combine data on costs and effects, including quality of life, to 
produce data on lifetime costs, life expectancy and quality of life for alternative 
treatments for the same condition. 237 238 The hypothetical cohort enters the model, 
and if they go down the ‘no treatment’ or ‘control’ branch, the model will assign 
proportions of the cohort to different health states, according to epidemiological 
evidence. For example, these states might be different Child-Pugh classifications. 
Based on epidemiological evidence, cases move between the states in pre-specified 
time periods (e.g. annually) until the cohort dies out. The different health states have 
costs and health outcomes associated with them, and so, once the cohort dies out, it is 
possible to aggregate the costs and outcomes to obtain a cost per unit of health gain. 
Alternatively, the cohort could be modelled to go down the ‘new treatment’ arm 
where, according to data from randomised trials, they will experience health states at 
different rates and at different points in time, thus producing a different cost per unit 
of health gain which can be compared with that for the ‘control’ arm. 
 
Such ‘modelling’ allows us to see how ratios of cost to effectiveness change if key 
variables in the model are altered.  This would not be possible with primary data.  
However, although it is recognised that modelling has a key role to play in health 
economic evaluation, there are concerns about the quality and comparability of the 
data that enter into the model.  These concerns about modelling have led to some 
restrictions being placed on their use. 239 240 
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Economic evaluation of liver disease treatment 
 
Our search of the published literature (for the search strategy see Appendix III) found 
that, until recently, economic evaluations had focused on two main areas; screening 
and treatment for Hepatocellular carcinoma (HCC) and prophylaxis and treatment for 
variceal bleeding (VB).  
 
We are aware of an emerging literature on liver transplantation 241 and a recent work 
on screening, vaccination and treatment of chronic hepatitis which was covered in the 
relevant section. 47 242 However, in the time available for this review, we focused our 
attention on HCC and VB where there is a clear body of literature.  
 
The literature review identified 22 economic evaluation papers in these two key areas 
of liver disease treatment: 7 relating to HCC 243-249; and 15 relating to VB. 250-264 Each 
of these studies was assessed against six key criteria for economic evaluations as set 
out in Laupacis et al. 265  All of the studies are summarised in Appendix VIII and IX.    
 
Hepatocellular carcinoma (HCC) 
 
Screening 
 
Due to an increased incidence of HCC in patients with cirrhosis, surveillance for HCC 
in patients with liver cirrhosis may seem appropriate.  We identified 5 studies 
involving economic evaluation in the area of screening for HCC (Appendix VIII). The 
method of screening for HCC in all 5 economic evaluations involved Alpha 
Fetoprotein (AFP) and ultra-sound.  
 
Sarasin et al 243 used a modelling approach to assess the cost-effectiveness of 
screening Child-Pugh A patients. 243  Child-Pugh B and C patients were not used as 
they would not be medically able to stand the treatment given if HCC were found.  
The treatment option given was partial hepatic resection.  The model compared the 
cost of each life year saved from screening every six months and detection from 
clinical symptoms only.  The model used a set of assumptions which included that: 
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small HCC would be undetected without screening; small tumours do not increase 
mortality above that of the underlying cirrhosis; and the sensitivity and specificity of 
the ultra sound and AFP in detecting large HCC is 100%.  The model used a 
hypothetical cohort of 55 year old males and conducted extensive sensitivity analysis 
to estimate an incremental cost per life year gained of screening over not screening of 
between $26,000 and $284,000.  The results also gave a maximum gain in life 
expectancy of nine months as a result of screening in the best case scenario. 
Therefore, it was concluded that, for most patients, screening did not prove to be 
worthwhile.   
 
This was also the conclusion of the Bolondi et al study 245 Using a prospective cohort 
study of patients with cirrhosis but not HCC, they report a cost per life year saved of 
US$113,534.  However, Farinati and Gianni 244 concluded that screening for HCC 
increased mean survival time and was not as costly as a prioiri expectations. Their 
mean cost per year of life saved was based on the cost of the screening plus the cost of 
treatment.  The treatment options considered were orthotopic liver transplantation 
(OLTx), percutaneous ethanol injection (PEI), trans-catheter arterial chemo-
embolization (TACE) and surgical resection.  The combined screening and treatment 
cost per year of life saved for a treatable HCC is $9152.    
 
Finally a recent health technology assessment (HTA) review in the UK developed a 
number of decision analysis models to asses the cost effectiveness of various 
strategies of screening using AFP and ultra sound either individually or in 
combination and either annually or six monthly versus no screening 247. This study 
reported a number of incremental cost per QALY ratios which ranged from £20,700 
per QALY for AFP annually versus no screening through to £60,100 per QALY for 
AFP and ultra sound every six month versus no screening.   
 
Treatment 
 
Once HCC has been diagnosed, the treatment options open to patients are limited.  
Despite this there is still no conclusive evidence on which treatment is the best way 
forward.  In patients in the early stages of HCC the choice of which treatment to give 
is still debatable with some favouring resection 266 and some OLTx. 267  With this 
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issue still undecided the cost and effectiveness of the treatments may become a factor 
in the decision; especially in hospitals where resources are limited.  In a small cohort 
study of compensated cirrhosis patients, four treatment options (OLTx, Surgical 
resection, PEI and TACE) were compared with best supportive care. 248  The cost per 
life year saved for OLTx was $21,664; however, only the cost of the treatment was 
taken into account and the extra cost of the treatment over best supportive care was 
not presented.  The cost per life year for TACE was $4009, for surgical resection 
$1959 and for PEI was $1233. These estimates, like that of OLTx, are based only on 
the costs of treatment.   
 
Variceal bleeding (VB) 
 
Screening 
 
Variceal bleeding (VB) is one of the most severe and life threatening symptoms of 
cirrhosis of the liver. Interest has arisen in the prevention of an initial episode of VB 
due to the mortality rates associated with it; about 20-30% of deaths of cirrhosis 
patients are associated with VB.  Fifteen economic evaluations have been conducted 
in the area of VB; of which, eight studies examine interventions for primary 
prophylaxis of VB and 7 studies evaluate interventions following an initial episode of 
VB (Appendix IX).   
 
Screening for varices has been recommended for all patients with cirrhosis 268.  The 
evidence to support the cost effectiveness of universal screening is mixed. From the 
published economic evaluations of screening for VB, it is difficult to give a definitive 
recommendation as the studies have examined different methods of screening and 
other forms of primary prophylaxis such as universal β-blockers and endoscopic 
variceal ligation.  In each study a different comparator is chosen, thus it is difficult to 
compare the results across studies  
 
The study by Chalasani et al was designed to determine whether it was possible to use 
clinical variables to predict the presence of large esophageal varices. 251  Two 
different interventions were evaluated against a baseline of ‘do nothing’, these were 
screen all cirrhosis patients or screen only those considered as high risk.  The 
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incremental cost effectiveness ratios (ICER) were: US$15,160 per case of VB averted 
for the screen all strategy; and US$3,533 per VB case averted for the screen only high 
risk patients strategy.  This study was the only one in this area which did not use 
decision analysis modelling approach.  
 
 
Imperiale et al 255 carried out a cost utility analysis which incorporated data on 
patients’ quality of life in the form of utility data.  In this health context, ‘utility’ is a 
judgement of how ‘good’ or ‘bad’ a health state is. Thus different degrees of 
impairment are weighted (or given a utility value) between 0 and 1, where 0 is 
assumed to be equated to ‘being dead’ and 1 is equated with ‘full/normal health’. 
These weights can be used to ‘quality adjust’ survival gains or remaining years of life, 
and are used in the calculation of quality adjusted life years (QALYs).  The authors 
estimated an incremental cost per QALY of £25,548 for using endoscopic variceal 
ligation as primary prophylaxis for VB versus β-blockers.  Within the field of liver 
disease there are very few studies which have estimated quality of life data for health 
states associate with different stages of liver disease. 269   
 
Treatment 
 
Treatments for active VB that have been evaluated include; transjugular intrahepatic 
portosystemic shunt (TIPS), H-graft portacaval shunt and endoscopic sclerotherapy.  
TIPS has been recommended as an initial treatment as it appeared to offer cost-
savings over other forms of treatment. 270-272 However, this is subject to debate. In the 
studies by Rosemurgy et al 260 and Helton et al 261 only the total costs of treatment and 
follow up have been reported with both reporting higher total cost for TIPS over other 
forms of surgical treatment.  However, these studies did not combined the information 
on costs and outcomes together, thus, it is not possible to determine an ICER and 
make a judgment about the interventions.   
 
In the area of secondary prophylaxis of VB there have been three studies published 
which used decision analysis models. 262-264  However, only the study by Targownik et 
al 2004 262 reported on cost-effectiveness using an ICER. They evaluated the cost-
effectiveness of reducing the incidence of VB by measuring hepatic venous pressure 
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gradient monitoring (HVPG) following treatment with β-blockers and nitrates versus 
endoscopic band ligation. The reports an ICER of $5974 per recurrent bleed 
prevented.  
 
Conclusion 
 
The evidence on cost and effectiveness of screening and treatment in both HCC and 
VB is mixed.   
 
In HCC screening, all the studies found that screening using AFP and/or ultrasound 
increased costs compared with the option of not screening.  The evidence on 
effectiveness was more mixed but it suggests that screening would result in only a 
small increase in life expectancy.  A key issue is whether it is worthwhile screening to 
detect cases of HCC earlier if the relevant treatment (OLTx through the transplant 
programme) cannot be provided for these cases i.e. due to donor shortage.  
 
The limited number of studies of treatment for HCC reviewed in this report makes it 
difficult to draw a conclusion on which form of treatment would be recommended, 
especially as these studies date from the 1990’s and may not represent the latest state 
of the art in treatment for HCC. 
 
The studies which evaluated screening and pharmacoprophylaxis for VB generally 
reported that it was cost-effective.  However, for endoscopy screening followed by 
prophylaxis using β-blockers, there was no clear consensus on whether this approach 
should be universal or just for patients with a higher risk of developing VB 
(decompensated cirrhosis patients).   
 
A more recent addition to the treatment of VB is the incorporation of haemodynamic 
monitoring alongside prophylaxis with β-blockers which is used to determine the 
effectiveness of the drug treatment. There was conflicting evidence from the studies 
which incorporated additional haemodynamic monitoring of the pharmacoprohylaxis; 
one study reported cost-savings from HVPG whilst another reported very large cost 
per year of life saved values.  The decision on whether to add HVPG measurement is 
Liver disease – A rapid review of epidemiology, treatment and service provision 
 
126 
dependent on the local costs of measuring HVPG and the life expectancy of the 
patient group being screened.   
 
The large variation in the ways in which each of these studies were conducted means 
that it is not easy to interpret the ICERs calculated.  Screening and treatment for HCC 
and VB increases costs. Thus the decision on whether an intervention is ‘cost 
effective’ must be based on considering the opportunity costs of allocating resources 
for these interventions away from other currently provided treatments if there is to be 
no increase in the overall health care budget.   
 
Most of the studies reviewed did not meet all the quality requirements for economic 
evaluations. 265  The most common areas to be excluded are the year and country the 
study took part in, and discounting of the costs.  Without this the interventions 
evaluated can look more (or less) attractive than they really are.   
 
Similarly, by only providing the total cost of the treatment or intervention rather than 
an incremental analysis the true return on any additional resource use cannot be 
determined, which diminishes the usefulness of the study for making decisions on 
allocation of resources.  The studies which were based on decision models did 
however meet more of these criteria.  It is easier to do in a decision model because it 
is designed to include such factors as discounting and sensitivity analysis which 
clinically based economic evaluations often miss out.   
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6. SERVICE PROVISION FOR LIVER DISEASE 
 
In earlier sections we described the key risk factors for liver disease in England 
(heavy drinking, chronic hepatitis infections and obesity) and outlined ways of 
preventing these cases of liver disease. 
 
Liver disease of behavioural origin may be ameliorated by changes in patterns of risky 
behaviour (heavy drinking, excess calorie intake leading to obesity). 
 
Identifying liver disease early in its development is ideal. However, liver function 
tests are often inaccurate (not particularly specific) at identifying liver disease.273 In 
addition, abnormal results for liver function are often not adequately investigated, thus 
the opportunity for early identification of treatable liver disease is often missed. 62  
 
There are treatments which have beneficial effects on liver disease, particularly if it is 
identified at an early stage (e.g. interferon treatment to tackle hepatitis C). Hence it is 
important to encourage individuals in high-risk groups to come forward for testing. 
 
However, we also described a range of hepatic conditions that were caused by genetic, 
auto-immune and other factors which are not currently modifiable.  
 
As liver disease progresses to cirrhosis and primary liver cancer, the damage becomes 
permanent and significantly life-limiting.  
 
Median survival with compensated cirrhosis (without complications) is 12 years 
compared to around 2 years for decompensated cirrhosis(symptoms include bleeding 
from varices, ascites, jaundice and encephalopathy). 274. Transition from compensated 
to decompensated cirrhosis occur at a rate of 5-7% per year. 274 
 
In the following section we describe current treatment demand and service provision 
for liver disease in England. 
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Service Demand 
 
Tables 11 and 12 show finished hospital episodes (HES data) per 100,000 population 
by English government region during 2005/2006 (from April 1st 2005 until March 
31st 2006).  Relevant ICD-10 codes for liver disease are reported in Appendix V.  
 
For men and women, the highest incidence of alcoholic liver disease (K70) occurs in 
the North West of England. However, the highest incidence of all other types of liver 
disease and liver cancer is generally found in London; although there appears to be a 
North East spike for women in chronic hepatitis (K73) and fibrosis and cirrhosis of 
the liver (K74). 
 
 
Males 
Region K70 K73_K74 K71_K72_K75_K76 C22 
North East 36.3 9.4 20.0 12.1 
North West 41.8 4.7 15.3 8.9 
Yorkshire and The Humber 33.3 5.3 17.7 7.3 
East Midlands 26.7 7.3 18.8 6.1 
West Midlands 30.9 7.5 20.0 8.8 
East of England 23.8 7.6 16.7 6.1 
London 34.9 11.9 25.5 15.8 
South East 22.8 5.4 13.5 6.3 
South West 28.4 7.8 18.8 6.7 
TOTAL 30.8 7.3 18.3 8.7 
Table 11. Male Patients (based on finished episodes in HES 2005/2006) per 
100,000 population of each English government region Source: HES 2005/2006  
 
 
Females 
Region K70 K73_K74 K71_K72_K75_K76 C22 
North East 18.5 11.4 19.4 5.3 
North West 24.7 7.9 15.8 6.0 
Yorkshire and The Humber 15.1 8.6 17.8 4.3 
East Midlands 14.4 8.4 15.5 3.9 
West Midlands 14.8 9.3 19.0 5.0 
East of England 13.0 7.3 13.1 4.0 
London 12.0 9.1 21.4 7.6 
South East 10.1 6.0 11.7 3.9 
South West 13.5 7.0 14.7 4.7 
TOTAL 14.9 8.0 16.2 5.1 
Table 12. Female Patients (based on finished episodes in HES 2005/2006) per 
100,000 population of each English government region Source: HES 2005/2006  
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Tables 13 and 14 show similar HES data by ethnicity. For men and women, the 
highest incidence of alcoholic liver disease (K70) occurs in people classified as White 
British and White Other.  The incidence of other types of liver disease shows a less 
clear pattern by ethnicity. However, new cases of liver cell cancer (C22) are highest in 
men and women who are classified as Black or Mixed Black. 
 
 
 Males 
      
Ethnic group K70 K73_K74 K71_K72_K75_K76 C22 
White British  24.8 5.2 13 6.1 
White Other 31.7 10.6 19 9.7 
Asian or mixed Asian 21 8.5 21.1 9.6 
Black or mixed black 8.6 6 23.3 13.3 
Other 16.8 10.2 17.2 12.2 
general_population (excluding unspecified 
ethnicity) 24.7 5.8 14.1 6.8 
general_population (including unspecified 
ethnicity) 30 7.1 17.8 8.5 
Table 13. Male Patients (based on finished episodes in HES 2005/2006) per 
100,000 population of each ethnic group Source: HES 2005/2006  
 
 
 Females 
      
Ethnic group K70 K73_K74 K71_K72_K75_K76 C22 
White British  12.8 6.1 12.2 3.8 
White Other 11.1 7.3 15.6 5.4 
Asian or mixed Asian 1.7 7.8 15.2 3.9 
Black or mixed black 4.1 7.1 17.6 6.7 
Other 3.6 6.3 11.5 2.5 
general_population (excluding unspecified 
ethnicity) 12 6.4 12.8 4 
general_population (including unspecified 
ethnicity) 14.5 7.8 15.8 4.9 
Table 14. Female Patients (based on finished episodes in HES 2005/2006) per 
100,000 population of each ethnic group Source: HES 2005/2006  
 
 
There is a difficulty in interpreting HES data since they are reliant on current ICD-10 
codes which do not clearly distinguish  between different forms of liver disease. Also, 
current analyses tend to group several codes together (K71-72 and K75-76). Thus 
whilst it is relatively clear to identify Alcoholic Liver Disease (K70), it is not easy to 
ascertain the number of new cases of liver disease due to other causes and, in 
particular, Non-Alcoholic Fatty Liver Disease.  
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Service Distribution 
 
Three categories of hospital provide liver services in the UK: 5 
 
• District general and university-associated hospitals that usually have a 
gastroenterologist with a primary interest in liver disease (District hospitals).  
• Teaching hospitals with a major interest in liver disease that do not undertake liver 
transplantation (Hepatology centres).  
• Liver transplant centres (Transplant centres). 
 
Although we were not provided with any data on general hospital activity or from 
primary care, it is widely recognised that the majority of liver disease is managed in 
district general hospitals with no trained hepatologist and the majority of patients 
initially present and are cared for in primary care.  
 
A recent survey in England 275 identified 89 hospitals where some Hepatology 
services were provided; 34 identified themselves as a Hepatology centre and six were 
liver transplant centres . Thus 49 District hospitals provided liver services but did not 
consider themselves to be Hepatology centres. Of these 49, only 2 had designated a 
hepatologist. In the remaining 47 district hospitals, the workload was managed either 
by gastroenterologists alone (n=21) or with support from general physicians in 
(n=26).275  
 
In the 34 Hepatology centres, 28 (82%) reported a severe shortage of key staff. Nearly 
a third did not have a consultant Hepatologist in post. 275 276 
 
All six Transplant centres with core funding for tertiary liver care had more than one 
hepatologist and half had more than 3. Patients referred to these centres that do not 
need a transplant (30-60% of total referrals) benefit from the broader range of services 
available as well as more expert staff. 276 
 
Appendix X shows the geographical distribution of Transplant and Hepatology 
centres in England.  
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The six adult transplant centres in England are located in Birmingham, Cambridge, 
London (Kings and the Royal Free), Leeds, and Newcastle (see Table 15). It is 
notable that there are no transplant centres in the North West of England which has 
one of the highest rates of liver disease and there is no coverage of the South West. 
Recent data reported that each of the six transplant centres received referrals from all 
over the country and from more than 50 PCTs. 275 
 
Liver Transplant Centres   
Birmingham Queen Elizabeth Hospital 
Cambridge Addenbrooke's Hospital 
Leeds St James's University Hospital 
London King's College Hospital  
London The Royal Free Hospital  
Newcastle Freeman Hospital 
Table 15. Location of Liver Transplant Centres in England. Source: 275 
 
This unequal distribution of services is of concern and it has been reported that a 
patient living in Leeds is four times more likely to be referred for a liver transplant 
than a patient living in Cornwall. 275  
 
Despite 34 hospitals reporting that they provide specialist liver services, the National 
Plan for Liver Services UK 5 reported that only 10-15 hospitals in the UK (including 7 
transplant centres, 6 English and 1 Scottish) would qualify as  Hepatology centres; 
defined as having the clinical expertise and treatment facilities to deliver specialised 
care for liver disease. 5 
 
Workforce Training 
 
Gastroenterologists manage the majority of liver disease in the UK 1. However the 
increasing burden of liver disease and the increasing complexity of managing 
complicated liver conditions has led for calls from clinicians for the better training 
and the recruitment of more hepatologists that that have received adequate training. 1 5 
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The current specialist registrar (SpR) training programme (where one of a 5 year 
training programme is spent in a “liver post”) has been reported to be insufficient. In a 
report published by the British Association for the Study of the Liver (BASL) 277 it 
was noted that the 3 Consultant hepatologists appointed in the first 6 months of 2007 
all received their specialist training as clinical research fellows in Liver Transplant 
Units rather than in the SpR training programme. Furthermore there were only two 
applicants for each of these positions compared to 10+ for consultant 
gastroenterologist posts, suggesting a rarity of adequately trained hepatologists in 
England. 277  
 
Thus BASL recommended that: 277 
• Hepatology becomes recognised as a sub-speciality normally entered by CCST 
– accredited gastroenterologists. 
• Approximately 14 new posts need to be created to enable SPRs accredited in 
Gastroenterology to spend a sixth year in training in the sub-speciality of 
Hepatology 
• Sub-speciality accreditation should only be available to SpRs who have spent, 
in total, a minimum of two years training in designated Liver Units, 18 months 
of which should be spent in clinical posts. 
• A minimum of six months of the 2 years should be spent training in a 
designated Liver Unit with an active liver transplant programme and at least 
six months should also be spent in a designated Liver Unit with no transplant 
programme. 
• As for other trainees in Gastroenterology, trainees in Hepatology will be 
expected to be trained in diagnostic and therapeutic endoscopy to JAG 
standards. 
A 2002 survey of gastroenterologists 278 also concluded  that the number of consultant 
hepatologists needs to increase to meet the growing demand of increasing liver 
disease in England and to provide an appropriate level of care in large district general 
hospitals as well as in specialist centres. It was estimated in 2002 that to provide an 
appropriate level of care there would need to be one hepatologist to every four 
gastroenterologists appointed. 278 
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Hospital activity - Liver transplantation 
 
Transplantation is a successful treatment for end-stage cirrhosis, with a 75% five year 
survival rate. 10  However, there is limited availability of organs for donation. Also 
issues of compatibility and comorbidity factors mean that not every person with liver 
disease can be transplanted. 
 
The age of liver donors has increased significantly over the last 15 years in Europe 
and this has had an adverse impact on graft and patient survival in patients with 
Alcoholic Liver Disease (ALD) and cirrhosis due to hepatitis C virus (HCV). 279 
 
In 2000-1, there were 896 episodes of liver surgery resection and this number rose to 
1451 by 2004-5; this represented a 62% increase over this five year time period. 280 
 
The highest numbers of liver transplants occur in the South East of England and 
London. 280 Whilst the highest number of liver disease cases are found in the North 
West and North East. 281 
 
The lowest rates of liver transplants occurred in the South West of England.280 
 
There is a suggestion that transplant surgery rates are led by the availability of 
services (specialist transplant centres) rather than by case need. 280 
 
The number of deceased liver donors and transplants in the UK has remained 
relatively constant in the last ten years. In 2006/7, 636 organs were retrieved and 588 
used in transplantation. (see Figure 20). 282 
 
However, the number of patients waiting for a liver transplant has steadily increased. 
In 2006, the number of people on the active liver transplant list was 38% greater than 
in the previous year. 282 
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 Figure 20. Liver transplant figures for the UK (1997-2007). 
 
Prior to transplantation, patients attend Hepatology clinics for general management 
and assessment for transplantation. Data supplied by University Hospital Birmingham 
show that 591 men attending the Hepatology clinic had 1565 episodes of care and 322 
women had 896 episodes of care. 173 
 
Of these Hepatology episodes in men: 67% were related to ALD; 21% to NAFLD and 
12% to NASH. 173 Of these Hepatology episodes in women: 62% were related to 
ALD; 26% to NAFLD; and 11% to NASH. 173 
 
The age range of patients attending Hepatology clinics was wide (patients in their 20’s 
to their 70’s).173 However, the modal age group was 50-59 for ALD and NASH and 
40-49 for NAFLD (see Figure 21).  
 
 
Liver disease – A rapid review of epidemiology, treatment and service provision 135 
 
Figure 21. Age of patients attending Hepatology clinics in Birmingham in 2007. 
Source: 173 
 
The numbers of new referrals seems to be rising exponentially each year; the tailing 
off in 2007 is due to incomplete data for the current year (see Figure 22). 173 
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Figure 22. Year of original referral of patients attending Hepatology clinics at 
the University Hospital Birmingham. Source: 173 
 
Although ALD is the most common presenting condition, the number of referrals due 
to NAFLD and NASH has been growing steadily since the 1990’s (see Figure 22). 
 
If NAFLD and NASH cases are added together then the cases of liver disease due to 
obesity and the metabolic syndrome almost reach those for ALD. It would be 
important to see if this trend is similar in other parts of the country.  
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Hospital activity - Non-transplant specialist care 
 
Data supplied by the Plymouth Hospitals NHS Trust in the South West of England 
show that specialist hospital (non-transplant) activity on liver disease has steadily 
increased over recent years (see Tables 13-17).  
 
This activity includes treatment for primary and secondary liver cancer, liver biopsies, 
drainage of ascites and management of different forms of liver disease. 
 
Patients with advanced liver disease tend to have multiple admissions each year. 
 
Hospital activity includes liver disease as a main diagnosis or as a secondary 
diagnosis (often much higher figures), where patients present for other reasons. 
 
In all these aspects of liver disease treatment, clinical activity seems to be rising year 
on year. 
 
 
 
 Primary liver tumours C22.0-C22.9 
year Admissions – main diagnosis Admissions – any diagnosis 
2001 20 (9) 30 (14) 
2002 33 (17) 41 (20) 
2003 22 (15) 31 (19) 
2004 39 (18) 36 (17) 
2005 56 (26) 25 (11) 
2006 82 (34) 70 (30) 
Table 13. Counts per finished consultant episode (FCE) – the figure in the 
bracket is the number of patients that made up the admissions total. Source: 283 
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 Secondary liver tumours C76.7 
year Admissions – main diagnosis Admissions – any diagnosis 
2001 216 (51) 1454 (327) 
2002 196 (42) 1236 (342) 
2003 176 (43) 1225 (324) 
2004 148 (52) 1005 (307) 
2005 169 (46) 1448 (342) 
2006 216 (69) 1544 (378) 
Table 14. Counts per FCE (number of patients that made up the admission 
total). Source: 283 
 
 Management of Alcoholic liver disease K700-709 
year Admissions – main diagnosis Admissions – any diagnosis 
2001 120 (70) 285 (153) 
2002 126 (98) 341 (186) 
2003 141 (102) 353 (195) 
2004 126 (68) 342 (135) 
2005 142 (70) 365 (138) 
2006 182 (98) 512 (169) 
Table 15. Counts per FCE (number of patients that made up the admission 
total). Source: 283 
 
 Liver biopsies – OPCS J091-92, J131-2, J141, J171 
year Admissions – main 
diagnosis 
Admissions – any 
diagnosis 
2004 13 (13) 148 (141) 
2005 16 (16) 161 (152) 
2006 12 (12) 215 (204) 
Table 16 Counts per FCE (number of patients that made up the admission total). 
Source: 283 
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 Drainage of ascites – T462 
year Admissions – main 
diagnosis 
Admissions – any 
diagnosis 
2004 23 (23) 51 (42) 
2005 30 (29) 118 (86) 
2006 31 (30) 141 (99) 
Table 17 Counts per FCE (number of patients that made up the admission total). 
Source: 283 
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Hospital activity – Paediatric liver care 
 
In paediatric liver disease, children are often born with a liver condition and require 
life-long care. 
 
Paediatric liver services are available in 3 centres in England: Birmingham 
(Birmingham Children's Hospital), London (King’s College Hospital) and Leeds (St 
James’s University Hospital). 
 
Outcomes of liver transplantation in children have improved over time, particularly 
children under one year of age; one-year patient and graft survival rates improved 
from 50-58% in the 1986-9 to 81-88% in 2000-3. 284 A corollary of this positive 
outcome is the likely need for more care of young people living with liver disease.  
 
Data supplied by King’s College Hospital in London show 614 referrals and/or 
admissions for paediatric liver disease in 2006, 313 cases were new referrals (see 
Figure 23). 
 
There appears to have been a slight increase in the number of cases of liver disease 
treated in this paediatric centre since 2003/4 (see Figure 23). 
 
As with adults, individual patients present repeatedly for care each year and so there 
are more hospital episodes compared to patient cases (see Figure 24). 
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Figure 23. All cases of paediatric liver disease and new cases each year. Source: 
285
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Figure 24. Numbers of day and outpatient cases by child and hospital episode. 
Source: 285 
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The most common conditions were genetic in origin (biliary atresia in children <1 
year old and 1-5 years old). However, children also present with acute liver failure 
(n=29 in 2006/7). 
 
However, paediatric services treat a wide range of liver disease including (2006/7 
figures) 285 autoimmune disease (n=25), hepatitis B (n=4), hepatitis C (n=1), 
metabolic liver disease (n=11), non-alcoholic fatty liver disease (n=10), primary liver 
tumours (n=17) and disorders of the bile duct (n=19). 
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7. PATIENT PERSPECTIVE  
 
We were unable to find any published research on patients’ perspectives of being 
diagnosed with, or of accessing treatment for, liver disease. The only in-depth 
research identified was with prisoners (service users and potential service users) who 
were interviewed about views on hepatitis C testing in the prison setting. 99 
 
However, we were sent some qualitative data by the British Liver Trust (BLT) which 
describes patient and carers’ experiences of liver services. 286  These data were 
obtained from a survey of patients and carers at a conference organised by the Charity 
in October 2007 and visitors to their website and helpline during October and 
November 2007. Although based on a small and self-selected sample these data 
provide a valuable insight into service user views.  
 
The following is a broad summary of the patients’ views of liver services:   
 
• Respondents seemed to highly value specialist treatment and care for liver 
problems. Those people that have received specialised treatment praised the 
quality of their care. However some patients reported having to travel up to 
300 miles to access specialist care. Conversely, others reported travelling less 
than five miles for their care, suggesting that at least some of these people 
were not receiving care from doctors with specialist expertise i.e. in 
Hepatology centres.  
 
• Some respondents reported a reluctance from GPs to refer them to specialist 
centres. The survey found an average a 564 day delay from the onset of 
symptoms to diagnosis. It was perceived that this wait was due to delays in 
primary care rather than waiting lists for specialists.  
 
• In some cases patients with health conditions which can have major liver 
implications were never seen by a hepatologist because the liver disease was 
not considered to be the primary aetiology. For example, patients with NASH 
managed purely by a cardio-vascular specialist. Furthermore patients with 
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mental health problems who had taken drug overdoses had not received liver 
treatment after they have had emergency care.  
 
• Many respondents reported experiencing stigma due to their condition. This 
arose from misconceptions about alcohol use (e.g. it was presumed to be 
excessive when alcohol might not have be the causal factor for their liver 
disease) or acquisition of the hepatitis virus (e.g. it was assumed to be due to 
injecting drug use or risky sexual behaviour rather than contaminated blood 
products). Many patients felt that these misconceptions had led to poor quality 
of care and may have influenced referral and treatment decisions.  
 
• Patients reported that they would like to receive more holistic treatment. 
Centres that offered the additional support of specialist nurses, counsellors, 
social workers and seamless access to other professionals seemed to be very 
much valued by patients.  
 
• Respondents reported a common experience of administrative errors regarding 
communication about test results or liaison between different treatment 
providers.  Thus test results went missing or were miscommunicated between 
different clinicians. It was not clear if this was particular to Hepatology or an 
inherent problem in situations where patients have complex needs. 
 
 
The lack of rigorously conducted research on patients’ views is a significant gap in 
our knowledge about liver disease treatment and service provision and should be 
addressed as a priority in future research work. 
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8. CONCLUSIONS 
 
Liver disease in England is increasing; there are more cases developing each year and 
people are dying earlier from this condition. 
 
The steady rise in liver disease in England is in contrast to most countries of the 
world. 
 
Most cases of liver disease are due to modifiable (lifestyle) factors. 
 
The largest numbers of liver disease cases in England are due to excessive drinking in 
the population and to chronic hepatitis infections. 
 
Obesity can also cause liver disease and high obesity rates in England are likely to 
lead to a rapid increase in liver disease in the near future. 
 
The NHS needs more capacity to respond to liver disease in England, particularly in 
the North West and the South West of England. 
 
The NHS needs to prepare for a potentially large future burden of liver disease. 
 
Current research tends to focus on treating existing liver disease; future work needs to 
address effective means of preventing liver disease. 
 
Behaviour change interventions are effective at reducing excessive drinking and 
obesity and should be implemented in England. 
 
We need better screening for hepatitis infections and early treatment of hepatitis C. 
 
Patient s’ perspectives of living with (and often dying early from) liver disease are 
absent from the current literature and this needs to be rectified. 
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Appendix I 
 
Liver review – Key Informants contacted 
 
Response 
received 
Expert clinicians group Contact details 
 Professor Ian Gilmore President of the Royal College of Physicians and 
Consultant gastroenterologist, Liverpool.  
The Royal College of Physicians, 11 St Andrews 
Place, Regent's Park, London, NW1 4LE  
Ian.gilmore@rcplondon.ac.uk 
020 7935 1174 (main RCP line) 
 Professor Howard Thomas  Head of Department of Hepatology and 
Gastroenterology, Imperial College London, St 
Mary’s, Norfolk Place, London, W2 1PG 
h.thomas@imperial.ac.uk 
020 7886 6454 
 Charles Millson  Department of Gastroenterology, St James's 
University Hospital, Beckett Street, Leeds, LS9 7TF 
charles.millson@leedsth.nhs.uk 
0113 2433144 (main hospital line) 
 Mark Thursz  Professor of Hepatology, Imperial College London, 
St Mary's, Norfolk Place, London, W2 1PG  
mark.thursz@imperial.ac.uk 
020 7594 3851 
 Matthew Cramp  Gastroenterology Unit, Derriford Hospital, Derriford 
Road, Crownhill, Plymouth, Devon, PL6 8DH  
matthew.cramp@phnt.swest.nhs.uk 
0845 155 8155 (main hospital line) 
 Jane Collier  Department of Gastroenterology, John Radcliffe 
Hospital, Headington , Oxford, OX3 9DU 
jane.collier@orh.nhs.uk 
01865 220944 
 David Mutimer  Queen Elizabeth Hospital, Queen Elizabeth Medical 
Centre, Birmingham, B15 2TH 
David.mutimer@uhb.nhs.uk 
0121 472 1311 (switchboard) 
 Prof Kevin Moore 
 
Professor of Hepatology, Centre for Hepatology, 
Dept. of Medicine, Hampstead Campus, University 
College London, Rowland Hill St, London, NW3 
2PF  
K.moore@medsch.ucl.ac.uk,  
02074332876 
 Prof Giorgina Miele-Vergani 
 
Professor of Paediatric Hepatology 
Kings College Hospital 
Denmark Hill 
London, SE5 9RS 
giorgina.vergani@kcl.ac.uk 
Tel: 020 3299 4643 
 Mr Darius Mirza 
 
Consultant Surgeon, Liver Unit, Queen Elizabeth 
Hospital, Queen Elizabeth Medical Centre, 
Birmingham , B15 2TH 
Darius.mirza@uhb.nhs.uk 
0121 697 8391 
 Williams et al. 2007 review 
(principal team) 
 
 
Professor John Williams Consultant Gastroenterologist / Professor of Health 
Services Research, Centre for Health Improvement 
Research and Evaluation (CHIRAL), School of 
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Medicine, Swansea University, Swansea, SA2 8PP 
j.g.williams@swansea.ac.uk,  
01792 513402 
 
Dr Faiz Ali Specialist Registrar in Gastroenterology / Research 
Fellow, Centre for Health Improvement Research 
and EvaLuation (CHIRAL), Swansea Clinical 
School, University of Wales Swansea, SA2 8PP 
m.f.ali@swansea.ac.uk 
01792 513420 
 
Dr Wai -Yee Cheung Senior Lecturer in Health Service Research, Centre 
for Health Improvement Research and Evaluation 
(CHIRAL), Swansea Clinical School, University of 
Wales Swansea, SA2 8PP 
w.y.cheung@swansea.ac.uk 
01792 513410 
 
Professor David Cohen Professor of Health Economics, School of Care 
Sciences, University of Glamorgan, Glyntaf 
Campus, Glyntaf, CF37 4BL 
dcohen@glam.ac.uk 
01443 483827 
 Dr Adrian Edwards Reader in Primary Care, Centre for Health 
Improvement Research and Evaluation (CHIRAL), 
Swansea Clinical School, University of Wales 
Swansea, SA2 8PP 
a.g.k.edwards@swansea.ac.uk 
 Dr Mike Hellier President, British Society of Gastroenterology, West 
Leaze, Ogbourne Road, Aldborough, SN8 2LD 
 Dr Stephen Roberts Senior Lecturer in Epidemiology, Centre for Health 
Improvement Research and Evaluation (CHIRAL), 
Swansea Clinical School, University of Wales 
Swansea, SA2 8PP 
Stephen.e.roberts@swansea.ac.uk   
01792 513433 
 Professor Ian Russell Professor of Public Health/Director of Institute of 
Medical and Social Care Research, University of 
Wales Bangor, Gwynedd LL57 2UW 
Ian.russell@bangor.ac.uk 
01248 383617 
 Professor Helen Snooks Professor of Health Services Research, Centre for 
Health Improvement Research and Evaluation 
(CHIRAL), School of Medicine, Swansea 
University, Swansea, SA2 8PP 
h.a.snooks@swansea.ac.uk 
01792 513418 
 Williams et al. 2007 review 
(named contributors) 
 
 Dr Giles Croft Research Fellow, Royal College of Physicians iLab, 
Swansea Clinical School, University of Wales 
Swansea, Singleton Park 
Swansea SA2 8PP 
g.p.croft@swansea.ac.uk 
01792 513224 
  Dr Ian Frayling Director, All Wales Laboratory Genetics Service & 
Consultant in Genetic Pathology, Institute of 
Medical Genetics, University Hospital of Wales, 
Cardiff, CF14 4XW 
ian.frayling@cardiffandvale.wales.nhs.uk  
029 2074 4203   
  Dr Alistair McIntyre Consultant Gastroenterologist, Wycombe General 
Hospital, High Wycombe, Buckinghamshire, HP11 
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2TT 
Alistair.McIntyre@sbucks.nhs.uk 
01494 526161 (main hospital line) 
 Dr Roland Valori Consultant Gastroenterologist, Gloucestershire 
Royal Hospital, Great Western Road, Gloucester, 
GL1 3NN 
Roland.valori@btopenworld.com  
teri.hopson@glos.nhs.uk (secretary)  
08454 22 6620 (secretary) 
 Professor Anne Williams Professor of Nursing Nursing, Health & Social Care 
Research Centre, Cardiff School of Nursing and 
Midwifery Studies, Cardiff University, 4th Floor, 
EastGate House, 35-43 Newport Road, CARDIFF, 
CF24 0AB 
williamsam7@cardiff.ac.uk 
02920 917816 
 Williams et al. 2007 review 
(consulted experts) 
 
  Professor Qasim Aziz Professor of gastroenterology, School of Medicine, 
The University of Manchester, Oxford Road, 
Manchester M13 9PT 
qasim.aziz@manchester.ac.uk 
0161 206 4416 
 Professor Andrew Burroughs Consultant Hepatologist, Royal Free & University 
College, Medical School, UCL Institute of 
Hepatology Hampstead Campus, U3rd Floor, 
Rowland Hill Street, Hampstead  
London, NW3 2PF 
a.burroughs@medsch.ucl.ac.uk 
0207 4332851 
  Shona Campbell Clinical Director of Imaging, Leicester General 
Hospital, Gwendolen Road, Leicester, LE5 4PW  
shona.campbell@uhl-tr.nhs.uk 
0116 258 6720 
 
 
Dr John de Caestecker Consultant gastroenterologist  
Glenfield Hospital, University Hospitals of 
Leicester NHS Trust, UK 
john.decaestecker@uhl-tr.nhs.uk  
Direct telephone: 0116 276 9401 
 Professor RM Charnely R. M. Charnley, Consultant Surgeon, Freeman 
Hospital, High Heaton, Newcastle upon Tyne NE7 
7DN 
Richard.Charnley@nuth.northy.nhs.uk 
Tel: 0191 223 1030 
  Dr Ian Forgacs Consultant gastroenterologist  
Kings College Hospital, Denmark Hill, London, 
SE5 9RS 
Ian.forgacs@kcl.ac.uk  
020 3299 2728 
  Dr Barry Jones Consultant gastroenterologist, Dept 
Gastroenterology, Russell hall Hospital, Dudley, 
West Midlands, DY1 2HQ 
b.j.m.j@btinternet.com 
01384 456111 (main hospital line) 
 Ms Norma McGough Dietetic services manager / Coeliac UK 
Coeliac UK, Suites A-D Octagon Court, High 
Wycombe 
Bucks, HP11 2HS 
norma.mcgough@coeliac.org.uk 
01494 437 278 (main switchboard) 
Liver disease – A rapid review of epidemiology, treatment and service provision 167 
 
Professor Paul Moayyedi Professor of gastroenterology 
Gastroenterology Unit, City Hospital NHS Trust, 
Birmingham B18 7QH 
Department of Medicine, Division of 
Gastroenterology, McMaster University Medical 
Center, 1200 Main St., West, HSC 3N51D, 
Hamilton, Ontario, Canada L8N 3Z5 
moayyep@mcmaster.ca 
905-525-9140 x25679 
 
Professor Christine Norton Burdett Professor of Gastrointestinal Nursing & 
Nurse Consultant, St. Mark's Hospital, Burdett 
Institute of Gastrointestinal Nursing, St Mark's 
Hospital, Watford Road, Harrow, Middlesex HA1 
3UJ 
christine.s.norton@kcl.ac.uk 
0208 235 4167 
 
Dr KR Palmer Consultant gastroenterologist 
Gastrointestinal Unit, Western General Hospital, 
Crewe Rd, Edinburgh, EH4 2XU 
kpalmer@golf5063.freeserve.co.uk 
0131 537 1000 (main switchboard) 
 Lynne Smith Chair of the Association of GI physiologists, 
Oesophageal Laboratory, GI Investigation, 
Chesterman Wing, Northern General Hospital, 
Herries Road, Sheffield, S5 7AU 
Lyn.Smith@sth.nhs.uk    
0114 271 4293 
 Dr Richard Stevens 
 
GP, Chair of Primary Care Society for 
Gastroenterology  
Gable House, 40 High Street, Rickmansworth, 
Herts, WD3 1ER 
Richard.stevens@public-health.oxford.ac.uk 
01923 712 711 (main line) 
  Professor Robert Sutton 
 
 
Professor of surgery  
The Division of Surgery and Oncology, 5th Floor, 
UCD Block, Royal Liverpool University Hospital, 
Daulby Street,  
Liverpool, L69 3GA. 
r.sutton@liverpool.ac.uk  
0151 706 4187 
  Dr Simon Travis 
 
 
Consultant gastroenterologist, John Radcliffe 
Hospital, Headley Way, Headington, Oxford, OX3 
9DU  
simon.travis@orh.nhs.uk| 
01865 851072 (secretary) 
 
Dr Kevin Wedgwood Consultant General Surgeon 
Hull and East Riding Hospital, Lowfield Road, 
Anlaby, Hull, East Yorkshire, HU10 7AZ 
kevin.wedgwood@hey.nhs.uk 
01482 672444 
 Department of Heath scoping 
report  
(named experts – not above) 
 
 Alison Rogers Chief Executive of the British Liver Trust, British 
Liver Trust, 2 Southampton Road, Ringwood, BH24 
1HY ala@britishlivertrust.org.uk 
0870 770 8028 (switchboard) 
 Professor Chris Day Head Clinical Medical Sciences, SCMS 
(Gastroenterology & Hepatology), Newcastle 
University, 4th Floor William Leech Building, The 
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Medical School, Framlington Place, Newcastle upon 
Tyne, NE2 4HH  
c.p.day@newcastle.ac.uk  
01912225784 
 Professor Oliver James Provost of Medical Sciences,  Faculty of Medical 
Sciences, Medical School, Framlington Place, 
University of Newcastle, Newcastle upon Tyne, 
NE2 4HH 
o.f.w.james@newcastle.ac.uk  
01912227003 
 
Dr. Edmund Jessop 
 
Medical Adviser NSCAG, National Commissioning 
Group 
Southside, 105 Victoria Street, London SW1E 6QT 
edmund.jessop@ncg.nhs.uk  
020 7932 3949 
 
Prof William Rosenberg 
 
Southampton University Liver Research Unit 
MP811, Level D, South Block, Southampton 
General Hospital, Tremona Road, Southampton, 
SO16 6YD 
wmr@soton.ac.uk 
023 8079 6883 (PA) 
 Prof Richard Lilford 
 
Professor of Public Health, Department of Public 
Health and Epidemiology, University of 
Birmingham, Edgbaston, Birmingham, B15 2TT 
r.j.lilford@bham.ac.uk,  
0121 414 6772 
 
Mr Graeme Poston Consultant in Hepato-biliary surgery, Aintree 
University Hospital NHS Foundation Trust, 
University Hospital Aintree, Longmoor Lane, 
Liverpool L9 7AL 
graeme.poston@aht.nwest.nhs.uk 
0151 525 5980 
 
Prof Mike Richards 
 
DH Medical Director – Cancer 
Department of Palliative Care, 1st Floor Block 6, 
South Wing, St Thomas’ Hospital, Lambeth Palace 
Road, London, SE1 7EH  
PA: Jo.Aracena@gstt.nhs.uk  
PA: 020 7188 4732 
 Prof Humphrey Hodgson Director of the Centre for Hepatology, Royal Free 
and University College Medical School (UCL) 
Hampstead Campus Centre for Hepatology, 
Department of Medicine Rowland Hill Street 
London NW3 2PF UK 
h.hodgson@ucl.ac.uk 
020 7433 2850/1  
 Other nominated experts  
  Professor James Neuberger 
 
Liver Transplantation. Liver unit, Queen Elizabeth 
Hospital, Birmingham 
James.Neuberger@uhb.nhs.uk 
0121 472 1311, ext 2414 
  Dr Jim McCambridge 
 
Lecturer in Epidemiology, London School of 
Hygiene and Tropical Medicine, Keppel Street, 
London, WC1E 7HT 
Jim.mccambridge@lshtm.ac.uk  
02079272945 
 Dr Nick Sheron Consultant Hepatologist, University of 
Southampton, School of Medicine, Southampton 
General Hospital, Tremona Road, Southampton, 
Hampshire, SO16 6YD 
Nick.sheron@soton.ac.uk 
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02380 795099 
  Dr Steve Ryder Consultant Hepatologist, University Hospital, 
Queen's Medical Centre, Nottingham, NG7 2UH 
Stephen.ryder@nuh.nhs.uk 
(0115) 924 9924 ext. 43450 
  Dr Guruprasad Aithal University Hospital, D Floor, South Block 
Queen's Medical Centre, Nottingham, NG7 2UH 
guru.aithal@nuh.nhs.uk 
(0115) 924 9924 ext. 65747 
 Dr Joe West Clinician Scientist, 
Nottingham University 
Joe.west@nottingham.ac.uk  
  Professor David Jones 
 
 
Professor of Liver Immunology, School of Clinical 
Medical Sciences, 4th Floor William Leech 
Building , The Medical School, University of 
Newcastle upon Tyne, Newcastle upon Tyne, NE2 
4HH. #5784 
d.e.j.jones@newcastle.ac.uk 
 Professor Margaret Bassendine Professor of Hepatology, School of Clinical Medical 
Sciences (Hepatology), Institute of Cellular 
Medicine, 4th floor William Leech Builidng, The 
Medical School, University of Newcastle upon 
Tyne, Newcastle upon Tyne, NE2 4HH #6995 
m.bassendine@newcastle.ac.uk 
  Dr Peter Anderson 
 
WHO Public Health Advisor – Alcohol 
peteranderson.mail@gmail.com 
 
  Dr Guy Radcliffe Medical director, Medical Council on Alcohol, 3 St 
Andrew's Place, Regent's Park, London, NW1 4LB 
mca@medicouncilalcol.demon.co.uk  
020 7487 4445 
  Dr Ashley Adamson Public Health Career Scientist, Human nutrition 
a.j.adamson@newcastle.ac.uk  
 Mr Martin Hepke Service Management, Birmingham Children's 
Hospital 
martin.hepke@bch.nhs.uk 
0121 3338372 
 Ms Anna Clough Service Management, King's College Hospital 
Anna.clough@kch.nhs.uk 
0207 346 3408 or 0207 346 4774 (Garry PA) 
 Ms Jenny Hey Service Management, Leeds Teaching Hospital 
Jenny.Hey@leedsth.nhs.uk 
0113 2432799 
 Frances O'Callaghan 
 
General Manager (Liver & Renal), King's College 
Hospital 
Frances.O'Callaghan@kch.nhs.uk 
020 3299 4157/4833 
 Mr Geoff Apperley Head of Commissioning, Addenbrooke's Hospital 
Cambridge 
geoff.apperley@addenbrookes.nhs.uk 
01223 217683 
 Ms Susan Lawrence Clinical Services Manager - Transplant, 
Addenbrooke's Hospital Cambridge 
susan.lawrence@addenbrookes.nhs.uk 
01223 348289 
  Alex Christie Business Manager, Freeman Hospital Newcastle 
alex.christie@nuth.nhs.uk 
0191 213 7877 
 Mr Craig Brigg Head of CMT for Surgical Services and 
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Gastroenterology, Leeds Teaching Hospital 
Craig.Brigg@leedsth.nhs.uk 
0113 243 2799 
 Ms Janet Mustoe General Manager, Royal Free Hospital 
janet.mustoe@royalfree.nhs.uk 
02077940500 ext 5522 
 Mr Kevin Bolger Director of Operations, University Hospital 
Birmingham 
kevin.bolger@uhb.nhs.uk 
  Mr Patrick Hobbs National Commissioning Group, 4th 
floor, Southside 
105 Victoria Street, London , SW1E 6QT  
Patrick.Hobbs@ncg.nhs.uk 
020 7932 3952  
 Professor Dave Collett Director of Statistics and Audit, UK Transplant 
Communications Directorate, Fox Den Road, Stoke 
Gifford, Bristol, BS34 8RR 
dave.collett@uktransplant.nhs.uk 
0117 975 7438 
 Ms Bridget Gunson Bridget Gunson, Clinical Research Manager, Liver 
Research Laboratories, University Hospital 
Birmingham. bridget.gunson@uhb.nhs.uk  
 Mr Derek Manus Consultant Surgeon, Freeman Hospital, Newcastle 
upon Tyne. derek.manas@nuth.nhs.uk  
 Professor Mark Bellamy 
 
Professor of Critical Care Anaesthesia 
Intensive Care Unit 
St James's University Hospital 
Leeds LS9 7TF 
Tel: 0113 206 6813 
M.C.Bellamy@leeds.ac.uk  
 Snowball sample – response to 
our letter or DH stakeholder 
letter 
 
 
Dr Toby Delahooke 
 
Toby.delahooke@uhl-tr.nhs.uk 
Thesis on Hep C in Scotland 
 
Dr Allister Grant 
 
 
Allister.grant@uhl-tr.nhs.uk 
Leicester Royal Infirmary – trained in Birmingham 
– reorganisation of alcohol services 
 Dr Adrian Hamlyn 
 
Consultant Gastroenterologist, Russells Hall 
Hospital, Dudley. 
 Dr Neil Fisher Consultant Gastroenterologist, Russells Hall 
Hospital, Dudley. 
 Professor Deirdre Kelly Paediatric liver disease, Birmingham children’s 
Hospital. Tel: 0121 333 8263. 
Deirdre.kelly@bch.nhs.uk  
 Professor O. James Garden 
 
Professor of Clinical Surgery, Edinburgh transplant 
programme, Ward 106, Royal Infirmary of 
Edinburgh, 51 Little France Crescent, Edinburgh, 
EH16 4SA 
0131 242 3614 
ojgarden@ed.ac.uk 
 Professor Peter Hayes Lead Clinician for Research, Western General Site 
(WTCRF), Wellcome Trust Clinical Research 
Facility, Western General Hospital, Crewe Road 
South, Edinburgh, EH4 2XU 
0131 242 1628 
p.hayes@ed.ac.uk  
 Professor John Iredale 
 
Professor of Medicine, MRC/University of 
Edinburgh Centre for Inflammation Research, The 
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 Queen's Medical Research Institute, 47 Little France 
Crescent, Edinburgh, EH16 4TJ 
0131 242 9100 
John.Iredale@ed.ac.uk  
 Professor David Adams 
 
 
Professor of Hepatology, Liver Research Group 
Fifth Floor, Institute for Biomedical Research, 
Medical School, University of Birmingham, Vincent 
Drive, Edgbaston, B15 2TT 
0121 415 8700 
d.h.adams@bham.ac.uk 
 Professor Elwyn Elias 
 
 
Consultant Hepatologist, Liver Unit, Queen 
Elizabeth Hospital, 3rd Floor, Nuffield House, 
Edgbaston, Birmingham, B15 2TH 
elwyn.elias@uhb.nhs.uk 
  Margaret Clark West Yorkshire Critical Care Network, St James’ 
University Hospital Leeds 
  Dr Michael Allison Consultant Hepatologist, Box 210, Cambridge 
University Teaching Hospitals NHS Foundation 
Trust Hills Road, Cambridge CB2 2QQ Tel 01223 
586641 Fax 01223 216111 
Michael.allison@addenbrookes.nhs.uk 
 Sue Kellie British dietetics association 
s.kellie@bda.uk.com 
 Ian McAllister 
 
Principal Research Officer, Alcohol Misuse  
Scottish Government Office, Edinburgh EH1 3DG 
Iain.MacAllister@scotland.gsi.gov.uk 
 Peter Craig  
 
Chief Scientist Office, Scottish Government; 
peter.craig@scotland.gsi.gov.uk 
 Sally Haw NHS Health Scotland  
(Sally.Haw@health.scot.nhs.uk). 
 Sharon Hutchinson 
 
Health Protection Scotland 
Sharon.hutchinson@hps.nhs.uk 
 Patrick Hobbs National Commissioning Group 
Patrick.hobbs@ncg.nhs.uk 
 Laura Kinsey 
 
 
Specialist gastroenterology dietician, University 
Hospital, Aintree. 
Laura.kinsey@aintree.nhs.uk 
 Dr Sarah Cumbers  
 
 
Associate Director Information Services, National 
Institute for Health and Clinical Excellence (NICE), 
MidCity Place, 71 High Holborn, London  WC1V 
6NA. Direct line: 020 7067 5945. 
Sarah.cumbers@nice.org.uk 
 Penny Wilson-Webb 
 
Coordinator of the Hepatitis B Foundation 
coordinator@hepb.org.uk 
 AASLD 
 
American Association for the study of liver disease 
AASLD@AASLD.org 
 Naresh Chada SMO Northern Ireland 
Naresh.chada@dhssppsni.gov.uk 
  Charles Gore Hepatitis C Trust 
Charles.gore@hepctrust.org.uk 
  Dr William Williams Service user, Wales 
Rafidian@tiscali.co.uk 
 Mr John Bedlington Liver North, Service user organisation 
jeb@beamishwoodcraft.freeserve.co.uk  
  Dr Patricia McClean Chair, Paediatric liver steering group BSPGHAN 
Children’s Liver Unit, St James’ Hospital Leeds, 
LS9 7TF. Tel: 01132066880 
Patricia.mcclean@leedsth.nhs.uk 
 Imogen Shillitoe Imogen Shillito 
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Director of Information & Education, British Liver 
Trust, 2 Southampton Road, Ringwood  BH24 1HY  
Tel: 01425 481320 
imogen.shillito@britishlivertrust.org.uk  
 Department of Health  
(Relevant sections) 
 
 Substance misuse policy unit Don Lavoie/Conrad Ryan – alcohol statistics 
 Liver team 
 
Alan Bell/John Bromley/Sunita Shier/Mushi 
Rahman/Jules Crighton/Scott Nicholson 
 Hepatitis C team Gerry Robb/Dr Hugh Nicholas 
 Obesity team Dr Darren Hughes 
 Prison health Dr Mary Piper 
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Appendix II 
 
Search strategy for epidemiology papers. 
 
Original source for the search strategy (1-20) Roderick et al. 2004 
 
1.exp INCIDENCE/ 
2. exp PREVALENCE/ 
3. (incidence or prevalence).ti,ab. 
4. 1 or 2 or 3 
5. exp Risk Factors/ 
6. exp Time Factors/ 
7. exp Cohort Studies/ 
8. epidemiol$.ti,ab. 
9. aetiolo$.ti,ab. 
10. etiolog$.ti,ab. 
11. 8 or 9 or 10 
12. ((natural or disease$) adj (progress$ or course$ or histor$)).ti,ab. 
13. 4 or 5 or 6 or 7 or 11 or 12 
14. time trends$.mp 
15. trends$.mp.  
16. projection$.mp 
17. model$.mp.  
18. 13 or 14 or 15 or 16 or 17 
19. limit 18 to human 
20. 18 and 19 
 
21. Liver disease 
22. [relevant key word terms – see below) 
23. 21 or 22 
24. 20 and 23  
 
Keywords 
Alcohol, alcoholic, alcohol-related, drugs, substance 
hepatitis, infections, hepatitis C, hepatitis B, HCV, HBV 
Obesity, overweight, metabolic syndrome, NAFLD, NASH 
Genetic, inherited, heritable 
Autoimmune, acquired, immune system 
Cancer, tumours, primary liver cancer 
Paediatric, childhood, child, infant 
Budd Chiari, Primary Biliary Cirrhosis, Schlerosing Cholangitis, Biliary Atresia 
 
Liver disease – A rapid review of epidemiology, treatment and service provision 174 
Appendix III 
 
Search strategy - Economic Evaluations of treatment for liver disease 
 
Medline/PubMed (National Library of Medicine) 1966 to May 2003 
(((alcohol-related disorders OR alcohol drinking OR alcoholism[MeSH Subjects]) 
AND (liver OR liver diseases[MeSH Subjects])) OR liver diseases, alcoholic OR liver 
cirrhosis, alcoholic[MeSH Subjects]) 
AND 
(cost of illness OR economics OR health planning[MeSH Subjects] OR 
economics[subheading] OR burden of illness OR cost of illness Or cost OR 
costs[TextWords]) 
 
Embase (OVID) 1980 to May 2003 
(((Alcoholism[Embase Subject Headings] OR alcohol$[Text Word] AND (liver 
disease OR liver)) OR alcohol liver disease OR alcohol liver cirrhosis[Embase 
Subject Headings]) 
AND 
(cost of Illness OR economics OR health economics OR economic aspect OR health 
care cost OR cost of health care planning[Embase Subject Headings] OR “cost of 
illness” OR “burden of illness” OR cost OR costs[Text Words] 
 
EconLit (EBSCO) & Business Source Premiere (EBSCO) Mid 1960s to 2003 
alcohol* AND liver*[Default Fields] 
AND 
cost* OR burden of illness OR economic*[Default Fields] 
 
Sociological Abstracts (WebSPIRS) 1963 to 2003 
alcoholism OR alcohol[Descriptors] AND liver*[TextWord] 
AND 
costs OR health care costs OR economics[Descriptors] OR cost of illness OR burden 
of illness OR cost OR economic*[Text Words] 
 
Social Sciences Abstracts (Wilson Web) 1983 to 2003 
(alcoholism[Descriptor] OR alcohol*) AND (liver OR liver/diseases[Descriptors] OR 
liver[Text Word])  
AND 
economics OR cost[Descriptors] OR cost of illness OR burden of illness Or cost OR 
costs OR economic*[Text Words] 
 
Internet 
Freetext internet searching, using the Google search engine and the following 
combination of terms  
Alcohol* AND liver* 
AND 
(cost of illness OR burden of illness OR cost OR costs OR economic*)
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Appendix IV 
 
ACRONYMS 
 
AIH – Autoimmune hepatitis 
 
ALD – Alcoholic liver disease 
 
ALT – Alaine aminotranserase, a liver enzyme that enters the blood following liver 
damage. An ALT test is used to monitor and assess the degree of liver damage in 
patients with chronic HBV.  
 
ANARP - Alcohol Needs Assessment Research Project 
 
CCA  - Cholangiocarcinoma, cancer of the bile ducts  
 
CF - Cystic Fibrosis 
 
CFRD – Cystic Fibrosis Related Disease 
 
CFTR - Cystic fibrosis transmembrane conductance regulator 
 
CHD - Coronary heart disease 
 
COPD – Chronic obstructive pulmonary disease  
 
CSP - Comprehensive service provider 
 
CVD - Coronary vascular disease 
 
DM – Diabetes mellitus 
 
ELISA - Enzyme Linked Immunosorbent Assays 
 
ERCP - Endoscopic Retrograde Cholangiopancreatography 
 
FCE - finished consultant episode 
 
GHS - General Household Survey  
 
GI - Gastroenterology 
 
GUM - Genito-Urinary Medicine 
 
HAV – Hepatitis A Virus 
 
HBV – Hepatitis B virus  
 
HCC – Hepatocelluar carcinoma, also called hepatoma. With biliary tree cancer, HCC 
is one of the two main types of primary liver cancer. 
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HCV – Hepatitis C virus  
 
HES - Hospital Episode Statistics 
 
HIV – Human Immunodeficiency Virus 
 
IDU – Injecting drug user 
 
ID – Infectious disease 
 
NAFLD – Non-Alcoholic Fatty Liver Disease 
 
NASH – Non-Alcoholic Steatohepatitis  
 
NICE - National Institute for Health and Clinical Excellence 
 
PBC – Primary Biliary Cirrhosis 
 
NSF – National Service Framework 
 
PSA - Public Service Agreement 
 
PSC – Primary Schlerosing Cholangitis  
 
QALY - Quality adjusted life year 
 
RUCAM - The Rousssel - Uclaf causality assessment method 
 
URSO - Ursodexoycholic acid 
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Appendix V 
 
The International classification of diseases, 10th revision (ICD-10) codes used to for 
diseases of the liver. Chronic liver disease is specified by the codes K70, K73-K74. 
 
 
 
 
 
International classification of diseases, 10th 
revision 
Description 
ICD-10 
code 
Alcoholic liver disease K70 
Toxic liver disease K71 
Hepatic failure, not elsewhere 
classified K72 
Chronic hepatitis, not esewhere 
classified K73 
Fibrosis and cirrhosis of liver K74 
Other inflammatory liver diseases K75 
Other diseases of liver K76 
  
Liver cell carcinoma C22 
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Appendix VI 
 
Other Hepatitis Viruses A,D&E 
 
Hepatitis A. 
Hepatitis A and E are spread through faeces, usually when they have contaminated 
food or water i.e. poor sewage or through oral and anal sex.  The way hepatitis A 
works in the body is not well understood but the infection does not typically have a 
chronic stage and does not cause permanent liver damage as virtually all people get 
better on their own. However, the symptoms from the virus can be severe, even 
deadly: high liver enzymes, high fever, loss of appetite, nausea, vomiting, and 
jaundice, which is caused by the increased liver enzymes. The symptoms usually last 
1 to 4 weeks. The virus can only be contracted once as the immune system makes 
antibodies against the hepatitis A virus that confer immunity against future infection 
 At present there is no antiviral treatment for hepatitis A virus once it is contracted so 
the emphasis is on raising awareness of the precautions that individuals need to take 
and prevention through administering the vaccine, which can be given in combination 
with the vaccine for hepatitis B. 
 
Hepatitis D 
 
Main spread hepatitis D is contact with infected blood. However, hepatitis D is 
considered to be a subviral satellite because it can only develop in those already 
infected with hepatitis B. Co-infection with hepatitis D results in more severe 
complications compared to infection with hepatitis B alone. These complications 
include a greater likelihood of experiencing liver failure in acute infections and a 
greater likelihood of developing liver cancer in chronic infections. In combination 
with hepatitis B virus, hepatitis D has the highest mortality rate of all the hepatitis 
infections of 20%.  
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Hepatitis E 
 
Hepatitis E is prevalent in most developing countries, and not uncommon in any 
country with a hot climate. It is widespread in Southeast Asia, northern and central 
Africa, India, and Central America. It is spread mainly through fecal contamination 
of water supplies or food; person-to-person transmission is uncommon. However, 
domestic animals have been reported to act as a reservoir for the hepatitis E virus, 
with some surveys showing infection rates exceeding 95% among domestic pigs. 
Outbreaks of epidemic hepatitis E most commonly occur after heavy rainfalls and 
monsoons because of their disruption of water supplies. The incidence of hepatitis E 
is highest in adults between the ages of 15 and 40. Though children often contract this 
infection as well, they less frequently become symptomatic. Mortality rates are 
generally low, for hepatitis E is a “self-limiting” disease, in that it usually goes away 
by itself and the patient recovers, the duration of the infection is typically a few 
weeks. 
 
A recent study conducted with Nepalese male army recruits has indicated that the first 
vaccine against hepatitis E, which is yet to be named, is highly effective in protecting 
people from the disease. 287These are encouraging developments, however it must be 
noted that these are preliminary findings and work must be carried out with women 
and children. 
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Appendix VII 
 
Synopsis of published Cochrane Collaboration Reviews 
 
 Reference 
 
Prevention
or 
Treatment 
Review  
or 
Protocol 
Conclusion 
 
Number of 
Duplicate 
entries 
1 Liu JP, Gluud LL, 
Als-Nielsen B, 
Gluud C. 
Artificial and 
bioartificial 
support systems 
for liver failure. 
Cochrane 
Database of 
Systematic 
Reviews 2004, 
Issue 1. 
Treatment Review INCONCLUSIVE 
– more work 
needed before any 
support systems 
may be 
recommended for 
routine use.  
 
Artificial support 
systems may 
reduce mortality 
in acute-on-
chronic liver 
failure. Artificial 
and bioartificial 
support systems 
did not appear to 
affect mortality in 
acute liver failure. 
This Review 
indicates that 
artificial support 
systems may 
reduce mortality 
in acute-on-
chronic liver 
failure.  
11 
2 Gurusamy KS, 
Kumar Y, 
Davidson BR. 
Ischaemic 
preconditioning 
versus no 
ischaemic 
preconditioning 
for liver 
transplantation. 
(Protocol) 
Cochrane 
Database of 
Systematic 
Treatment Protocol ONGOING 2 
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Reviews 2007, 
3 Lee C, Gong Y, 
Brok J, Boxall 
EH, Gluud C. 
Hepatitis B 
immunisation for 
newborn infants 
of hepatitis B 
surface antigen-
positive mothers. 
Cochrane 
Database of 
Systematic 
Reviews 2006, 
Issue 2. 
Prevention Review EFFECTIVE - 
Vaccine, hepatitis 
B 
immunoglobulin, 
and vaccine plus 
hepatitis B 
immunoglobulin 
prevent hepatitis 
B occurrence in 
newborn infants 
of HBsAg positive 
mothers. 
4 
4 Schroth RJ, 
Hitchon CA, 
Uhanova J, 
Noreddin A, 
Taback SP, 
Moffatt MEK, 
Zacharias JM. 
Hepatitis B 
vaccination for 
patients with 
chronic renal 
failure. Cochrane 
Database of 
Systematic 
Reviews 2004, 
Issue 3. 
 
Prevention Review INCONCLUSIVE 
- Hepatitis B 
vaccines achieve 
antibody 
production in 
patients with 
chronic renal 
failure, unsure if 
the vaccines are 
protective. 
2 
5 Chen W, Gluud 
C. Vaccines for 
preventing 
hepatitis B in 
health-care 
workers. 
Cochrane 
Database of 
Systematic 
Reviews 2005, 
Issue 4. Art. No 
Prevention Review EFFECTIVE – 
plasma-derived 
vaccines (PDV) 
significantly 
prevents hepatitis 
B events. 
Recombinant 
vaccines (RV) 
seems to be able 
to elicit similar 
protective anti-
HBs levels.  
1 
6 Oberdorfer A, 
Oberdorfer AL, 
Tran DT. 
Behavioural 
interventions for 
preventing 
Prevention  Protocol ONGOING 2 
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hepatitis B and/or 
C. (Protocol) 
Cochrane 
Database of 
Systematic 
Reviews 2002, 
Issue 2. 
7 Hong Z, Gao RN, 
Zou S. Hepatitis 
B immune 
globulin for 
prevention of 
posttransplantatio
n hepatitis B. 
(Protocol) 
Cochrane 
Database of 
Systematic 
Reviews 2004, 
Issue 4. 
Prevention Protocol ONGOING 2 
8 Liu YX, Pang 
CK, Liu JP. 
Medicinal herbs 
for acute hepatitis 
B. (Protocol) 
Cochrane 
Database of 
Systematic 
Reviews 2004, 
Issue 1. 
Treatment Protocol  ONGOING 1 
9 Rambaldi A, 
Jacobs BP, Gluud 
C. Milk thistle for 
alcoholic and/or 
hepatitis B or C 
virus liver 
diseases. 
Cochrane 
Database of 
Systematic 
Reviews 2007, 
Issue 4. 
Treatment Review INCONCLUSIVE 
- No evidence 
supporting or 
refuting milk 
thistle for 
alcoholic and/or 
hepatitis B or C 
virus liver 
diseases 
5 
10 Chen W, Liu J, 
Gluud C. Bile 
acids for viral 
hepatitis. 
Cochrane 
Database of 
Systematic 
Reviews 2007, 
Treatment Review INCONCLUSIVE 
- Bile acids may 
improve liver 
biochemistry of 
patients with 
hepatitis B or C, 
but there is 
insufficient 
4 
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Issue 4. evidence about 
long-term 
beneficial effects 
11 Liu J, Wang J. 
Acupuncture for 
chronic hepatitis 
B virus infection. 
(Protocol) 
Cochrane 
Database of 
Systematic 
Reviews 2005, 
Issue 1 
Treatment Protocol  2 
12 He Q, Chen XY, 
He L. Tiopronin 
for chronic 
hepatitis B. 
(Protocol) 
Cochrane 
Database of 
Systematic 
Reviews 2006, 
Issue 4. 
Treatment Protocol  1 
13 Myers RP, 
Regimbeau C, 
Thevenot T, 
Leroy V, 
Mathurin P, 
Opolon P, Zarski 
JP, Poynard T. 
Interferon for 
acute hepatitis C. 
Cochrane 
Database of 
Systematic 
Reviews 2001, 
Issue 4. 
Treatment Review EFFECTIVE - 
Interferon alfa 
improves liver 
biochemistry and 
viral clearance in 
transfusion-
acquired acute 
hepatitis C.  
 
More work 
needed about 
long-term clinical 
outcomes.   
1 
14 Simin M, Myers 
RP, Stimac D, 
Gluud C. 
Pegylated 
interferon for 
acute hepatitis C. 
(Protocol) 
Cochrane 
Database of 
Systematic 
Reviews 2007, 
Issue 1 
Treatment Protocol   1 
15 Liu JP, Treatment Review INCONCLUSIVE 2 
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Manheimer E, 
Tsutani K, Gluud 
C. Medicinal 
herbs for hepatitis 
C virus infection. 
Cochrane 
Database of 
Systematic 
Reviews 2001, 
Issue 4. 
- Still awaiting 
evidence on 
efficacy of 
medicinal herbs 
for viral hepatitis 
C. 
16 Gurusamy KS, 
Kumar Y, Sharma 
D, Davidson BR. 
Methods of 
vascular 
occlusion for 
elective liver 
resections. 
Cochrane 
Database of 
Systematic 
Reviews 2007, 
Treatment Review INCONCLUSIVE 
- Intermittent 
vascular occlusion 
is safe in liver 
resection, but it 
does not seem to 
reduce mortality.  
1 
17 Sahar T, Brezis 
M, Soares-Weiser 
K. Antibiotic 
prophylaxis for 
bacterial 
infections in 
cirrhotic patients 
with ascites. 
(Protocol) 
Cochrane 
Database of 
Systematic 
Reviews 2004, 
Issue 2. 
Prevention Protocol   2 
18 Rambaldi A, 
Gluud C. 
Anabolic-
androgenic 
steroids for 
alcoholic liver 
disease. Cochrane 
Database of 
Systematic 
Reviews 2006, 
Issue 4 
Treatment Review NOT 
EFFECTIVE 
- No evidence to 
support anabolic-
androgenic 
steroids for 
alcoholic liver 
disease 
3 
19 Rambaldi A, 
Gluud C. 
Colchicine for 
Treatment Review INCONCLUSIVE 
- Evidence 
supporting 
2 
Liver disease – A rapid review of epidemiology, treatment and service provision 185 
alcoholic and 
non-alcoholic 
liver fibrosis and 
cirrhosis. 
Cochrane 
Database of 
Systematic 
Reviews 2005, 
Issue 2. 
colchicine for 
alcoholic, viral, 
and cryptogenic 
liver 
fibrosis/cirrhosis 
is still lacking 
20 Rambaldi A, 
Gluud C. 
Propylthiouracil 
for alcoholic liver 
disease. Cochrane 
Database of 
Systematic 
Reviews 2005, 
Issue 4. 
Treatment Review INCONCLUSIVE 
- Evidence 
supporting or 
refuting 
propylthiouracil 
for alcoholic liver 
disease was not 
found 
3 
21 Rambaldi A, 
Gluud C. S-
adenosyl-L-
methionine for 
alcoholic liver 
diseases. 
Cochrane 
Database of 
Systematic 
Reviews 2006, 
Issue 2. 
Treatment Review INCONCLUSIVE 
- No evidence to 
support or refute 
S-adenosyl-L-
methionine for 
alcoholic liver 
diseases.  
 
More high quality 
trials needed 
2 
22 Saconato H, Di 
Sena V, Gluud C, 
Christensen E, 
Atallah A. 
Glucocorticostero
ids for alcoholic 
hepatitis. 
(Protocol) 
Cochrane 
Database of 
Systematic 
Reviews 1999, 
Issue 1 
Treatment Protocol ONGOING 1 
23 Saab S, Nieto JM. 
Surgical versus 
medical treatment 
of refractory 
ascites. (Protocol) 
Cochrane 
Database of 
Systematic 
Treatment Protocol ONGOING 4 
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Reviews 2002, 
Issue 1 
24 Simonetti RG, 
Gluud C, Milazzo 
G, Pagliaro L. 
Albumin and 
other plasma 
expanders for 
paracentesis 
treatment of 
ascites in cirrhotic 
patients. 
(Protocol) 
Cochrane 
Database of 
Systematic 
Reviews 2003, 
Issue 1. 
Treatment Protocol ONGOING 1 
25 Efsen E, Gluud 
LL, Schlichting P. 
Immunosuppressi
ve drugs for 
autoimmune 
hepatitis. 
(Protocol) 
Cochrane 
Database of 
Systematic 
Reviews 2004, 
Issue 1 
Treatment Protocol ONGOING 1 
26 Liu JP, McIntosh 
H, Lin H. Chinese 
medicinal herbs 
for asymptomatic 
carriers of 
hepatitis B virus 
infection. 
Cochrane 
Database of 
Systematic 
Reviews 2001, 
Issue 2. 
Treatment Review  INCONCLUSIVE 
- Firm evidence 
for effect of 
Chinese medicinal 
herbs for 
asymptomatic 
hepatitis B virus 
carriers is still 
awaited 
2 
27 Wun YT, 
Dickinson JA. 
Alpha-fetoprotein 
and/or liver 
ultrasonography 
for liver cancer 
screening in 
patients with 
Treatment Review INCONCLUSIVE 
- Inadequate 
evidence on 
screening with 
alpha-fetoprotein 
and/or ultrasound 
of the liver for 
patients with 
2 
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chronic hepatitis 
B. Cochrane 
Database of 
Systematic 
Reviews 2003, 
Issue 2. 
chronic hepatitis 
B 
28 Mathew JL, El 
Dib R, Mathew 
PJM, Boxall EH, 
Brok J. Hepatitis 
B immunization 
in persons not 
previously 
exposed to 
hepatitis B or 
with unknown 
exposure status. 
(Protocol) 
Cochrane 
Database of 
Systematic 
Reviews 2007, 
Issue 2. 
Prevention Protocol ONGOING 1 
29 Schroth RJ, 
Hitchon CA, 
Uhanova J, 
Noreddin A, 
Taback SP, 
Moffatt MEK, 
Zacharias JM. 
Hepatitis B 
vaccination for 
patients with 
chronic renal 
failure. Cochrane 
Database of 
Systematic 
Reviews 2004, 
Issue 3. 
Prevention Review INCONCLUSIVE 
- Hepatitis B 
vaccines achieve 
antibody 
production in 
patients with 
chronic renal 
failure, but we do 
not know if the 
vaccines are 
protective 
1 
30 Katz LHAIM, 
Fraser A, 
Leibovici L, Tur-
kaspa R. 
Lamivudine for 
preventing 
reactivation of 
hepatitis B 
infection in 
patients planned 
to undergo 
Prevention Protocol ONGOING 2 
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immunosuppressi
ve therapy. 
(Protocol) 
Cochrane 
Database of 
Systematic 
Reviews 2005, 
Issue 1. 
31 Aggarwal R, 
Bhatia SJ, Ranjan 
P, Sachdev S. 
Adefovir 
dipivoxil for 
chronic hepatitis 
B. (Protocol) 
Cochrane 
Database of 
Systematic 
Reviews 2006, 
Issue 1. 
Treatment Protocol ONGOING 1 
32 Saconato H, Silva 
Filho CR, Atallah 
AN, Parise ER. 
Alpha-interferon 
for chronic 
hepatitis B. 
(Protocol) 
Cochrane 
Database of 
Systematic 
Reviews 2002, 
Issue 2 
Treatment  Protocol ONGOING 1 
33 Saconato H, 
Atallah AN, 
Souza GM, Parise 
ER. Beta-
interferon for 
chronic hepatitis 
B. (Protocol) 
Cochrane 
Database of 
Systematic 
Reviews 2002, 
Issue 2 
Treatment Protocol ONGOING 1 
34 Wu T, Roger H, 
Xie L, Liu G, Hao 
B. Bicyclol for 
chronic hepatitis 
B. Cochrane 
Database of 
Treatment Review INCONCLUSIVE 
- Evidence on 
beneficial or 
harmful effects of 
bicyclol for 
chronic hepatitis 
1 
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Systematic 
Reviews 2006, 
Issue 4. 
C is not found 
35 Woo GW, Krahn 
M, Prichett S. 
Entecavir for 
chronic hepatitis 
B. (Protocol) 
Cochrane 
Database of 
Systematic 
Reviews 2007, 
Issue 3. 
Treatment Protocol ONGOING 1 
36 Saconato H, 
Souza GM, 
Atallah AN, 
Parise ER. 
Foscarnet for 
chronic hepatitis 
B. (Protocol) 
Cochrane 
Database of 
Systematic 
Reviews 2001, 
Issue 3 
Treatment Protocol ONGOING 1 
37 Saconato H, 
Souza GM, 
Atallah AN, 
Parise ER. 
Gamma-
interferon for 
chronic hepatitis 
B. (Protocol) 
Cochrane 
Database of 
Systematic 
Reviews 2002, 
Issue 3. 
Treatment Protocol ONGOING 1 
38 Mellerup MT, 
Krogsgaard K, 
Gluud C. 
Glucocorticostero
ids for viral 
hepatitis B. 
(Protocol) 
Cochrane 
Database of 
Systematic 
Reviews 2001, 
Issue 1. 
Treatment Protocol ONGOING 1 
Liver disease – A rapid review of epidemiology, treatment and service provision 190 
39 Mellerup MT, 
Krogsgaard K, 
Mathurin P, 
Gluud C, Poynard 
T. Sequential 
combination of 
glucocorticosteroi
ds and alfa 
interferon versus 
alfa interferon 
alone for HBeAg-
positive chronic 
hepatitis B. 
Cochrane 
Database of 
Systematic 
Reviews 2005, 
Issue 3. 
Treatment Review INCONCLUSIVE 
- 
Glucocorticosteroi
d pretreatment 
may increase 
virologic response 
to interferon in 
hepatitis B 'e' 
antigen positive 
chronic hepatitis 
B 
1 
40 Mumtaz K, 
Subhan A, Hamid 
S, Jafri W. 
Lamivudine for 
chronic hepatitis 
B in adults. 
(Protocol) 
Cochrane 
Database of 
Systematic 
Reviews 2007, 
Issue 2. 
Treatment Protocol ONGOING 1 
41 Liu JP, McIntosh 
H, Lin H. Chinese 
medicinal herbs 
for chronic 
hepatitis B. 
Cochrane 
Database of 
Systematic 
Reviews 2000, 
Issue 4. 
Treatment Review INCONCLUSIVE 
- Firm evidence 
for effect of 
Chinese medicinal 
herbs for 
asymptomatic 
hepatitis B virus 
carriers is still 
awaited 
1 
42 Liu JP, Lin H, 
Gluud C. 
Comparison of 
medicinal herbs 
for chronic 
hepatitis B virus 
infection. 
(Protocol) 
Cochrane 
Database of 
Treatment Protocol ONGOING 1 
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Systematic 
Reviews 2001, 
Issue 1. 
43 Mumtaz K, 
Hamid S, Brok J, 
Jafri W. 
Pegylated 
interferon for 
chronic hepatitis 
B. (Protocol) 
Cochrane 
Database of 
Systematic 
Reviews 2007, 
Issue 1 
Treatment Protocol ONGOING 1 
44 RH Luo, JL Yao, 
ZX Zhao. 
Prostaglandin E1 
analogues for 
chronic hepatitis 
B. (Protocol) 
Cochrane 
Database of 
Systematic 
Reviews 2003, 
Issue 4. 
Treatment Protocol ONGOING 1 
45 Saconato H, 
Atallah AN, 
Souza GM, Parise 
ER. Thymosin 
alpha1 for chronic 
hepatitis B. 
(Protocol) 
Cochrane 
Database of 
Systematic 
Reviews 2002, 
Issue 2. 
Treatment Protocol ONGOING 1 
46 Abbas Z, Salih 
M, Jafri W. 
Interferon-alpha 
for hepatitis D. 
(Protocol) 
Cochrane 
Database of 
Systematic 
Reviews 2006, 
Issue 2. 
Treatment Protocol ONGOING 1 
47 Gurusamy KS, 
Samraj K, 
Treatment Protocol ONGOING 1 
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Davidson BR. 
Antiviral 
prophylactic 
intervention for 
hepatitis C virus 
in patients 
undergoing liver 
transplantation. 
(Protocol) 
Cochrane 
Database of 
Systematic 
Reviews 2007, 
Issue 3. 
48 Brok J, Mellerup 
MT, Krogsgaard 
K, Gluud C. 
Glucocorticostero
ids for viral 
hepatitis C. 
Cochrane 
Database of 
Systematic 
Reviews 2004, 
Issue 2. 
Treatment  Review INCONCLUSIVE 
- No evidence to 
support or refute 
glucocorticosteroi
ds for viral 
hepatitis C 
1 
49 Myers RP, 
Regimbeau C, 
Thevenot T, 
Leroy V, 
Mathurin P, 
Opolon P, Zarski 
JP, Poynard T. 
Interferon for 
interferon naive 
patients with 
chronic hepatitis 
C. Cochrane 
Database of 
Systematic 
Reviews 2002, 
Issue 2. 
Treatment Review EFFECTIVE - It 
is effective in 
interferon naive 
patients with 
chronic hepatitis 
C but the efficacy 
in patients with 
normal 
aminotransferases 
is unproven. 
1 
50 Myers RP, 
Poynard T. 
Interferon for 
interferon 
nonresponding 
and relapsing 
patients with 
chronic hepatitis 
C. Cochrane 
Treatment Review EFFECTIVE - 
Retreatment with 
interferon leads to 
sustained 
clearance of 
hepatitis C virus 
from the blood in 
a minority of 
patients with 
1 
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Database of 
Systematic 
Reviews 2002, 
Issue 4. 
previous 
nonresponse to or 
relapse following 
interferon therapy 
51 Brok J, Gluud 
LL, Gluud C. 
Ribavirin plus 
interferon versus 
interferon for 
chronic hepatitis 
C. Cochrane 
Database of 
Systematic 
Reviews 2005, 
Issue 2. 
Treatment Review EFFECTIVE - 
Adding ribavirin 
to interferon 
increases the 
number that clear 
hepatitis C virus 
but also increases 
the risk of several 
adverse events 
2 
52 Myers RP, Abdo 
A, Poynard T. 
Pegylated 
interferon alfa for 
chronic hepatitis 
C. (Protocol) 
Cochrane 
Database of 
Systematic 
Reviews 2003, 
Issue 1. 
Treatment Protocol ONGOING 1 
53 Simin M, Stimac 
D, Gluud C. 
Pegylated 
interferon alpha 
2a versus 
pegylated 
interferon alpha 
2b for acute and 
chronic hepatitis 
C. (Protocol) 
Cochrane 
Database of 
Systematic 
Reviews 2006, 
Issue 1. 
Treatment Protocol ONGOING 1 
54 Brok J, Gluud L, 
Gluud C. 
Ribavirin 
monotherapy for 
chronic hepatitis 
C. Cochrane 
Database of 
Systematic 
Reviews 2005, 
Treatment Review NOT 
EFFECTIVE 
- Ribavirin 
monotherapy 
seems without 
beneficial effects 
for patients with 
chronic hepatitis 
C 
1 
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Issue 4. 
55 Iorio A, Francisci 
D, Luchetta ML, 
Kjaer MS, Gluud 
LL. Antiviral 
therapy for 
chronic hepatitis 
C in patients with 
human 
immunodeficienc
y virus. (Protocol) 
Cochrane 
Database of 
Systematic 
Reviews 2004, 
Issue 3. 
Treatment Protocol ONGOING 1 
56 Yang XY, Zhuo 
Q, Wu TX, Liu 
GJ. Bicyclol for 
chronic hepatitis 
C. Cochrane 
Database of 
Systematic 
Reviews 2007, 
Issue 1 
Treatment Review INCONCLUSIVE 
-Evidence on 
beneficial or 
harmful effects of 
bicyclol for 
chronic hepatitis 
C is not found 
1 
57 Gurusamy KS, 
Kumar Y, 
Davidson BR. 
Methods of 
preventing 
bacterial sepsis 
and wound 
complications for 
liver 
transplantation. 
(Protocol) 
Cochrane 
Database of 
Systematic 
Reviews 2007, 
Issue 3 
Prevention Protocol ONGOING 1 
58 Soares-Weiser K, 
Brezis M, Tur-
Kaspa R, 
Leibovici L. 
Antibiotic 
prophylaxis for 
cirrhotic patients 
with 
gastrointestinal 
Prevention Review Effective - 
Antibiotic 
prophylaxis for 
cirrhotic 
inpatients with 
gastrointestinal 
bleeding is 
efficacious in 
reducing the 
1 
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bleeding. 
Cochrane 
Database of 
Systematic 
Reviews 2002 
 
 
number of deaths 
and bacterial 
infections, are 
well tolerated, and 
should be 
advocated. 
59 Yang J, Zhen G, 
Zongying W, 
Wang Y. 
Antacids for 
preventing 
oesophagogastric 
variceal bleeding 
and rebleeding in 
cirrhotic patients. 
(Protocol) 
Cochrane 
Database of 
Systematic 
Reviews 2005, 
Issue 3. 
Prevention Protocol ONGOING 1 
60 Liu T, Zhao N, 
Zhu C. Organic 
nitrates for 
prevention of 
esophageal 
varices bleeding 
and rebleeding. 
(Protocol) 
Cochrane 
Database of 
Systematic 
Reviews 2000, 
Issue 2. 
Prevention  Protocol ONGOING 1 
61 Ioannou G, Doust 
J, Rockey DC. 
Terlipressin for 
acute esophageal 
variceal 
hemorrhage. 
Cochrane 
Database of 
Systematic 
Reviews 2003, 
Issue 1. 
Treatment Review EFFECTIVE - On 
the basis of a 34% 
relative risk 
reduction in 
mortality, 
terlipressin should 
be considered to 
be effective in the 
treatment of acute 
variceal 
hemorrhage. 
Further, since no 
other vasoactive 
agent has been 
shown to reduce 
1 
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mortality in single 
studies or meta-
analyses, 
terlipressin might 
be the vasoactive 
agent of choice in 
acute variceal 
bleeding. 
62 Khan S, Tudur 
Smith C, 
Williamson P, 
Sutton R. 
Portosystemic 
shunts versus 
endoscopic 
therapy for 
variceal 
rebleeding in 
patients with 
cirrhosis. 
Cochrane 
Database of 
Systematic 
Reviews 2006, 
Issue 4. 
Treatment Review INCONCLUSIVE
- All shunts 
resulted in a 
significantly 
lower rebleeding 
rate at the expense 
of a higher 
incidence of 
encephalopathy. 
TIPS was 
complicated by a 
high incidence of 
shunt dysfunction. 
No survival 
advantage was 
demonstrated with 
any shunt. 
 
63 Khan SA, 
Williamson P, 
Sutton R, Tudur 
C. Surgical 
portosystemic 
shunts versus 
transjugular 
intrahepatic 
portosystemic 
shunt for variceal 
haemorrhage. 
(Protocol) 
Cochrane 
Database of 
Systematic 
Reviews 1998, 
Issue 1. 
Treatment Protocol ONGOING 2 
64 Khan SA, 
Williamson P, 
Sutton R, Tudur 
C. Total 
portosystemic 
shunt versus 
shunts preserving 
portal venous 
Treatment Protocol ONGOING 1 
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hepatic perfusion 
for variceal 
haemorrhage. 
(Protocol) 
Cochrane 
Database of 
Systematic 
Reviews 1998, 
Issue 1. 
65 Saab S, Nieto JM, 
Lewis SK, 
Runyon BA. 
TIPS versus 
paracentesis for 
cirrhotic patients 
with refractory 
ascites. Cochrane 
Database of 
Systematic 
Reviews 2006, 
Issue 4. 
Treatment  Review INCONCLUSIVE 
- The meta-
analysis supports 
that TIPS was 
more effective at 
removing ascites 
as compared with 
paracentesis 
without a 
significant 
difference in 
mortality, 
gastrointestinal 
bleeding, 
infection, and 
acute renal failure. 
However, TIPS 
patients develop 
hepatic 
encephalopathy 
significantly more 
often. 
1 
66 Wang RT, Koretz 
RL, Yee HF. 
Weight reduction 
for non-alcoholic 
fatty liver. 
(Protocol) 
Cochrane 
Database of 
Systematic 
Reviews 2002, 
Issue 1 
Treatment Protocol ONGOING 2 
67 Lirussi F, 
Azzalini L, 
Orando S, 
Orlando R, 
Angelico F. 
Antioxidant 
supplements for 
non-alcoholic 
Treatment Review INCONCLUSIVE  
- No evidence to 
support or refute 
antioxidant 
supplements for 
patients with non-
alcoholic fatty 
liver disease 
1 
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fatty liver disease 
and/or 
steatohepatitis. 
Cochrane 
Database of 
Systematic 
Reviews 2007, 
Issue 1. 
and/or 
steatohepatitis 
68 Orlando R, 
Azzalini L, 
Orando S, Lirussi 
F. Bile acids for 
non-alcoholic 
fatty liver disease 
and/or 
steatohepatitis. 
Cochrane 
Database of 
Systematic 
Reviews 2007, 
Issue 1. 
Treatment Review INCONCLUSIVE 
- No evidence to 
support or refute 
the effect of bile 
acids in patients 
with non-
alcoholic fatty 
liver disease 
and/or 
steatohepatitis 
1 
69 Angelico F, 
Burattin M, 
Alessandri C, Del 
Ben M, Lirussi F. 
Drugs improving 
insulin resistance 
for non-alcoholic 
fatty liver disease 
and/or non-
alcoholic 
steatohepatitis. 
Cochrane 
Database of 
Systematic 
Reviews 2007, 
Issue 1. 
Treatment Review INCONCLUSIVE 
- No evidence to 
support or refute 
drugs trying to 
influence insulin 
resistance in 
patients with non-
alcoholic fatty 
liver disease 
and/or 
steatohepatitis 
1 
70 Lirussi F, 
Mastropasqua E, 
Orando S, 
Orlando R. 
Probiotics for 
non-alcoholic 
fatty liver disease 
and/or 
steatohepatitis. 
Cochrane 
Database of 
Systematic 
Reviews 2007, 
Treatment Review INCONCLUSIVE 
- No evidence to 
support or refute 
probiotics for 
patients with non-
alcoholic fatty 
liver disease 
and/or 
steatohepatitis 
1 
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Issue 1. 
71 Brok J, Buckley 
N, Gluud C. 
Interventions for 
paracetamol 
(acetaminophen) 
overdose. 
Cochrane 
Database of 
Systematic 
Reviews 2006, 
Issue 2. 
Treatment Review INCONCLUSIVE 
- Activated 
charcoal seems 
the best choice to 
reduce absorption. 
N-acetylcysteine 
should be given to 
patients with 
overdose but the 
selection criteria 
are not clear. No 
N-acetylcysteine 
regime has been 
shown to be more 
effective than any 
other. It is a 
delicate balance 
when to proceed 
to liver 
transplantation, 
which may be 
life-saving for 
patients with poor 
prognosis. 
1 
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Appendix VIII 
 
Economic evaluations - Hepatocellular carcinoma (HCC) 
 
Reference Intervention Decision 
Model 
Patient 
Characteristics 
Country of 
Study 
Year 
of 
Costs 
Discount 
rate for 
costs and 
effects 
View 
point 
CE/CUA 
ratio 
243
  
 
Performing 
ultrasound and 
alpha-
fetoprotein 
(AFP) every six 
month v 
seeking tumours 
only if 
clinically 
suspected.   
Yes Child-Pugh A 
cirrhosis 
patients.  .    
Switzerland  1994 Costs and 
future life 
years by 
5%.   
Health 
Care 
system 
Best case 
scenario 
$26,000-
$55,000/life 
year 
gained.  
Intermediat
e case 
scenario 
$48,000-
$284,000/li
fe year 
gained.  
244
 
 
Screening using 
AFP and 
ultrasound 
approximately 
every 6 months 
v diagnosis 
 280 patients 
with cirrhosis of 
various causes   
Italy Not 
given 
Not given Health 
Care 
system 
Mean cost 
per life year 
saved 
$9,152. 
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because of other 
symptoms.   
245
 
 
Screening with 
AFP and US 
every 6 months 
v diagnosis of 
HCC by other 
symptoms.   
 313 patients 
with liver 
cirrhosis less 
than 60 years 
old if Child-
Pugh C.   
Italy Not 
given 
Not given Health 
Care 
system 
$113,534 
per life year 
saved.   
246
 Screening using 
AFP and ultra 
sound every six 
month vs. no 
screening 
 174 patients 
with proven 
HCC. Mean age 
58.9.   
Mexico Not 
given 
Not given Health 
Care 
system 
$309 -$346 
per correct 
diagnosis 
247
 Six strategies 
were compared 
against no 
screening:  
1) Annual 
screening using 
AFP 
2)  Annual 
screening using 
ultra sound 
3)  Annual 
screening using 
AFP and ultra 
sound 
4)  6 monthly 
screening using 
Yes People with 
cirrhosis up to 
age 70.  All 
causes of 
cirrhosis 
Try to use UK 
data or those 
from 
countries with 
similar 
disease 
epidemiology 
2004 3.5% Health 
care 
system 
£20,700 per 
QALY for  
AFPannual 
vs. no 
screening 
AFP  
£22,900 per 
QALY for 
6months vs. 
no 
screening 
 
£27,900 per 
QALY for 
AFP6month + 
ultrasound 
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AFP 
5)  6 monthly 
screening using 
ultra sound 
6) six monthly 
screening using 
AFP and 
ultrasound 
 
vs. no 
screening 
 
£60,100 per 
QALY for 
AFP6month 
+ultra 
sound 
248
 OLTx v no 
treatment. 
 
Surgery v no 
treatment.  
 
Percutaneous 
ethanol 
injection (PEI) 
v no treatment.  
 
Transcatheter 
lipiodol-
mediated 
arterial 
chemoemboliza
tion (TACE) v 
no treatment  
 Patients with 
small single 
HCC.  Mean 
age of over 60.  
Child-Pugh A 
and B.  
Italy Not 
given 
Not given  Health 
Care 
system 
OLTx 
£21,664/life 
year saved. 
Surgery, 
$1,959/life 
year saved. 
PEI 
$1,233/life 
year saved.  
 
TACE 
$4,009/life 
year saved  
249
 Surgical 
resection v 
Yes Child-Pugh A 
patients with 
Spain 1999 
$US 
Costs and 
benefit at 
Health 
Care 
$38,117/ye
ar of life 
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standard 
management as 
adjuvant 
therapy for 
HCC during the 
waiting list for 
OLT.   
single 
tumour<5cm on 
the waiting list 
for OLT.  
3% system saved 
(12 month 
waiting list) 
249
 PEI v standard 
management as 
adjuvant 
therapy for 
HCC during the 
waiting list for 
OLT. 
Yes Child-Pugh B 
patients with a 
single tumour 
<5cm or with 
three tumours 
<3cm on the 
waiting list for 
OLT.  
 
Spain 1999 
$US 
Costs and 
benefit at 
3% 
Health 
Care 
system 
$12,489/ye
ar of life 
saved 
(12 month 
waiting list) 
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Appendix IX 
 
Economic evaluation - variceal bleeding (VB) 
 
Reference Intervention Decision 
model 
Patient 
Characteristics 
Country Year of 
Cost 
estimati
on 
Discount 
Rate for 
costs and 
effects 
View 
Point 
CU/CE ratio 
250
 
 
No screening/no 
prophylaxis vs. 
universal 
screening 
 
No screening/no 
prophylaxis vs. 
universal 
screening/EVL1 
as needed 
 
No screening/no 
prophylaxis vs. 
universal primary 
prophylaxis using 
β blockers.   
 
Yes 
 
Two cohorts of 
50 yr old 
patients 
(compensated 
Child-Pugh A 
and 
decompensated 
Child-Pugh B 
or C).   
Hypothet
ical  
cohort 
(study 
based in 
US) 
2000 
$US 
3% for 
both 
Health 
Care 
Purchaser 
Compensated 
Universal screening 
US$3,771/life year 
saved.   
 
Universal 
prophylaxis 
compared to 
universal screening 
$66,000/life year 
saved 
Decompensated 
Universal 
prophylaxis 
compared to 
universal screening 
$1,154/life year 
saved 
 
                                                 
1
 Endoscopic Variceal Ligation 
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251
 
 
Scope all strategy 
v do nothing. 
Prediction rule2 v 
do nothing.   
 Mixed 
male/female 
mean age 
49.7yrs All 
patients with 
cirrhosis of 
differing 
etiology.  All 
patients who 
were evaluated 
for liver 
transplantation.   
US  Not 
Given 
Not given Health 
Care 
purchaser 
Scope all v do 
nothing 
US$15,160/case 
averted. Prediction 
rule v do nothing 
US$3,533/case 
averted. 
252
 Propranolol v 
observation  
 
Sclerotherapy v 
observation 
 
Surgery v 
observation.   
 
 
Yes Hypothetical 
cohort stratified 
by bleeding 
risk.   
US Not 
stated 
(year of 
study 
1997) 
Not given Health 
care 
purchaser  
Propranolol $1,277-
5,110/cost of 
prolonging QALE by 
1 year.  Results not 
given for 
sclerotherapy or 
surgery.   
253
 Universal 
prophylaxis with 
β blockers vs. no 
prophylaxis 
Screen all with 
upper endoscopy 
Yes Hypothetical 
cohort of 
patients with 
cirrhosis with 
no history of 
oesophageal 
Not 
specified 
2000 Varied 
betweem 
0-7% 
Health 
care 
provider 
Universal 
prophylaxis 
dominated but only 
CE ratio presented is 
$800 per QALY for 
endoscopy + β 
                                                 
2
 Patients divided into high and low risk.  High risks scoped, those found with large esophageal varices treated with β blockers and nitrates. 
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+ β blockers if 
large varices vs. 
no prophylaxis  
variceal 
bleeding 
blockers if large 
varices vs. no 
screening.   
254
 5 strategies vs. do 
nothing: 
1)  screen all –if 
small varices 
repeat screening 
biannually, if 
large varices give 
β blockers. 
2) screen all – 
medium/large 
varices treated 
with endoscopic 
band ligation 
(EBL) 
3)  selective 
screening – high 
risk get screening 
endoscopy, β 
blockers if large 
varices present 
4) selective 
screening – high 
risk get EBL 
5) β blockers for 
al.   
 
 
Yes Hypothetical 
cohort of 
patients with 
compensated 
cirrhosis with 
no prior 
evaluation for 
varices.  Newly 
diagnosed with 
Child-Pugh A 
or B cirrhosis. 
50 year old.   
Not 
states 
2001 No cost 
discountin
g due to 
short time 
frame of 
model 
3rd party 
payer 
$12,408 per 
additional VB 
prevented for 
Universal β blockers 
vs. do nothing 
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255
 β blockers vs. 
EVL as primary 
prophylaxis 
Yes Patients with 
Child-Pugh A 
or B cirrhosis.  
Medium to 
large varices 
Not 
given 
Not 
given 
3% Health 
care 
provider 
£ 25,548 per QALY 
for EVL vs. β 
blockers 
256
 1) β blockers 
vs β 
blockers 
+Hepatic 
venous 
gradient  
(HVPG) 
measurem
ent 4 
weeks 
after 
initial β 
blockers. 
2) β blockers 
vs. β 
blockers + 
HVPG 
prior to 
interventio
n and 4 
weeks 
after. 
 
 
Yes Hypothetical 
cohort of 
patients with 
non-bleeding, 
high risk 
varices.   
Not 
given 
2001 3% costs 
and effects 
Health 
care 
provider 
$108185 per VB 
episode prevented for 
β blockers +HVPG 4 
weeks late vs. β 
blockers  
 
$202 796 per VB 
episode prevented for 
β blockers + HPVG 
before and 4 weeks 
after initial treatment 
vs. β blockers. 
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257
 Hemodynamic 
monitoring of 
primary 
pharmacotherapy  
prophylaxis (β 
blockers)  vs. no 
monitoring  
Yes Hypothetical 
cohort of Child 
–Pugh A or B 
cirrhosis 
patients with 
medium to large 
varices. 
Not 
given 
2001 3% costs 
and effects 
Health 
care 
system 
Hemodynamic 
monitoring +nitrates 
for non-responders to 
β blockers are cost 
saving vs. no 
monitoring.   
 
$5659 per life saved 
for hemodynamic 
monitoring + EVL 
for non-responders to 
β blockers vs. no 
monitoring.   
258
 
 
TIPS v 
Endoscopic 
sclerotherapy 
(ES)  
 
 
 
 
 
 
 RCT of 38 
people (mainly 
men 27/38).  
With previous 
variceal 
bleeding  
Italy Not 
given 
(year of 
study 
1999) 
Not given Health 
care 
purchase
r 
TIPS IT2.26m/month 
free from re-
bleeding.  
 
ES IT2.16m/month 
free from re-bleeding   
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259
 
 
TER-GTN v 
placebo. At home 
before endoscopic 
diagnosis of 
rupture of varices 
and admittance to 
ICU.  
 84 cases of 
home 
management.   
France 1994 Not 
applicable 
42 day 
study.   
Health 
care 
purchase
r 
TER-GTN FF 
25,000/death 
avoided.   
260
 
 
TIPS v H-graft 
portacaval shunt.   
 80 adults with 
cirrhosis of 
varying etiology 
with bleeding 
due to portal 
hypertension.   
US 1996 Not given Health 
care 
purchase
r 
Total cost of 
treatment + follow 
up.  TIPS $69,276.  
H-graft $66,034.   
261
 
 
TIPS v Surgical 
shunt  
 Good risk 
cirrhotics (i.e. 
Child-Pugh A 
or B).  At least 
1 prior episode 
of bleeding 
from portal 
hypertension.   
US Not 
given 
Not given  Total cost of 
treatment + follow 
up. TIPS $111,573.  
 
PSS $61,934.   
262
 1) β blockers 
+nitrate 
therapy 
vs. 
endoscopi
c band 
ligation 
(EBL) 
Yes Hypothetical 
cohort of 
cirrhosis 
patients with  
previous 
variceal 
bleeding treated  
with EBL. 
Not 
given 
2001 No 
discounting 
due to short 
time 
horizon 
Health 
care 
provider 
$5974 per recurrent 
bleed prevented for 
HVPG+ β blockers 
and nitrates vs. EBL.   
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2) HVPG + β 
blockers 
and nitrate 
therapy 
vs. EBL 
263
 4 interventions 
for secondary 
prophylaxis for 
variceal 
haemorrhage vs. 
observation 
alone: 
1) medical 
therapy 
2) TIPS 
3) EBL 
4) EBL+ medical 
therapy 
Yes Hypothetical 
cohort of male 
patients with 
history of 
controlled 
bleeding 
varices. Child-
Pugh B 
cirrhosis with 
average age of 
50. 
Not 
given 
2001 3% costs 
and 
outcomes 
Health 
care 
provider 
EBL + medical 
therapy is reported as 
being dominant to all 
other strategies but 
no cost per QALY 
information is 
presented.   
264
 6 interventions 
for secondary 
prophylaxis of 
VB vs. 
combination 
therapy of β 
blockers 
+mononitrate 
with no 
haemodynamic 
screening: 
Yes Hypothetical 
cohort of 
patients with a 
Child-Pugh 
score of 8, 
average age of 
55.  Presenting 
with an initial 
episode of VB 
Not 
given 
2002 3% costs 
and effects  
Not 
given 
Combination β 
blockers 
+mononitrate 
dominates all other 
strategies except vs .  
combination therapy 
+ 2 HVPG with a 
cost per life year 
saved of $136,700 
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1) β blockers  + 
no screening 
2) EVL 
3) β blockers +1 
HPVG 
measurement 
taken 3 months 
after intervention 
4) β blockers  
+_mononitrate 
and HVPG 3 
months after 
intervention 
5) β blockers 
+mononitrate and 
HVPG before 
intervention and 3 
months after. 
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Appendix X 
 
Map of Liver Services in England 2004 275 
 
 
